<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Trimethoprim-sulfamethoxazole (co-trimoxazole): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Trimethoprim-sulfamethoxazole (co-trimoxazole): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Trimethoprim-sulfamethoxazole (co-trimoxazole): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9785" href="/d/html/9785.html" rel="external">see "Trimethoprim-sulfamethoxazole (co-trimoxazole): Drug information"</a> and <a class="drug drug_patient" data-topicid="11061" href="/d/html/11061.html" rel="external">see "Trimethoprim-sulfamethoxazole (co-trimoxazole): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F154885"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Bactrim;</li>
<li>Bactrim DS;</li>
<li>Sulfatrim Pediatric</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866456"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Septra;</li>
<li>Sulfatrim;</li>
<li>Sulfatrim DS;</li>
<li>Sulfatrim Pediatric;</li>
<li>TEVA-Trimel DS [DSC];</li>
<li>TEVA-Trimel [DSC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1046614"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antibiotic, Sulfonamide Derivative</span></li></ul></div>
<div class="block dop drugH1Div" id="F154900"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Dosage recommendations are based on the trimethoprim (TMP) component.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing:</b> Infants ≥2 months, Children, and Adolescents: Oral, IV: 8 to 12 mg TMP/kg/day in divided doses every 12 hours; maximum dose: 160 mg TMP/<b>dose</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.2021','lexi-content-ref-33903114']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.2021','lexi-content-ref-33903114'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="49929a72-f7cf-4de4-8d52-7a1d857c693e">Brucellosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Brucellosis:</b> Limited data available: <b>Note:</b> Recommended in patients &lt;8 years of age for whom prolonged use of doxycycline is not recommended or in older patients if tetracyclines are contraindicated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020.2','lexi-content-ref-AAP.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020.2','lexi-content-ref-AAP.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥2 months, Children, and Adolescents: Oral: 8 to 12 mg TMP/kg/day in divided doses every 12 hours in combination with rifampin for ≥6 weeks. Usual adult dose: 320 mg/day; however, doses up to 480 mg/day have been described. For serious infections, gentamicin should be added for the initial 1 to 2 weeks and therapy may be extended for up to 4 to 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18162038','lexi-content-ref-Bradley.1','lexi-content-ref-CDC.2020.2','lexi-content-ref-8327297','lexi-content-ref-2649867','lexi-content-ref-AAP.2021','lexi-content-ref-16732154']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18162038','lexi-content-ref-Bradley.1','lexi-content-ref-CDC.2020.2','lexi-content-ref-8327297','lexi-content-ref-2649867','lexi-content-ref-AAP.2021','lexi-content-ref-16732154'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="34026798-eadf-4e45-bb50-655e4aa27221">Cyclosporiasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cyclosporiasis</b>
<b> (<i>Cyclospora </i>infection):</b> Limited data available: Infants ≥2 months, Children, and Adolescents: Oral, IV: 8 to 10 mg TMP/kg/day in divided doses every 12 hours; maximum dose: 160 mg TMP/<b>dose</b>. Typical treatment duration is 7 to 10 days, though longer durations may be required in immunocompromised patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-AAP.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-AAP.2021'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="54ce3bb2-06a7-4f77-9c87-e5f90681021b">Cystoisosporiasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cystoisosporiasis (<i>Cystoisospora</i> infection; formerly isosporiasis):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment: </i>Infants ≥2 months, Children, and Adolescents: Oral: 8 to 10 mg TMP/kg/day in divided doses every 12 hours for 7 to 10 days; maximum dose: 160 mg TMP/<b>dose</b>; immunocompromised patients may require longer courses of therapy (eg, 3 to 4 weeks). In patients with HIV, dose may be increased to 15 to 20 mg TMP/kg/day in divided doses every 6 to 8 hours if symptoms worsen or do not improve (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.5','lexi-content-ref-AAP.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.5','lexi-content-ref-AAP.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Chronic maintenance therapy (secondary prophylaxis):</i> HIV-exposed/-infected: <b>Note:</b> Recommended in patients with HIV who are severely immunosuppressed (eg, adolescents with CD4 count &lt;200 mm<sup>3</sup>); may consider discontinuation when immunologic status is improved in response to antiretroviral therapy (ART) for &gt;6 months if no symptoms of active cystoisosporiasis are present (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2','lexi-content-ref-HHS.5']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2','lexi-content-ref-HHS.5'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥2 months and Children: Oral: 5 mg TMP/kg/day in divided doses every 12 hours 3 days per week; maximum dose: 80 mg TMP/<b>dose</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.5']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.5'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: Oral: 160 mg TMP/dose 3 times weekly, <b>or</b> alternatively, 160 mg TMP/dose once daily, <b>or</b> 320 mg TMP/dose 3 times weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9938d465-584f-48f7-8083-e90bc984c47e">Exit-site or tunnel infection, peritoneal dialysis catheter</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Exit-site or tunnel infection, peritoneal dialysis catheter:</b> Limited data available: Infants, Children, and Adolescents: Oral: 5 to 10 mg TMP/kg/dose once daily; maximum dose: 80 mg TMP/dose. Exit-site infection should be treated for ≥2 weeks and for at least 7 days after complete resolution, or for ≥3 weeks for <i>Staphylococcus aureus</i>; tunnel infection should be treated for 2 to 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22851742']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22851742'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8713978a-d495-46cd-89da-072b22dab991">Melioidosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Melioidosis (<i>Burkholderia pseudomallei</i> infection):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Initial intensive therapy (as a potential add-on to primary therapy [eg, in focal disease of the CNS, bone, or joint]):</i> Children and Adolescents: Oral, IV: 12 mg TMP/kg/day in divided doses every 12 hours; maximum dose: 320 mg TMP/<b>dose</b>. Duration is ≥14 days, though a longer duration may be necessary depending on disease severity and site of infection; should be followed by eradication therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32986699','lexi-content-ref-29388572']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32986699','lexi-content-ref-29388572'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Eradication therapy (begin after completion of initial intensive therapy):</i> Children and Adolescents: Oral: 12 mg TMP/kg/day in divided doses every 12 hours; maximum dose: 320 mg TMP/<b>dose</b>. Duration is ≥3 months, but may be longer (eg, 6 months) in some cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29388572']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29388572'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="63a1da04-9672-40b9-bbfe-cb4d46354a2e">Meningitis, including health care-associated ventriculitis/meningitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningitis, including health care-associated ventriculitis/meningitis (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥2 months, Children, and Adolescents: IV: 10 to 20 mg TMP/kg/day in divided doses every 6 to 12 hours. Duration should be individualized based on pathogen, patient characteristics, and response; treatment duration for gram-negative bacilli and <i>S. aureus</i> is a minimum of 10 to 14 days, although some experts recommend ≥21 days for gram-negative bacilli; <i>Listeria monocytogenes</i> should be treated ≥21 days. With repeatedly positive cultures, therapy should be continued for at least 10 to 14 days after first negative cerebrospinal fluid culture (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15494903','lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15494903','lexi-content-ref-28203777'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e01e9053-4cab-43d5-982b-2eaac05c1b5a">Osteoarticular infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteoarticular infection (step-down therapy following parenteral treatment):</b> Very limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥2 months, Children, and Adolescents: Oral: 6 to 20 mg TMP/kg/day in divided doses every 6 to 12 hours; maximum dose: 160 mg TMP/<b>dose</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28708801','lexi-content-ref-21817950']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28708801','lexi-content-ref-21817950'])">Ref</a></span>); in a retrospective evaluation of 20 patients (age 9 months to 17 years), the median dose was 16.4 mg/kg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21817950']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21817950'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a96b8104-65d0-48ba-b460-4308464e6db6">Otitis media, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Otitis media, acute (alternative agent):</b>
<b>Note:</b> Not considered appropriate empiric therapy for acute otitis media due to significant <i>Streptococcus pneumoniae</i> resistance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23439909']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23439909'])">Ref</a></span>). May be considered when a susceptible pathogen has been isolated.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥2 months, Children, and Adolescents: Oral: 8 mg TMP/kg/day in divided doses every 12 hours for 10 days; maximum dose: 160 mg TMP/<b>dose</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11303827','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11303827','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2d90b72e-8893-4719-a107-be19527d217f">
<i>Pneumocystis jirovecii</i> pneumonia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Pneumocystis jirovecii</i> pneumonia (PCP):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prophylaxis, primary and secondary: </i></p>
<p style="text-indent:-2em;margin-left:6em;">HIV-infected:</p>
<p style="text-indent:-2em;margin-left:8em;">Infants and Children: Oral: 5 to 10 mg TMP/kg/day or 150 mg TMP/<b>m<sup>2</sup></b>/day; may be administered in divided doses every 12 hours 2 to 3 days per week on alternating or consecutive days, or as a single daily dose every day (ie, 7 days/week); maximum dose: 160 mg TMP/<b>dose</b>. In HIV-infected or indeterminate infants, continue until 12 months of age regardless of CD4 cell count/percentage. In children, continue until patient has been receiving ART for ≥6 months and achieves a CD4 percentage ≥15% or age-specific CD4 cell count targets (age &lt;6 years: ≥500 cells/mm<sup>3</sup>; age ≥6 years: ≥200 cells/mm<sup>3</sup>) for &gt;3 consecutive months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.5']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.5'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents: Oral: 80 to 160 mg TMP daily <b>or</b> alternatively, 160 mg TMP 3 times weekly. Continue until CD4 cell count is ≥200 cells/mm<sup>3</sup> for ≥3 months in response to ART; may also consider discontinuing when CD4 cell count is ≥100 cells/mm<sup>3</sup> and viral load is undetectable for ≥3 to 6 months in response to ART (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Immunocompromised, HIV-uninfected (eg, solid organ or hematopoietic cell transplant recipients, patients with hematologic malignancies or primary immunodeficiencies):</p>
<p style="text-indent:-2em;margin-left:8em;">Infants, Children, and Adolescents: Oral: 5 mg TMP/kg/day or 150 mg TMP/<b>m<sup>2</sup></b>/day; may be administered in divided doses every 12 hours 2 to 3 days per week on alternating or consecutive days, or as a single daily dose given 7 days per week or 3 times weekly on consecutive days; maximum dose: 160 mg TMP/<b>dose</b>. Duration of prophylaxis varies based on underlying condition (eg, type of transplant) and presence of risk factors including continuing immunosuppression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-412099','lexi-content-ref-3495732','lexi-content-ref-17606548','lexi-content-ref-27550992','lexi-content-ref-AAP.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-412099','lexi-content-ref-3495732','lexi-content-ref-17606548','lexi-content-ref-27550992','lexi-content-ref-AAP.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment</i>: <b>Note:</b> Patients with moderate or severe infection (PaO<sub>2</sub> &lt;70 mm Hg at room air or alveolar-arterial oxygen gradient ≥35 mm Hg) should receive adjunctive corticosteroids. Secondary prophylaxis should be initiated upon completion of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2','lexi-content-ref-HHS.5','lexi-content-ref-31507152','lexi-content-ref-AAP.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2','lexi-content-ref-HHS.5','lexi-content-ref-31507152','lexi-content-ref-AAP.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children: IV, Oral: 15 to 20 mg TMP/kg/day in divided doses every 6 to 8 hours; in patients with mild to moderate disease and no diarrhea/malabsorption issues, may transition to oral therapy following clinical improvement; treat for a total of 21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-HHS.5','lexi-content-ref-AAP.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-HHS.5','lexi-content-ref-AAP.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-HHS.2','lexi-content-ref-AAP.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-HHS.2','lexi-content-ref-AAP.2021'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">Mild to moderate: Oral, IV: 15 to 20 mg TMP/kg/day in divided doses every 6 to 8 hours, <b>or </b>320 mg TMP every 8 hours; treat for a total of 21 days.</p>
<p style="text-indent:-2em;margin-left:8em;">Moderate to severe: IV, Oral: 15 to 20 mg TMP/kg/day in divided doses every 6 to 8 hours; may switch to oral after clinical improvement; treat for a total of 21 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bf60d391-0edd-42b9-833b-70dc8c4157fd">Q-Fever, acute symptomatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Q-Fever (<i>Coxiella burnetii</i>), acute symptomatic (alternative agent):</b>
<b>Note:</b> Treatment is most effective if given within the first 3 days of symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23535757']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23535757'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children &lt;8 years: Limited data available: Dose should be based on severity of illness: Oral: Usual dose range: 8 to 10 mg TMP/kg/day in divided doses twice daily for 14 days; a wider dose range of 4 to 20 mg TMP/kg/day divided twice daily has been suggested to address varying degrees of severity; however, reported pediatric efficacy experience is lacking; monitor patients receiving doses at the high and low end of the range closely for efficacy and possible adverse effects. Maximum dose: 160 mg TMP/<b>dose</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-23535757','lexi-content-ref-AAP.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-23535757','lexi-content-ref-AAP.2021'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7febef5a-46fb-4e6b-a370-93a2d7c9a1c1">Shigellosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Shigellosis (alternative agent):</b>
<b>Note:</b> Not recommended as empiric therapy due to reported resistance; may be used for documented susceptible strains (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-CDC.2012','lexi-content-ref-WHO.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-CDC.2012','lexi-content-ref-WHO.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥2 months, Children, and Adolescents: Oral, IV: 8 to 10 mg TMP/kg/day in divided doses every 12 hours for 3 to 5 days; maximum dose: 160 mg TMP/<b>dose</b>. May divide IV therapy up to every 6 hours. Longer treatment durations of 7 to 10 days have been suggested for immunocompromised patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11170940','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11170940','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5fe294fd-4626-4e48-9579-84675accedc8">Skin and soft tissue infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection (SSTI):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥2 months, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Cellulitis, purulent/fluctuant SSTI: </i>Oral, IV: 8 to 12 mg TMP/kg/day in divided doses every 12 hours; may divide IV therapy every 6 hours; maximum dose: 320 mg TMP/<b>dose</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28657870','lexi-content-ref-24973422','lexi-content-ref-25785967','lexi-content-ref-28535235','lexi-content-ref-23457080']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28657870','lexi-content-ref-24973422','lexi-content-ref-25785967','lexi-content-ref-28535235','lexi-content-ref-23457080'])">Ref</a></span>). Typical duration is ≥5 days for uncomplicated infection but may be extended if clinical response is inadequate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30777258','lexi-content-ref-24973422']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30777258','lexi-content-ref-24973422'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Impetigo, ecthyma</i>: Oral: 8 to 12 mg TMP/kg/day in divided doses every 12 hours for 7 days. Shorter courses of 3 to 5 days have also been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25172376','lexi-content-ref-Bradley.1','lexi-content-ref-24973422','lexi-content-ref-20415992']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25172376','lexi-content-ref-Bradley.1','lexi-content-ref-24973422','lexi-content-ref-20415992'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d30e1f79-4cc9-4f83-8590-fee942eaa71a">
<i>Toxoplasma gondii</i> encephalitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Toxoplasma gondii</i> encephalitis (toxoplasmosis): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Primary prophylaxis: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Patients with HIV: <b>Note: </b>Primary prophylaxis is indicated for <i>T. gondii</i> seropositive patients with CD4 cell percentage &lt;15% if &lt;6 years of age or CD4 count &lt;100 cells/mm<sup>3</sup> if ≥6 years of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.5']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.5'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Infants and Children: Oral: 150 mg TMP/<b>m<sup>2</sup></b>/day; dose may be administered as a single daily dose (preferred) or in divided doses every 12 hours; alternatively, may also be given 3 times weekly for 3 consecutive or alternating days; maximum dose: 160 mg TMP/<b>dose</b>. In HIV-infected or indeterminate infants, continue until 12 months of age regardless of CD4 cell count. In children, continue until patient has been receiving ART for ≥6 months and achieves age-specific target CD4 count (age 1 to &lt;6 years: ≥15%; age ≥6 years: &gt;200 cells/mm<sup>3</sup>) for &gt;3 consecutive months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.5']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.5'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents: Oral: 160 mg TMP daily (preferred) <b>or</b> 160 mg TMP 3 times weekly <b>or</b> 80 mg TMP daily. Continue primary prophylaxis following initiation of ART until CD4 count &gt;200 cells/mm<sup>3</sup> for &gt;3 months; can consider discontinuation in patients with a CD4 count between 100 to 200 cells/mm<sup>3</sup> who are receiving ART and have had an undetectable viral load for ≥3 to 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Recipients of hematopoietic cell transplant (<i>T. gondii</i> seropositive): Infants ≥2 months, Children, and Adolescents: Oral: 150 mg TMP/<b>m<sup>2</sup></b>/day or 5 mg/kg/day; dose may be administered as a single daily dose (preferred) or in divided doses every 12 hours; alternatively, may also be given 3 times weekly; maximum dose: 160 mg TMP/<b>dose</b>. Recommended to be used from engraftment until 6 months post-transplant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33840441']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33840441'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment (alternative agent):</i>
<b>Note: </b>Recommended only until first-line therapy is available or can be tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2','lexi-content-ref-HHS.5','lexi-content-ref-AAP.2021','lexi-content-ref-33840441']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2','lexi-content-ref-HHS.5','lexi-content-ref-AAP.2021','lexi-content-ref-33840441'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: Oral, IV: 10 to 15 mg TMP/kg/day in divided doses every 8 to 12 hours for ≥6 weeks; longer duration may be needed if clinical or radiologic disease is extensive or response is incomplete at 6 weeks; following treatment, patients with HIV should receive chronic maintenance therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2','lexi-content-ref-AAP.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2','lexi-content-ref-AAP.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Chronic maintenance therapy (secondary prophylaxis) (alternative agent):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children: Oral: 150 mg TMP/<b>m<sup>2</sup></b>/day once daily; maximum dose: 160 mg TMP/<b>dose</b>. For patients with HIV, continue until patient has been receiving ART for ≥6 months, has no toxoplasmosis symptoms, and achieves age-specific target CD4 count (age 1 to &lt;6 years: ≥15%; age ≥6 years: &gt;200 cells/mm<sup>3</sup>) for &gt;6 consecutive months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.5','lexi-content-ref-33840441']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.5','lexi-content-ref-33840441'])">Ref</a></span>). <b>Note:</b> Only use when pyrimethamine is unavailable or not tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.5']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.5'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: Oral: 160 mg TMP twice daily <b>or</b>, alternatively, 160 mg TMP once daily. For patients with HIV, continue following initiation of ART until CD4 count &gt;200 cells/mm<sup>3</sup> for &gt;6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>). <b>Note:</b> Once-daily dosing may be associated with an increased risk of relapse; if used, a gradual transition (eg, follow acute treatment with 4 to 6 weeks of 160 mg TMP twice daily before lowering to once-daily dosing) may be beneficial (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5ac615e6-688a-461c-8a9f-5e7703d06ac9">Urinary tract infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment: </i>
<b>Note: </b>Duration of therapy should be individualized based on patient age, severity/extent of infection, and clinical response; typical duration is 7 to 14 days, though may be as short as 3 days in older children and adolescents with uncomplicated cystitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31958969','lexi-content-ref-29292282','lexi-content-ref-Bradley.1','lexi-content-ref-25477258','lexi-content-ref-2513939']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31958969','lexi-content-ref-29292282','lexi-content-ref-Bradley.1','lexi-content-ref-25477258','lexi-content-ref-2513939'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: Infants ≥2 months, Children, and Adolescents: 6 to 12 mg TMP/kg/day in divided doses every 12 hours; maximum dose: 160 mg/<b>dose</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21873693','lexi-content-ref-29292282','lexi-content-ref-25477258','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21873693','lexi-content-ref-29292282','lexi-content-ref-25477258','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">IV: Infants ≥2 months, Children, and Adolescents: 8 to 10 mg TMP/kg/day in divided doses every 6 to 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prophylaxis:</i> Infants ≥2 months, Children, and Adolescents: Oral: 2 to 3 mg TMP/kg/dose once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.2021','lexi-content-ref-24795142','lexi-content-ref-18082208']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.2021','lexi-content-ref-24795142','lexi-content-ref-18082208'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51160224"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Oral, IV:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Dosing is based on pharmacokinetic parameters, limited pediatric studies, adult studies, and expert opinion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1','lexi-content-ref-Golightly.2013','lexi-content-ref-8672842','lexi-content-ref-2678767','lexi-content-ref-14969569','lexi-content-ref-HHS.7','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1','lexi-content-ref-Golightly.2013','lexi-content-ref-8672842','lexi-content-ref-2678767','lexi-content-ref-14969569','lexi-content-ref-HHS.7','lexi-content-ref-Manu.1'])">Ref</a></span>):</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<caption style="text-align:left;">
<b>Dose Adjustments for Kidney Impairment: Oral, IV</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>CrCl </b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>If usual recommended dose is 5 to 12 mg TMP/kg/day in 1 or 2 divided doses </b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>If usual recommended dose is 15 to 20 mg TMP/kg/day in 3 or 4 divided doses</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>If usual recommended dose is 80 mg to 160 mg TMP daily or 160 mg TMP 3 times a week</b></p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">&gt;30 mL/minute/1.73 m<sup>2</sup></p></td>
<td align="left">
<p style="text-indent:0em;">No dosage adjustment necessary.</p></td>
<td align="left">
<p style="text-indent:0em;">No dosage adjustment necessary.</p></td>
<td align="left">
<p style="text-indent:0em;">No dosage adjustment necessary.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">15 to 30 mL/minute/1.73 m<sup>2</sup></p></td>
<td align="left">
<p style="text-indent:0em;">Use with caution and appropriate monitoring.</p>
<p style="text-indent:0em;margin-top:2em;">Administer 50% of daily dose for indication in 1 or 2 divided doses.</p></td>
<td align="left">
<p style="text-indent:0em;">Use with caution and appropriate monitoring.</p>
<p style="text-indent:0em;margin-top:2em;">Administer 50% of daily dose for indication in 2 or 3 divided doses.</p></td>
<td align="left">
<p style="text-indent:0em;">Use with caution and appropriate monitoring.</p>
<p style="text-indent:0em;margin-top:2em;">80 mg TMP once daily or 3 times a week.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">&lt;15 mL/minute/1.73 m<sup>2</sup></p></td>
<td align="left">
<p style="text-indent:0em;">Use not recommended; if used, monitor carefully.</p>
<p style="text-indent:0em;margin-top:2em;">Administer 25% to 50% of daily dose for indication in 1 or 2 divided doses.</p></td>
<td align="left">
<p style="text-indent:0em;">Use not recommended; if used, monitor carefully.</p>
<p style="text-indent:0em;margin-top:2em;">Administer 25% to 50% of daily dose for indication in 1 or 2 divided doses.</p></td>
<td align="left">
<p style="text-indent:0em;">Use not recommended; if used, monitor carefully.</p>
<p style="text-indent:0em;margin-top:2em;">80 mg TMP 3 times a week.</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent: </b>Dialyzable (~44% of TMP and ~57% of SMX removed with low flux filter in adults) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3500644']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3500644'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14969569']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14969569'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>General infections:</i> Oral, IV: 3 to 5 mg TMP/kg/dose every 24 hours; on dialysis days, administer after dialysis; consider administering an additional 2.5 mg TMP/kg dose after intermittent hemodialysis (IHD) sessions if daily dose administered prior to dialysis.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Pneumocystis pneumonia: </i>Oral, IV: 5 mg TMP/kg/dose every 12 hours; on dialysis days, administer after dialysis; consider administering an additional 2.5 mg TMP/kg dose after IHD sessions if daily dose administered prior to dialysis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Pediatric data are lacking; however, based on adult information, not efficiently dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7075646']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7075646'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Oral, IV: Follow dosage recommendations for CrCl &lt;15 mL/minute/1.73 m<sup>2</sup>; if used, monitor carefully (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1','lexi-content-ref-Golightly.2013','lexi-content-ref-Nemecek.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1','lexi-content-ref-Golightly.2013','lexi-content-ref-Nemecek.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection) and consideration of initial loading doses. Close monitoring of response and adverse reactions due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">CVVH/CVVHD/CVVHDF: Children and Adolescents: Oral, IV: Based on adult data, sulfamethoxazole and trimethoprim are substantially removed by CRRT. No dosage adjustment likely necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24910807','lexi-content-ref-20823279','lexi-content-ref-25531772']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24910807','lexi-content-ref-20823279','lexi-content-ref-25531772'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51160225"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Use with caution; use is contraindicated in cases of marked hepatic damage.</p></div>
<div class="block doa drugH1Div" id="F154889"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9785" href="/d/html/9785.html" rel="external">see "Trimethoprim-sulfamethoxazole (co-trimoxazole): Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing: </b>Weight-based dosing recommendations are based on the trimethoprim component.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> Each <b>double-strength</b> tablet contains trimethoprim 160 mg and sulfamethoxazole 800 mg. Each <b>single-strength</b> tablet contains trimethoprim 80 mg and sulfamethoxazole 400 mg. The undiluted IV solution contains trimethoprim 16 mg per mL and sulfamethoxazole 80 mg per mL.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> For outpatients receiving high dose therapy (&gt;5 mg/kg/day trimethoprim component]), monitor serum creatinine and potassium concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24259630']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24259630'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing guidelines:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 1 to 2 double-strength tablets every 12 to 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 8 to 20 mg/kg/day (trimethoprim component) divided every 6 to 12 hours.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="452a5fca-911d-417a-b625-1b0f7a95ccab">
<i>Bartonella</i> spp. infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Bartonella</i> spp. infection (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Not a recommended agent for patients with HIV (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Cat scratch disease, lymphadenitis: <b>Oral: </b>1 double-strength tablet twice daily for 7 to 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Spach.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Spach.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Cat scratch disease, disseminated (CNS infection, neuroretinitis):</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Use in combination with rifampin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Spach.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Spach.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV: </b>160 mg (trimethoprim component) twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Spach.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Spach.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral: </b> 1 double-strength tablet twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Spach.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Spach.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Duration of therapy:</b> 10 to 14 days for CNS infection; 4 to 6 weeks for neuroretinitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Spach.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Spach.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bb1f0aaf-41ff-4651-ad53-d81e2f072c7d">Bite wound infection, prophylaxis or treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bite wound infection, prophylaxis or treatment (animal or human bite) (alternative agent) (off-label use):</b>
<b>Oral:</b> 1 double-strength tablet twice daily; in combination with an appropriate agent for anaerobic coverage. Duration of therapy for prophylaxis is 3 to 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24973422']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24973422'])">Ref</a></span>); duration of therapy for established infection is typically 5 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Baddour.2019a','lexi-content-ref-Baddour.2019b']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Baddour.2019a','lexi-content-ref-Baddour.2019b'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="49929a72-f7cf-4de4-8d52-7a1d857c693e">Brucellosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Brucellosis (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Alterative to preferred therapy; however, preferred in patients who are pregnant and &lt;36 weeks' gestation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31782698','lexi-content-ref-34734902','lexi-content-ref-CDC.2020.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31782698','lexi-content-ref-34734902','lexi-content-ref-CDC.2020.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Neurobrucellosis, endocarditis: <b>Oral: </b>One double-strength tablet twice daily for ≥12 weeks (may be needed for up to 6 months) as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34734902','lexi-content-ref-CDC.2020.2','lexi-content-ref-28768443']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34734902','lexi-content-ref-CDC.2020.2','lexi-content-ref-28768443'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Uncomplicated (nonfocal):<b> Oral: </b>One double-strength tablet twice daily for 6 weeks as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18162038','lexi-content-ref-CDC.2020.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18162038','lexi-content-ref-CDC.2020.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postexposure prophylaxis (high-risk laboratory exposure):</i>
<b>Oral:</b> One double-strength tablet twice daily for 3 weeks as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bbd52e21-dcfe-472c-a480-3587971723ab">Chronic obstructive pulmonary disease, acute exacerbation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic obstructive pulmonary disease, acute exacerbation (alternative agent):</b>
<b>Note:</b> Avoid use in patients with risk factors for <i>Pseudomonas</i> infection or poor outcomes (eg, ≥65 years of age with major comorbidities, FEV<sub>1</sub> &lt;50% predicted, frequent exacerbations) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Sethi.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Sethi.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 1 double-strength tablet every 12 hours for 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GOLD.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GOLD.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2e598d8e-f681-420c-9f01-28a8efdcdac6">Diabetic foot infection, mild to moderate</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetic foot infection, mild to moderate (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For empiric or directed coverage of methicillin-resistant <i>S. aureus</i>. When used as empiric therapy, give as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22619242']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22619242'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 2 double-strength tablets twice daily, usually for 1 to 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22619242','lexi-content-ref-20459324']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22619242','lexi-content-ref-20459324'])">Ref</a></span>).<b></b></p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5d023e55-125d-4860-afd8-9934c605a1da">Diarrhea, infectious</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diarrhea, infectious:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cyclosporiasis (off-label use):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Treatment: <b>Oral:</b> 1 double-strength tablet twice daily for 7 to 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2013','lexi-content-ref-7885125']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2013','lexi-content-ref-7885125'])">Ref</a></span>). A 10-day duration is preferred in solid organ transplant recipients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31145496']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31145496'])">Ref</a></span>) and 14 days for patients with HIV (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Weller.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Weller.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Secondary prophylaxis (patients who are immunocompromised): <b>Oral:</b> 1 double-strength tablet 3 times weekly, starting after completion of a treatment course (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31145496','lexi-content-ref-7944073','lexi-content-ref-10836915']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31145496','lexi-content-ref-7944073','lexi-content-ref-10836915'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cystoisosporiasis (isosporiasis) (off-label use):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Patients who are immunocompetent (usually self-limited; treatment not always indicated): <b>Oral:</b> 1 double-strength tablet twice daily for 7 to 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2017'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Patients who are immunocompromised: <b>Oral, IV:</b> 160 mg (trimethoprim component) 4 times daily for 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31145496','lexi-content-ref-HHS.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31145496','lexi-content-ref-HHS.3'])">Ref</a></span>) <b>or</b> 160 mg (trimethoprim component) twice daily for 7 to 10 days; if symptoms worsen or persist, may increase dose to 160 mg (trimethoprim component) 4 times daily and/or prolong duration to 21 to 28 days. In patients with HIV and CD4 &lt;200 cells/mm<sup>3</sup>, follow treatment with secondary prophylaxis of one double-strength tablet orally 3 times weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Shigellosis (alternative agent)</i>
<i>:</i>
<b>Note:</b> Not recommended for empiric therapy due to widespread resistance:<b> Oral:</b> 1 double-strength tablet twice daily for 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Agha.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Agha.2021'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="65cfe90c-560a-4faa-a54f-70183efe21d9">Endocarditis, treatment, oral step-down therapy in patients who inject drugs</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endocarditis, treatment, oral step-down therapy in patients who inject drugs (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Not first-line treatment; data are limited. Reserve use for patients who inject drugs who had initial clinical improvement with IV treatment for methicillin-resistant <i>S. aureus</i> or penicillin allergy for methicillin-susceptible <i>S. aureus</i> infection but cannot complete IV standard of care therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36043414','lexi-content-ref-31181351','lexi-content-ref-36052413']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36043414','lexi-content-ref-31181351','lexi-content-ref-36052413'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>2 double-strength tablets twice daily for a total duration, including initial IV therapy, of 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36043414']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36043414'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="485d58ca-9e0e-4284-8228-d55fd4f946ff">Intra-abdominal infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-abdominal infection (off-label use) (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Diverticulitis, acute (for uncomplicated infection that meets criteria for outpatient therapy or as step-down therapy after clinical improvement on initial parenteral therapy):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Some experts suggest deferring antibiotics in otherwise healthy immunocompetent patients with mild disease; however, data on this approach in outpatients are limited (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26453777','lexi-content-ref-30664553','lexi-content-ref-28719679','lexi-content-ref-28085573','lexi-content-ref-32073652']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26453777','lexi-content-ref-30664553','lexi-content-ref-28719679','lexi-content-ref-28085573','lexi-content-ref-32073652'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 1 double-strength tablet every 12 hours in combination with metronidazole for 10 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Pemberton.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Pemberton.2021'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="89ceb6d9-1a11-4cf3-be3c-d9863bfad7ac">Intracranial abscess and spinal epidural abscess</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intracranial abscess (brain abscess, intracranial epidural abscess) and spinal epidural abscess (alternative agent for methicillin-resistant <i>S. aureus</i>) (off-label use):</b>
<b>IV:</b> 5 mg/kg/<b>dose</b> (trimethoprim component) every 8 to 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21208910','lexi-content-ref-Sexton2019a']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21208910','lexi-content-ref-Sexton2019a'])">Ref</a></span>). Duration generally ranges from 4 to 8 weeks for brain abscess and spinal epidural abscess and 6 to 8 weeks for intracranial epidural abscess (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Sexton2019a','lexi-content-ref-Sexton.2019b','lexi-content-ref-Southwick.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Sexton2019a','lexi-content-ref-Sexton.2019b','lexi-content-ref-Southwick.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1378dcb0-a2fc-424f-8753-558943d5f1e0">Mastitis, lactational</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mastitis, lactational (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Reserve for patients unable to use first-line agents or for patients at risk for methicillin-resistant <i>S. aureus</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35576513']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35576513'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>1 double-strength tablet twice daily for 10 to 14 days; shorter courses (eg, 5 to 7 days) may be considered for patients with rapid clinical resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35576513','lexi-content-ref-Dixon.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35576513','lexi-content-ref-Dixon.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8713978a-d495-46cd-89da-072b22dab991">Melioidosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Melioidosis (</b>
<i>
<b>Burkholderia pseudomallei </b></i>
<b>infection) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Initial intensive therapy:</i>
<b>Note:</b> For use as a potential add-on to primary therapy [ceftazidime or a carbapenem] in focal disease (eg, CNS, prostate) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23171644']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23171644'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">40 to 60 kg: <b>Oral, IV:</b> 240 mg (trimethoprim component) every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23171644']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23171644'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;60 kg: <b>Oral, IV: </b>320 mg (trimethoprim component) every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23171644']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23171644'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Duration: ≥14 days; a longer duration may be necessary depending on disease severity and site of infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Currie.2021','lexi-content-ref-23171644']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Currie.2021','lexi-content-ref-23171644'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Eradication therapy (begin after completion of initial intensive therapy):</i></p>
<p style="text-indent:-2em;margin-left:6em;">40 to 60 kg: <b>Oral: </b>240 mg (trimethoprim component) every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23171644']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23171644'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;60 kg: <b>Oral: </b>320 mg (trimethoprim component) every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23171644']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23171644'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Duration: ≥3 months; extend to 6 months for bone or CNS involvement. Longer duration may be necessary following vascular surgery with graft for mycotic aneurysm (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Currie.2021','lexi-content-ref-23171644']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Currie.2021','lexi-content-ref-23171644'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="90b4bed4-9c84-419c-9067-b0892c7eeb49">Meningitis, bacterial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningitis, bacterial (alternative agent for methicillin-resistant <i>S. aureus</i>, <i>L. monocytogenes</i>, <i>E. coli</i>, and other Enterobacteriaceae) (off-label use):</b>
<b>IV:</b> 5 mg/kg/<b>dose</b> (trimethoprim component) every 6 to 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20308389','lexi-content-ref-21208910','lexi-content-ref-15494903','lexi-content-ref-28203777','lexi-content-ref-8329509']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20308389','lexi-content-ref-21208910','lexi-content-ref-15494903','lexi-content-ref-28203777','lexi-content-ref-8329509'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b1e4676d-acfb-4622-bd32-467372cbc36c">Nocardiosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nocardiosis (off-label use): Note:</b> Due to concerns for resistance, susceptibility testing should be performed on isolates (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2016']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2016'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cutaneous infection (superficial; no other organ involvement):</i>
<b>Oral:</b> 5 to 10 mg/kg/day (trimethoprim component) in 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Spelman2019b']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Spelman2019b'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pulmonary infection (mild to moderate):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Immunocompetent patients: <b>Oral:</b> 5 to 10 mg/kg/day (trimethoprim component) in 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Spelman2019b']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Spelman2019b'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Immunocompromised patients: <b>Oral:</b> 15 mg/kg/day (trimethoprimcomponent) in 3 to 4 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30817024','lexi-content-ref-Spelman2019b']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30817024','lexi-content-ref-Spelman2019b'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pulmonary infection (severe), CNS, disseminated, or multi-site infection:</i>
<b> IV:</b> 15 mg/kg/day (trimethoprim component) in 3 to 4 divided doses as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30817024','lexi-content-ref-Spelman2019b']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30817024','lexi-content-ref-Spelman2019b'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Duration: Prolonged treatment is required (range: 3 months to ≥1 year [combined parenteral/oral therapy]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30817024','lexi-content-ref-Spelman2019b']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30817024','lexi-content-ref-Spelman2019b'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0021bfed-a0e0-417e-8d87-c3531d3ac075">Osteomyelitis due to methicillin-resistant <i>S. aureus</i></span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteomyelitis due to methicillin-resistant <i>S. aureus</i> (alternative agent) (off-label use):</b>
<b>Oral, IV:</b> 4 mg/kg/<b>dose</b> (trimethoprim component) every 12 hours with rifampin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21208910']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21208910'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2d4cf660-fc6c-4182-9e8b-10ee80fcb30b">Plague</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Plague </b>
<b>(</b>
<i>
<b>Yersinia pestis</b></i>
<b>) (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Consult public health officials for event-specific recommendations.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postexposure prophylaxis: </i>
<b>Oral: </b>5 mg/kg/<b>dose</b> (trimethoprim component) every 12 hours for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34264565']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34264565'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment: </i>
<b>Oral, IV:</b> 5 mg/kg/<b>dose</b> (trimethoprim component) every 8 hours for 7 to 14 days and for at least a few days after clinical resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34264565','lexi-content-ref-Stout.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34264565','lexi-content-ref-Stout.2022'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="33a782fc-bbc8-4f83-9823-06d7e365fe69">
<i>Pneumocystis</i> pneumonia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Pneumocystis</b></i>
<b> pneumonia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prophylaxis, primary and secondary: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Patients with HIV: <b>Oral:</b> 1 double-strength tablet once daily <b>or</b> 1 single-strength tablet once daily (preferred regimens) <b>or</b> 1 double-strength tablet 3 times weekly (alternative regimen). <b>Note:</b> In patients also requiring prophylaxis for toxoplasmosis, 1 double-strength tablet once daily should be used (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.3'])">Ref</a></span>).</p>
<p style="text-indent:0em;margin-left:6em;">
<i>Duration in patients with HIV receiving antiretroviral therapy:</i> Continue until CD4 count &gt;200 cells/mm<sup>3</sup> for &gt;3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.3'])">Ref</a></span>); may consider discontinuing primary prophylaxis in patients with CD4 counts between 100 and 200 cells/mm<sup>3</sup> who are receiving antiretroviral therapy and have had an undetectable viral load for ≥3 to 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20645862','lexi-content-ref-HHS.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20645862','lexi-content-ref-HHS.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Immunocompromised host, HIV-uninfected (eg, transplant recipients, cancer-related, hematopoietic cell transplant [HCT]): <b>Oral:</b> 1 double-strength tablet once daily <b>or </b>1 single-strength tablet once daily (preferred regimens); alternatively, 1 double-strength tablet 3 times weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629','lexi-content-ref-11565082','lexi-content-ref-11486285']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629','lexi-content-ref-11565082','lexi-content-ref-11486285'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Duration after solid organ transplant:</i> ≥6 to 12 months and during periods of increased immunosuppression (eg, treatment for acute rejection). Lifelong prophylaxis may be considered for high-risk recipients (eg, history of <i>Pneumocystis</i>, receipt of lung allograft) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31077616']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31077616'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Duration for cancer-related (including HCT) in patients at high risk for Pneumocystis infection: </i>Duration is at least through periods of significant immunosuppression and/or for ~6 months in allogeneic HCT recipients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629','lexi-content-ref-23412562']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629','lexi-content-ref-23412562'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Moderate to severe infection: <b>IV:</b> 15 to 20 mg/kg/day (trimethoprim component) in 3 or 4 divided doses for 21 days; may switch to oral therapy after clinical improvement.<b> Note:</b> Patients with moderate or severe infection (PaO<sub>2</sub> &lt;70 mm Hg at room air or alveolar-arterial oxygen gradient ≥35 mm Hg) should receive adjunctive glucocorticoids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31077616','lexi-content-ref-21193785','lexi-content-ref-HHS.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31077616','lexi-content-ref-21193785','lexi-content-ref-HHS.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Mild to moderate infection: <b>Oral:</b> 15 to 20 mg/kg/day (trimethoprim component) in 3 divided doses for 21 days <b>or</b> two double-strength tablets 3 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31077616','lexi-content-ref-21193785','lexi-content-ref-HHS.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31077616','lexi-content-ref-21193785','lexi-content-ref-HHS.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Some data suggest lower doses (~10 mg/kg/day [trimethoprim component]) may have similar efficacy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32391402','lexi-content-ref-28893787','lexi-content-ref-28779879']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32391402','lexi-content-ref-28893787','lexi-content-ref-28779879'])">Ref</a></span>). Secondary prophylaxis should be initiated immediately upon completion of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21193785','lexi-content-ref-HHS.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21193785','lexi-content-ref-HHS.3'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1fd32e36-aea8-4922-9fc3-8f98fc89d1d8">Prostatitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostatitis (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Acute bacterial prostatitis</i>: <b>Oral:</b> 1 double-strength tablet twice daily for 4 to 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22619242','lexi-content-ref-Meyrier.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22619242','lexi-content-ref-Meyrier.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Chronic bacterial prostatitis (alternative agent)</i>: <b>Oral:</b> 1 double-strength tablet twice daily for ≥6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22619242','lexi-content-ref-236820','lexi-content-ref-Meyrier.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22619242','lexi-content-ref-236820','lexi-content-ref-Meyrier.2021'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9d1b4c51-5035-4766-b50d-dd4e58990353">Prosthetic joint infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prosthetic joint infection (off-label use):</b>
<b>Note:</b> For oral continuation therapy for methicillin-resistant <i>S. aureus</i> and Enterobacteriaceae (following pathogen-specific IV therapy in patients undergoing 1-stage exchange or debridement with retention of prosthesis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23223583']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23223583'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 1 double-strength tablet twice daily. For <i>S. aureus</i> infections, combine with rifampin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23223583']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23223583'])">Ref</a></span>). Duration is a minimum of 3 months, depending on patient-specific factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Berbari.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Berbari.2022'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ee8efb2f-e456-4469-b78b-759eb66e5e69">Q fever, acute symptomatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Q fever (<i>Coxiella burnetii</i>), acute symptomatic (off-label use): Note:</b> Treatment is most effective if given within the first 3 days of symptoms; alternative agent for patients who are not pregnant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23535757']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23535757'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 1 double-strength tablet twice daily; duration is 14 days for patients who are not pregnant. For patients who are pregnant, consult an infectious diseases expert (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23535757']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23535757'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="11e44d53-87a0-4ecf-9780-beb9ff909af5">Septic arthritis due to methicillin-resistant <i>S. aureus</i></span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Septic arthritis (without prosthetic material) due to methicillin-resistant <i>S. aureus</i> (following initial IV therapy with an appropriate antibiotic) (off-label use): Oral:</b> 2 double-strength tablets twice daily or 4 mg/kg/dose (trimethoprim component) twice daily (maximum: 320 mg [trimethoprim component]/dose) for completion of 3- to 4-week total treatment course (IV and oral) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Goldenberg.2019','lexi-content-ref-21208910']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Goldenberg.2019','lexi-content-ref-21208910'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8597b7bf-d38b-46ed-ae30-27103563bc5c">Sexually transmitted infections</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sexually transmitted infections:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Epididymitis in patients ≥35 years of age and who are at low risk for sexually transmitted infections (ie, likely to be caused by enteric organisms) (alternative agent) (off-label use):</i>
<b>Oral:</b> 1 double-strength tablet twice daily for 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Eyre.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Eyre.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Granuloma inguinale (donovanosis) (alternative agent) (off-label use):</i>
<b> Oral:</b> 1 double-strength tablet every 12 hours for &gt;3 weeks and until lesions have healed. <b>Note:</b> If symptoms do not improve within the first few days of therapy, another agent can be added (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5fe294fd-4626-4e48-9579-84675accedc8">Skin and soft tissue infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Abscess:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Systemic antibiotics may be reasonably withheld in healthy, immunocompetent patients with a single, small abscess that has been drained if they are clinically well and have no indwelling device, risk factors for endocarditis, or risk for methicillin-resistant <i>S.</i>
<i> aureus</i> transmission (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24973422','lexi-content-ref-Spelman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24973422','lexi-content-ref-Spelman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral: </b>1 to 2 double-strength tablets twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21208910','lexi-content-ref-24973422']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21208910','lexi-content-ref-24973422'])">Ref</a></span>). For patients who weigh &gt;70 kg, some experts prefer the higher dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Spelman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Spelman.1'])">Ref</a></span>). Treat for ≥5 days but may extend up to 14 days depending on severity and clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24973422','lexi-content-ref-Spelman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24973422','lexi-content-ref-Spelman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Cellulitis, purulent or with risk for methicillin-resistant <i>S. aureus</i>:</b>
<b>Oral: </b>1 to 2 double-strength tablets twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21208910','lexi-content-ref-24973422','lexi-content-ref-25785967']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21208910','lexi-content-ref-24973422','lexi-content-ref-25785967'])">Ref</a></span>). For patients who weigh &gt;70 kg, some experts prefer the higher dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Spelman.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Spelman.2018'])">Ref</a></span>). Some experts suggest adding an additional agent (eg, amoxicillin, cephalexin) for coverage of beta-hemolytic streptococci (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21208910','lexi-content-ref-24973422']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21208910','lexi-content-ref-24973422'])">Ref</a></span>). Treat for ≥5 days but may extend up to 14 days depending on severity and clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24973422','lexi-content-ref-Spelman.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24973422','lexi-content-ref-Spelman.2018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Cellulitis, long-term suppression of recurrent infection: Note:</b> For patients with recurrent presumptive staphylococcal cellulitis at the same anatomic site despite addressing predisposing factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Spelman.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Spelman.2018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral: </b>1 double-strength tablet twice daily after completion of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Spelman.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Spelman.2018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Impetigo or ecthyma if methicillin-resistant <i>S. aureus</i></b>
<b> is suspected or confirmed: Note: </b>For impetigo, reserve systemic therapy for patients with numerous lesions or in outbreak settings to decrease transmission (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24973422']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24973422'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 1 to 2 double-strength tablets twice daily for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Baddour.2018','lexi-content-ref-24973422']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Baddour.2018','lexi-content-ref-24973422'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a0ae1fc5-2f2e-4d8b-98f2-20932ab0eea9">Spontaneous bacterial peritonitis, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Spontaneous bacterial peritonitis, prophylaxis (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For secondary prophylaxis in patients with prior spontaneous bacterial peritonitis (SBP) and primary prophylaxis in patients at high risk for SBP (eg, low ascites protein [&lt;1.5 g/dL] with advanced liver failure or impaired kidney function). Some experts also use for prophylaxis during hospitalization in patients with cirrhosis and either acute GI bleeding or ascites protein &lt;1 g/dL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33942342','lexi-content-ref-Runyon.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33942342','lexi-content-ref-Runyon.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 1 double-strength tablet once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24612987','lexi-content-ref-Runyon.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24612987','lexi-content-ref-Runyon.1'])">Ref</a></span>). For patients with cirrhosis and acute GI bleeding, some experts use 1 double-strength tablet twice daily following, or as an alternative to, parenteral prophylaxis, for a total antibiotic duration of 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33942342','lexi-content-ref-Runyon.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33942342','lexi-content-ref-Runyon.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fd74af30-8028-468f-a2b9-a199970f94cb">
<i>Stenotrophomonas maltophilia</i> infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Stenotrophomonas maltophilia </b></i>
<b>infection</b>
<b> (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Cystitis: IV, Oral:</b> 160 mg (trimethoprim component) every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34864936']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34864936'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hospital-acquired or ventilator-associated pneumonia, bacteremia: IV, Oral:</b> 8 to 12 mg/kg/day (trimethoprim component) in 2 or 3 divided doses, as part of a combination regimen when appropriate; some experts suggest considering a maximum dose of 960 mg (trimethoprim component)/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34864936']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34864936'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Duration depends on site of infection; some experts recommend 14 days for bacteremia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Lewis.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Lewis.2021'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fa7b6aef-11c5-4b72-97a0-a39f0f808184">Surgical prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical prophylaxis (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Reserve use for high-risk cystoscopy (eg, urine culture positive or unavailable, preoperative catheter, or placement of prosthetic material), cystoscopy with manipulation (eg, transrectal prostate biopsy), or upper GU tract instrumentation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Anderson.2021','lexi-content-ref-23327981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Anderson.2021','lexi-content-ref-23327981'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>1 double-strength tablet within 60 to 120 minutes prior to surgical incision (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Anderson.2021','lexi-content-ref-23327981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Anderson.2021','lexi-content-ref-23327981'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d30e1f79-4cc9-4f83-8590-fee942eaa71a">
<i>Toxoplasma gondii</i> encephalitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Toxoplasma gondii</b></i>
<b> encephalitis (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Primary prophylaxis:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Patients with HIV: <b>Oral:</b> 1 double-strength tablet once daily (preferred) <b>or</b> 1 double-strength tablet 3 times weekly <b>or</b> 1 single-strength tablet once daily; primary prophylaxis is indicated for <i>T. gondii</i> IgG-seropositive patients with CD4 count &lt;100 cells/mm<sup>3</sup>. Continue primary prophylaxis following initiation of antiretroviral therapy (ART) until CD4 count &gt;200 cells/mm<sup>3</sup> for &gt;3 months; some experts discontinue primary prophylaxis in patients with a CD4 count between 100 to 200 cells/mm<sup>3</sup> who are receiving ART and have had an undetectable viral load for ≥3 to 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Solid organ transplant recipients: <b>Oral:</b> 1 double-strength tablet 3 times weekly <b>or </b>1 single-strength tablet once daily; primary prophylaxis is indicated for donor-seropositive/recipient-seronegative (D+/R−) cardiac recipients for at least 12 months; prophylaxis may be considered for D+/R− noncardiac recipients with duration dependent on patient-specific factors and/or institutional protocols (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30900295','lexi-content-ref-37080658']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30900295','lexi-content-ref-37080658'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment (alternative agent):</i>
<b>Oral, IV:</b> 10 mg/kg/day (trimethoprim component) in 2 divided doses for at least 6 weeks; longer duration may be needed if clinical or radiologic disease is extensive or response is incomplete at 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30900295','lexi-content-ref-HHS.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30900295','lexi-content-ref-HHS.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Secondary prophylaxis (chronic maintenance therapy) (alternative agent):</i>
<b>Oral:</b> 1 double-strength tablet twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30900295','lexi-content-ref-HHS.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30900295','lexi-content-ref-HHS.3'])">Ref</a></span>) <b>or</b>, alternatively, 1 double-strength tablet once daily (lower dose may be associated with increased relapse risk) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.3'])">Ref</a></span>). For patients with HIV, continue following initiation of ART until CD4 count &gt;200 cells/mm<sup>3</sup> for &gt;6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.3'])">Ref</a></span>); for solid organ transplant recipients, continue lifelong (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30900295']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30900295'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5ac615e6-688a-461c-8a9f-5e7703d06ac9">Urinary tract infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cystitis, acute uncomplicated or acute simple cystitis (infection limited to the bladder without signs/symptoms of upper tract, prostate, or systemic infection), treatment:</i>
<b>Note:</b> Avoid use if resistance prevalence is &gt;20% or if patient has risk factors for multidrug-resistant gram-negative infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hooton.2021a','lexi-content-ref-Hooton.2021b']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hooton.2021a','lexi-content-ref-Hooton.2021b'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 1 double-strength tablet twice daily; treat females for 3 days and males for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hooton.2021a','lexi-content-ref-Hooton.2021b','lexi-content-ref-21292654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hooton.2021a','lexi-content-ref-Hooton.2021b','lexi-content-ref-21292654'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cystitis, prophylaxis for recurrent infection:</i>
<b>Note:</b> May be considered in nonpregnant women with bothersome, frequently recurrent cystitis despite nonantimicrobial preventive measures. The optimal duration has not been established; duration ranges from 3 to 12 months, with periodic reassessment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31042112','lexi-content-ref-Hooton.2021c']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31042112','lexi-content-ref-Hooton.2021c'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous prophylaxis: <b>Oral:</b> One-half of a single-strength tablet once daily or 3 times weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31042112','lexi-content-ref-6992677']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31042112','lexi-content-ref-6992677'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Postcoital prophylaxis (females with cystitis temporally related to sexual intercourse):<b> Oral:</b> One-half to 1 single-strength tablet as a single dose immediately before or after sexual intercourse (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31042112','lexi-content-ref-2197450']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31042112','lexi-content-ref-2197450'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Urinary tract infection, complicated (including pyelonephritis) (outpatient targeted therapy [if the isolate is known to be susceptible]):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 1 double-strength tablet twice daily for 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21292654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21292654'])">Ref</a></span>); for patients who have a rapid response to treatment, some experts treat for 7 to 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hooton.2021d']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hooton.2021d'])">Ref</a></span>). <b>Note:</b> Oral therapy should generally follow appropriate parenteral therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hooton.2021d','lexi-content-ref-21292654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hooton.2021d','lexi-content-ref-21292654'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990802"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Weight-based dosing recommendations are based on the trimethoprim component. Each <b>double-strength</b>
<b>(DS)</b> tablet contains trimethoprim 160 mg and sulfamethoxazole 800 mg. Each <b>single-strength</b>
<b>(SS)</b> tablet contains trimethoprim 80 mg and sulfamethoxazole 400 mg.</p>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Sulfamethoxazole/Trimethoprim Dose Adjustments for Kidney Impairment - Oral</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center" colspan="5">
<p style="text-indent:0em;">Dose Adjustments for Kidney Impairment<sup class="footnote-number">a</sup>: Oral<sup class="footnote-number">b</sup></p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;">CrCl (mL/minute)</p></th>
<th align="center">
<p style="text-indent:0em;">If usual recommended dose is 1 DS tablet every 24 hours or 3 times per week</p></th>
<th align="center">
<p style="text-indent:0em;">If usual recommended dose is 1 DS tablet every 12 hours</p></th>
<th align="center">
<p style="text-indent:0em;">If usual recommended dose is 2 DS tablets every 12 hours</p></th>
<th align="center">
<p style="text-indent:0em;">If usual recommended dose is 2 DS tablets every 8 hours</p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="left" colspan="5" valign="middle">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup>Expert opinion derived from Golightly 2013, HHS (OI adult 2020), Nahata 1995, Nemecek 2019</p></td></tr>
<tr>
<td align="left" colspan="5" valign="middle">
<p style="text-indent:0em;">
<sup>b</sup>Abbreviations: DS: Double strength; SS: Single strength.</p></td></tr>
<tr>
<td align="left" colspan="5" valign="middle">
<p style="text-indent:0em;">
<sup>c</sup>For severe infections, some experts recommend giving unadjusted doses for the first 1 to 2 days (Nahata 1995).</p></td></tr>
<tr>
<td align="left" colspan="5" valign="middle">
<p style="text-indent:0em;">
<sup>d</sup>Recommended by HHS (OI adult 2020) for treatment of <i>Pneumocystis</i> pneumonia in dialysis patients (administer once daily [on dialysis days administer post HD]).</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">&gt;30</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary.</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary.</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary.</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">15 to 30<sup class="footnote-number">c</sup></p></td>
<td align="center">
<p style="text-indent:0em;">Reduce dose to ~50% of usual dose.</p>
<p style="text-indent:0em;">Example: 1 SS tablet every 24 hours or 3 times per week</p></td>
<td align="center">
<p style="text-indent:0em;">Reduce dose to ~50% of usual dose.</p>
<p style="text-indent:0em;">Example: 1 DS tablet once, followed by 1 SS tablet every 12 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Reduce dose to ~50% of usual dose.</p>
<p style="text-indent:0em;">Example: 1 DS tablet every 12 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Reduce dose to ~50% of usual dose.</p>
<p style="text-indent:0em;">Example: 2 DS tablets every 12 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&lt;15</p></td>
<td align="center">
<p style="text-indent:0em;">Reduce dose to ~25 to 50% of usual dose. Use with caution and appropriate monitoring.</p>
<p style="text-indent:0em;">Example: 1 SS tablet every 24 hours or 3 times per week</p></td>
<td align="center">
<p style="text-indent:0em;">Reduce dose to ~25 to 50% of usual dose. Use with caution and appropriate monitoring.</p>
<p style="text-indent:0em;">Example: 1 DS tablet once, followed by 1 SS tablet every 12 or 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Reduce dose to ~25 to 50% of usual dose. Use with caution and appropriate monitoring.</p>
<p style="text-indent:0em;">Example: 1 DS tablet every 12 hours <b>or</b> 1 DS tablet once, followed by 1 SS tablet every 12 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Reduce dose to ~25 to 50% of usual dose. Use with caution and appropriate monitoring.</p>
<p style="text-indent:0em;">Example: 1 to 2 DS tablets every 12 hours <b>or </b> 2 DS tablets every 24 hours<sup class="footnote-number">d</sup></p></td></tr></tbody></table>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Sulfamethoxazole/Trimethoprim Dose Adjustments for Kidney Impairment - IV</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center" colspan="4">
<p style="text-indent:0em;">Dose Adjustments for Kidney Impairment<sup class="footnote-number">a</sup>: IV</p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;">CrCl (mL/minute)</p></th>
<th align="center">
<p style="text-indent:0em;">If usual recommended daily dose is 10 mg/kg/day (trimethoprim component)</p></th>
<th align="center">
<p style="text-indent:0em;">If usual recommended daily dose is 8 to 12 mg/kg/day (trimethoprim component)</p></th>
<th align="center">
<p style="text-indent:0em;">If usual recommended daily dose is 15 to 20 mg/kg/day (trimethoprim component)</p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="left" colspan="4" valign="middle">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup>Expert opinion derived from Golightly 2013, HHS (OI adult 2020), Nahata 1995, Nemecek 2019.</p></td></tr>
<tr>
<td align="left" colspan="4" valign="middle">
<p style="text-indent:0em;">
<sup>b</sup>In severe infections, some experts recommend giving unadjusted doses for the first 1 to 2 days (Nahata 1995).</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">&gt;30</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary.</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary.</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">15 to 30<sup class="footnote-number">b</sup></p></td>
<td align="center">
<p style="text-indent:0em;">Reduce dose to ~50% of usual dose.</p>
<p style="text-indent:0em;">Example: 5 mg/kg once daily</p></td>
<td align="center">
<p style="text-indent:0em;">Reduce dose to ~50% of usual dose.</p>
<p style="text-indent:0em;">Example: 4 to 6 mg/kg/<b>day</b> in 2 divided doses</p></td>
<td align="center">
<p style="text-indent:0em;">Reduce dose to ~50% of usual dose.</p>
<p style="text-indent:0em;">Example: 7.5 to 10 mg/kg/<b>day</b> in 2 to 4 divided doses</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&lt;15</p></td>
<td align="center">
<p style="text-indent:0em;">Reduce dose to ~25 to 50% of usual dose. Use with caution and appropriate monitoring.</p>
<p style="text-indent:0em;">Example: 2.5 to 5 mg/kg once daily. <b>Note: </b>When treating toxoplasmosis encephalitis, use 5 mg/kg once daily or use alternative agent (HHS [OI Adult 2020]</p></td>
<td align="center">
<p style="text-indent:0em;">Reduce dose to ~25 to 50% of usual dose. Use with caution and appropriate monitoring.</p>
<p style="text-indent:0em;">Example: 2 to 3 mg/kg once daily <b>or </b> 4 to 6 mg/kg every 24 to 48 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Reduce dose to ~25 to 50% of usual dose. Use with caution and appropriate monitoring.</p>
<p style="text-indent:0em;">Example: 4 to 5 mg/kg once daily <b>or</b> 7.5 to 10 mg/kg every 24 to 48 hours</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Dialyzable (44% of trimethoprim and 57% sulfamethoxazole and its metabolites over 4 hours utilizing a low-flux filter (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3500644']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3500644'])">Ref</a></span>)):</p>
<p style="text-indent:-2em;margin-left:4em;">Oral, IV: Follow dose recommendations for patients with CrCl &lt;15 mL/minute not on dialysis; doses due on dialysis days should be administered after hemodialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Golightly.2013','lexi-content-ref-HHS.7']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Golightly.2013','lexi-content-ref-HHS.7'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> If treating <i>Pneumocystis</i> pneumonia, consider utilizing therapeutic drug monitoring to optimize therapy (target trimethoprim concentration: 5 to 8 mcg/mL) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.7']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.7'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Oral, IV: Not efficiently dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7075646']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7075646'])">Ref</a></span>). Follow dose recommendations for a patient with a CrCl &lt;15 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7075646','lexi-content-ref-2488182']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7075646','lexi-content-ref-2488182'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> If treating <i>Pneumocystis</i> pneumonia, consider utilizing therapeutic drug monitoring to optimize therapy (target trimethoprim concentration: 5 to 8 mcg/mL) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.7']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.7'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations assume high-flux dialyzers and flow rates of ~1,500 to 3,000 mL/hour, unless otherwise noted. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection). Close monitoring of response and adverse reactions due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">CVVH/CVVHD/CVVHDF: Oral, IV: Sulfamethoxazole and trimethoprim are substantially removed by CRRT (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20823279','lexi-content-ref-25531772']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20823279','lexi-content-ref-25531772'])">Ref</a></span>). No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24910807','lexi-content-ref-20823279']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24910807','lexi-content-ref-20823279'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained low-efficiency diafiltration):</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection). Close monitoring of response and adverse reactions due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral, IV (blood and dialysate flow rates 170 mL/minute; 6- to 8-hour session): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24910807','lexi-content-ref-23551893']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24910807','lexi-content-ref-23551893'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987999"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The hepatic dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Matt Harris, PharmD, MHS, BCPS, FAST; Jeong Park, PharmD, MS, BCTXP, FCCP, FAST; Arun Jesudian, MD; Sasan Sakiani, MD.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> The manufacturer's labeling states use is contraindicated in patients with marked hepatic damage (not defined); however, use in patients with any degree of hepatic dysfunction is generally considered appropriate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOH'])">Ref</a></span>). Additionally, it should be noted that use of prophylactic sulfamethoxazole/trimethoprim doses in patients with varying degrees of hepatic impairment may be associated with mild self-limiting adverse effects (eg, mild skin rash, epigastric pain, diarrhea) and renal dysfunction that resolved with discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33942342','lexi-content-ref-16444382','lexi-content-ref-34983426','lexi-content-ref-20633946','lexi-content-ref-24612987','lexi-content-ref-7887554']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33942342','lexi-content-ref-16444382','lexi-content-ref-34983426','lexi-content-ref-20633946','lexi-content-ref-24612987','lexi-content-ref-7887554'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic impairment prior to treatment initiation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Child-Turcotte-Pugh class A to C:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33942342','lexi-content-ref-16444382','lexi-content-ref-34983426','lexi-content-ref-20633946','lexi-content-ref-24612987','lexi-content-ref-7887554']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33942342','lexi-content-ref-16444382','lexi-content-ref-34983426','lexi-content-ref-20633946','lexi-content-ref-24612987','lexi-content-ref-7887554'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment in patients with chronic, worsening hepatic function during treatment (eg, progression from Child-Turcotte-Pugh class A to B):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Progression from baseline to Child-Turcotte-Pugh class A to C:</b> No dosage adjustment necessary; however, avoid use in patients with suspected or confirmed sulfamethoxazole-induced liver injury unless the benefits outweigh the risks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24879980','lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24879980','lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute worsening of hepatic function (eg, requiring hospitalization): </b>No dosage adjustment necessary; however, consider discontinuation of sulfamethoxazole/trimethoprim therapy in patients with suspected sulfamethoxazole-induced liver injury unless the benefits outweigh the risks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24879980','lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24879980','lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p></div>
<div class="block arsc drugH1Div" id="F54972568"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Clostridioides difficile infection</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<i>Clostridioides difficile</i> infection (CDI) has occurred with sulfamethoxazole/trimethoprim, specifically including <b>diarrhea</b>, <b>abdominal pain</b>, and <b>
<i>Clostridioides difficile</i> colitis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8304370']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8304370'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; may start on the first day of antibiotic therapy or up to 3 months postantibiotic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22146873','lexi-content-ref-29053792']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22146873','lexi-content-ref-29053792'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Antibiotic exposure (highest risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Long durations in a hospital or other health care setting (recent or current) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Immunocompromised conditions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• A serious underlying condition (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• GI surgery/manipulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29462280','lexi-content-ref-27216385']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29462280','lexi-content-ref-27216385'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Antiulcer medications (eg, proton pump inhibitors and H2 blockers) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Chemotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Drug-induced liver injury</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The most typical pattern of drug-induced liver injury (<b>hepatotoxicity</b>) observed with sulfamethoxazole/trimethoprim is a mixed hepatocellular cholestasis. Cholestasis without inflammation, hepatocellular necrosis (including fatalities), and <b>hepatic failure</b> have also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18637204','lexi-content-ref-3501774','lexi-content-ref-7393813','lexi-content-ref-7202951']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18637204','lexi-content-ref-3501774','lexi-content-ref-7393813','lexi-content-ref-7202951'])">Ref</a></span>). Some cases may be manifestations of drug reaction with eosinophilia and systemic symptoms (DRESS) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3501774','lexi-content-ref-16165719','lexi-content-ref-25754159','lexi-content-ref-31495421','lexi-content-ref-14712321','lexi-content-ref-20949552']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3501774','lexi-content-ref-16165719','lexi-content-ref-25754159','lexi-content-ref-31495421','lexi-content-ref-14712321','lexi-content-ref-20949552'])">Ref</a></span>). May also cause mild symptoms with elevated aminotransferases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18637204']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18637204'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non-dose-related; immunologic. Delayed hypersensitivity reactions, including hepatotoxicity associated with DRESS, are mediated by T-cells which may be induced by the toxic hydroxylamine and nitroso metabolites of sulfonamide antimicrobials (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31495421','lexi-content-ref-1678095']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31495421','lexi-content-ref-1678095'])">Ref</a></span>). Other immune mechanisms have been suggested, including action of complement within the immune complex disease or binding of complement activating antibodies to membranes of hepatocytes or bile ducts (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3501774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3501774'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Intermediate; most cases occur 1 to 3 weeks after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18637204','lexi-content-ref-14712321']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18637204','lexi-content-ref-14712321'])">Ref</a></span>). Upon rechallenge, symptoms may develop more rapidly, often within 3 days of initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6331808']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6331808'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• African Americans (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28762375','lexi-content-ref-32270503']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28762375','lexi-content-ref-32270503'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Genetic risk factors (ie, HLA-B*35:01 in African Americans; HLA-B*14:01 in European Americans) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32270503']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32270503'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with HIV (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32270503']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32270503'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hematologic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Various blood dyscrasias (including fatalities) have been reported with sulfamethoxazole/trimethoprim, including <b>agranulocytosis</b>, <b>hemolytic anemia</b>, <b>leukopenia</b>, and <b>thrombocytopenia</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17470834','lexi-content-ref-21175904','lexi-content-ref-15996741','lexi-content-ref-28905389','lexi-content-ref-30549322','lexi-content-ref-29121838']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17470834','lexi-content-ref-21175904','lexi-content-ref-15996741','lexi-content-ref-28905389','lexi-content-ref-30549322','lexi-content-ref-29121838'])">Ref</a></span>). Some cases may be manifestations of a hypersensitivity drug reaction with eosinophilia and systemic symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10877016']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10877016'])">Ref</a></span>). Thrombocytopenia usually resolves within 1 week following discontinuation of therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non-dose-related. Thrombocytopenia is an immune-mediated process caused by platelet destruction by drug-dependent platelet antibodies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29492352']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29492352'])">Ref</a></span>). Hemolytic anemia is also immune-related (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21175904']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21175904'])">Ref</a></span>). The pathogenesis for agranulocytosis is unknown, although in some cases an immune-mediated mechanism may be responsible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28879784']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28879784'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; ranges from 6 days up to 5 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9205827']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9205827'])">Ref</a></span>). Upon rechallenge, symptoms may develop within 1 hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6230976']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6230976'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• HIV/AIDS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6230976']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6230976'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Glucose-6-phosphate dehydrogenase deficiency may be at risk for the development of hemolytic anemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2498187','lexi-content-ref-10157546']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2498187','lexi-content-ref-10157546'])">Ref</a></span>); although, most patients are able to tolerate the drug (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3495027']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3495027'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hyperkalemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperkalemia</b> may occur with sulfamethoxazole/trimethoprim and be life threatening (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8328737']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8328737'])">Ref</a></span>); usually reversible following discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11200867','lexi-content-ref-8328737']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11200867','lexi-content-ref-8328737'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; trimethoprim blocks sodium channels in the distal nephron, inhibiting potassium secretion. Results in decreased renal potassium excretion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8328738']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8328738'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Variable; usually occurs within 5 to 10 days after sulfamethoxazole/trimethoprim is initiated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11200867','lexi-content-ref-8328737']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11200867','lexi-content-ref-8328737'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• High doses (trimethoprim 20 mg/kg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12924488','lexi-content-ref-10738846']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12924488','lexi-content-ref-10738846'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12924488','lexi-content-ref-10738846']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12924488','lexi-content-ref-10738846'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12924488','lexi-content-ref-10738846']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12924488','lexi-content-ref-10738846'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypoaldosteronism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12924488','lexi-content-ref-10738846']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12924488','lexi-content-ref-10738846'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of medications causing or exacerbating hyperkalemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12924488','lexi-content-ref-10738846']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12924488','lexi-content-ref-10738846'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypoglycemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypoglycemia</b> may occur with sulfamethoxazole/trimethoprim and be life threatening (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21375132','lexi-content-ref-16500599']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21375132','lexi-content-ref-16500599'])">Ref</a></span>); usually reversible following discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10826870']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10826870'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Proposed to be related to the sulfamethoxazole component binding to receptors on the pancreatic islet cells and causing the release of insulin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9184713']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9184713'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; range from 1.5 hours to 5 days after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10826870']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10826870'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Kidney or hepatic impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9184713','lexi-content-ref-10826870','lexi-content-ref-21375132']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9184713','lexi-content-ref-10826870','lexi-content-ref-21375132'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prolonged fasting conditions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9184713','lexi-content-ref-10826870','lexi-content-ref-21375132']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9184713','lexi-content-ref-10826870','lexi-content-ref-21375132'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Malnourished (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9184713','lexi-content-ref-10826870','lexi-content-ref-21375132']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9184713','lexi-content-ref-10826870','lexi-content-ref-21375132'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant medications that decrease plasma glucose levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9184713','lexi-content-ref-10826870','lexi-content-ref-21375132','lexi-content-ref-25179404']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9184713','lexi-content-ref-10826870','lexi-content-ref-21375132','lexi-content-ref-25179404'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hyponatremia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Severe and symptomatic <b>hyponatremia</b> may occur with sulfamethoxazole/trimethoprim and be life threatening (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3873890']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3873890'])">Ref</a></span>); usually reversible following discontinuation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27542610']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27542610'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose-related; large volume of fluid required for IV infusion and/or due to diuretic actions (blockade of epithelial sodium channels in the distal nephron) of trimethoprim (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3873890','lexi-content-ref-23891358','lexi-content-ref-27542610']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3873890','lexi-content-ref-23891358','lexi-content-ref-27542610'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Rapid; ~5 days after initiation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27542610']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27542610'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Dose (trimethoprim &gt;8 mg/kg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27542610']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27542610'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Delayed hypersensitivity reactions may occur with sulfamethoxazole/trimethoprim, including maculopapular <b>skin rash</b>, <b>fixed drug eruption</b>, and severe cutaneous adverse reactions (SCARs) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24750132','lexi-content-ref-22053600']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24750132','lexi-content-ref-22053600'])">Ref</a></span>). SCARs include<b> acute generalized exanthematous pustulosis</b>, <b>drug reaction with eosinophilia and systemic symptoms</b> (DRESS), <b>Stevens-Johnson syndrome</b> (SJS), <b>Sweet’s syndrome, </b>and <b>toxic epidermal necrolysis</b> (TEN) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12861854','lexi-content-ref-19221284','lexi-content-ref-23855313','lexi-content-ref-29758282','lexi-content-ref-17805350','lexi-content-ref-31400461']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12861854','lexi-content-ref-19221284','lexi-content-ref-23855313','lexi-content-ref-29758282','lexi-content-ref-17805350','lexi-content-ref-31400461'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non-dose-related; immunologic. T-cell mediated, which may be induced by the toxic hydroxylamine and nitroso metabolites of sulfonamide antimicrobials (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31495421','lexi-content-ref-31899808']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31495421','lexi-content-ref-31899808'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Variable; typically occur days to weeks after drug exposure but may occur more rapidly (usually within 1 to 4 days) upon reexposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-26120552','lexi-content-ref-29876667']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-26120552','lexi-content-ref-29876667'])">Ref</a></span>). In patients with HIV/AIDS, a morbilliform reaction with fever usually occurs 1 to 2 weeks after initiation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31700852']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31700852'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• HIV/AIDS (most often a maculopapular rash, often associated with fever) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12077579','lexi-content-ref-31700852','lexi-content-ref-16912251']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12077579','lexi-content-ref-31700852','lexi-content-ref-16912251'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• <b>Note:</b> Cross-reactivity between antibiotic sulfonamides and nonantibiotic sulfonamides may not occur, or at the very least this potential is extremely low (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15303450','lexi-content-ref-31495421','lexi-content-ref-15242722','lexi-content-ref-23943179']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15303450','lexi-content-ref-31495421','lexi-content-ref-15242722','lexi-content-ref-23943179'])">Ref</a></span>). Drugs that should be avoided in patients who develop hypersensitivity reactions to sulfamethoxazole-trimethoprim include other sulfonamide antimicrobials (regardless of route of administration), dapsone, fosamprenavir, darunavir, and sulfasalazine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25985401','lexi-content-ref-31495421','lexi-content-ref-20413982']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25985401','lexi-content-ref-31495421','lexi-content-ref-20413982'])">Ref</a></span>). In addition, trimethoprim should also be avoided, as it is unknown whether this drug may have contributed or been responsible for the initial reaction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31495421']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31495421'])">Ref</a></span>). In patients with serious reactions (eg, SJS/TEN, DRESS), some clinicians may elect to avoid all sulfonamide medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31495421']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31495421'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (immediate)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Immediate <b>hypersensitivity reactions</b> may occur with sulfamethoxazole/trimethoprim, including <b>urticaria</b>, <b>angioedema</b>, and <b>anaphylaxis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31796504','lexi-content-ref-3237218','lexi-content-ref-25201401','lexi-content-ref-9027435']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31796504','lexi-content-ref-3237218','lexi-content-ref-25201401','lexi-content-ref-9027435'])">Ref</a></span>). The sulfonamide component is often implicated as the causative agent, but some patients may be reacting to the trimethoprim component (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9641580']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9641580'])">Ref</a></span>). An immediate hypersensitivity reaction (“anaphylactic-like”) can occur in patients with HIV/AIDS that may resemble sepsis, with fever and hypotension; in some of these patients, pulmonary infiltrates and rash may be present (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25999169']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25999169'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non-dose-related; immunologic (ie, IgE-mediated with antibodies to sulfamethoxazole and trimethoprim) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3608139','lexi-content-ref-3237218']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3608139','lexi-content-ref-3237218'])">Ref</a></span>). The N1-substitute and not the sulfonamide group has been found to have direct specificity to IgE antibodies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31495421']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31495421'])">Ref</a></span>). The mechanism for anaphylactic-like reactions in patients with HIV/AIDS is not known (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25999169']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25999169'])">Ref</a></span>), although it may be caused by higher levels of IgE and tumor necrosis factor in patients with AIDS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2287564']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2287564'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; typically occur within 1 hour of administration but may occur up to 6 hours after exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3237218']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3237218'])">Ref</a></span>). Anaphylactic-like reactions usually occur within 4 hours of administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25999169']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25999169'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• HIV/AIDS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29876667','lexi-content-ref-25999169']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29876667','lexi-content-ref-25999169'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• <b>Note:</b> Cross-reactivity between antibiotic sulfonamides and nonantibiotic sulfonamides may not occur, or at the very least this potential is extremely low (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15303450','lexi-content-ref-31495421','lexi-content-ref-15242722','lexi-content-ref-23943179']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15303450','lexi-content-ref-31495421','lexi-content-ref-15242722','lexi-content-ref-23943179'])">Ref</a></span>). Cross-reactions due to antibody production (anaphylaxis) are unlikely to occur with nonantibiotic sulfonamides and antibiotic sulfonamides (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31495421']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31495421'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Kernicterus</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Sulfa antibiotics have been shown to displace bilirubin from protein binding sites, which may potentially lead to <b>hyperbilirubinemia</b> and <b>kernicterus</b> in neonates and young infants. There are limited data with sulfamethoxazole; therefore, the risk for kernicterus is extrapolated from data with sulfisoxazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-13553575','lexi-content-ref-Odell1958','lexi-content-ref-5561865','lexi-content-ref-13370229','lexi-content-ref-24099411','lexi-content-ref-3190184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-13553575','lexi-content-ref-Odell1958','lexi-content-ref-5561865','lexi-content-ref-13370229','lexi-content-ref-24099411','lexi-content-ref-3190184'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism<b>:</b></i> Displaces bilirubin from albumin, resulting in higher concentrations of free unconjugated bilirubin, leading to kernicterus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24099411','lexi-content-ref-3190184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24099411','lexi-content-ref-3190184'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Neonates and infants &lt;2 month of age, especially those born premature</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F154849"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Circulatory shock (Liu 2018), hypersensitivity myocarditis (Nayak 2013), polyarteritis nodosa, thrombophlebitis (migrans; Verne-Pignatelli 1989)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis (Anliker 2003), erythema multiforme, exfoliative dermatitis, skin photosensitivity, skin rash, Stevens-Johnson syndrome (Acharya 2020), Sweet’s syndrome (Azfar 2009), toxic epidermal necrolysis (Zhang 2019), urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperkalemia (Alappan 1999), hyponatremia (Babyev 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, anorexia, diarrhea, glossitis, nausea, pancreatitis, stomatitis, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Anuria, diuresis, oliguria</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis (Andres 2003), aplastic anemia (IAAAS 1989), eosinophilia, hemolysis (with G6PD deficiency) (Calabrò 1989), hemolytic anemia (Williams 2017), Henoch-Schönlein purpura, hypoprothrombinemia, leukopenia (Gordin 1984), megaloblastic anemia (Kobrinsky 1981), methemoglobinemia (Carroll 2016), neutropenia, thrombocytopenia (Mitta 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestatic jaundice (Ogilvie 1980), hepatotoxicity (including hepatitis, cholestasis, and hepatic necrosis) (Slim 2017), hyperbilirubinemia, increased serum transaminases</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema, serum sickness (Platt 1988)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Drug reaction with eosinophilia and systemic symptoms (Kardaun 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Inflammation at injection site, infusion site irritation, infusion-site pain</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Apathy, aseptic meningitis (Bruner 2014), ataxia, chills, depression, fatigue, hallucination, headache, insomnia, kernicterus (neonates), nervousness, peripheral neuritis, seizure, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, asthenia, myalgia, rhabdomyolysis, systemic lupus erythematosus (Mahmood 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctival injection, injected sclera, uveitis</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen, increased serum creatinine (may not be reflective of a true reduction in glomerular filtration rate [Masters 2003]), interstitial nephritis, renal insufficiency</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Acute respiratory failure, cough, dyspnea, eosinophilic pneumonitis (acute), interstitial pulmonary disease (Yuzurio 2010), pulmonary infiltrates, pulmonary injury (acute and delayed)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (Gordin 1984)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Prolonged QT interval on ECG (Lopez 1987), torsades de pointes (Lopez 1987)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypoglycemia (Nunnari 2010; Strevel 2006), metabolic acidosis (Porras 1998)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: <i>Clostridioides difficile</i> colitis (Brown 2013; Gordin 1994; Hensgens 2012), dysgeusia (Syed 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombotic thrombocytopenic purpura (Bapani 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic failure (Abusin 2008)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (Harle 1988; Kuyucu 2014), fixed drug eruption (Can 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (Fraser 2012)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Acute respiratory distress syndrome (Miller 2019)</p></div>
<div class="block coi drugH1Div" id="F154864"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to any sulfa drug, trimethoprim, or any component of the formulation; history of drug induced-immune thrombocytopenia with use of sulfonamides or trimethoprim; megaloblastic anemia due to folate deficiency; infants &lt;2 months (manufacturer's labeling), infants &lt;4 weeks (CDC 2009); marked hepatic damage or severe renal disease (if patient not monitored); concomitant administration with dofetilide.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Although the FDA-approved product labeling states this medication is contraindicated in patients with hypersensitivity to sulfonamide-containing drugs, the scientific basis of this cross-sensitivity has been challenged. See “Warnings/Precautions” for more detail.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Blood dyscrasias; evidence of marked parenchymal damage; pregnancy; breastfeeding; premature infants; acute porphyria.</p></div>
<div class="block war drugH1Div" id="F154846"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Asthma/Allergies: Use with caution in patients with allergies or asthma.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; dosage adjustment recommended. Maintain adequate hydration to prevent crystalluria.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in older adult patients; greater risk for more severe adverse reactions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Patients with potential for folate deficiency: Use with caution in patients with potential folate deficiency (malnourished, chronic antiseizure therapy, or elderly).</p>
<p style="text-indent:-2em;margin-left:4em;">• Porphyria: Avoid use in patients with porphyria.</p>
<p style="text-indent:-2em;margin-left:4em;">• Slow acetylators: May be more prone to adverse reactions.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP ["Inactive" 1997]; Zar 2007).</p>
<p style="text-indent:-2em;margin-left:4em;">• Sulfite sensitivity: Injection may contain sodium metabisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible persons. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic persons.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: When used for uncomplicated urinary tract infections, this combination should not be used if a single agent is effective. Additionally, sulfonamides should not be used to treat group A beta-hemolytic streptococcal infections.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878401"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Sulfa antibiotics have been shown to displace bilirubin from protein binding sites which may potentially lead to hyperbilirubinemia and kernicterus in neonates and young infants; do not use in neonates; avoid use in infants &lt;2 months unless other options are not available (eg, <i>Pneumocystis</i>).</p>
<p style="text-indent:0em;margin-top:2em;">Some dosage forms may contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block dosfc drugH1Div" id="F45703744"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">The 5:1 ratio (SMX:TMP) remains constant in all dosage forms.</p></div>
<div class="block foc drugH1Div" id="F154857"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Sulfamethoxazole 80 mg and trimethoprim 16 mg per mL (5 mL, 10 mL, 30 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sulfatrim Pediatric: Sulfamethoxazole 200 mg and trimethoprim 40 mg per 5 mL (473 mL) [contains alcohol, usp, fd&amp;c red #40 (allura red ac dye), fd&amp;c yellow #6 (sunset yellow), methylparaben, polysorbate 80, propylene glycol, propylparaben, saccharin sodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Sulfamethoxazole 200 mg and trimethoprim 40 mg per 5 mL (20 mL, 473 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Bactrim: Sulfamethoxazole 400 mg and trimethoprim 80 mg [scored; contains sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Bactrim DS: Sulfamethoxazole 800 mg and trimethoprim 160 mg [scored; contains sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Sulfamethoxazole 400 mg and trimethoprim 80 mg, Sulfamethoxazole 800 mg and trimethoprim 160 mg</p></div>
<div class="block geq drugH1Div" id="F154842"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F154866"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Sulfamethoxazole-Trimethoprim Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400-80 mg/5 mL (per mL): $1.51 - $1.52</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Sulfamethoxazole-Trimethoprim Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200-40 mg/5 mL (per mL): $0.46 - $1.21</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Sulfatrim Pediatric Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200-40 mg/5 mL (per mL): $0.24</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Bactrim DS Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">800-160 mg (per each): $3.12</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Bactrim Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400-80 mg (per each): $1.73</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Sulfamethoxazole-Trimethoprim Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400-80 mg (per each): $0.66 - $0.78</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">800-160 mg (per each): $0.37 - $1.40</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866457"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Septra: Sulfamethoxazole 80 mg and trimethoprim 16 mg per mL (5 mL) [contains alcohol, usp, propylene glycol, sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Sulfamethoxazole 80 mg and trimethoprim 16 mg per mL (5 mL, 10 mL, 30 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Sulfamethoxazole 200 mg and trimethoprim 40 mg per 5 mL ([DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sulfatrim Pediatric: Sulfamethoxazole 100 mg and trimethoprim 20 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Sulfamethoxazole 400 mg and trimethoprim 80 mg, Sulfamethoxazole 800 mg and trimethoprim 160 mg</p></div>
<div class="block admp drugH1Div" id="F52612460"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer without regard to meals. Shake suspension well before use. Patient should maintain adequate fluid intake during use.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: IV infusion: Do not administer IM. Must be diluted in D5W prior to administration. Inspect solution for evidence of cloudiness or precipitation prior to administration; infuse diluted solution IV over 60 to 90 minutes (administration over 30 to 60 minutes has also been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Septra.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Septra.2'])">Ref</a></span>)).</p></div>
<div class="block adm drugH1Div" id="F154861"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Infuse diluted solution over 60 to 90 minutes (administration over 30 to 60 minutes has also been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Septra.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Septra.2'])">Ref</a></span>)); not for IM injection.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer without regard to meals. Administer with at least 8 ounces of water.</p></div>
<div class="block sts drugH1Div" id="F154877"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Injection: Store intact vial at 20°C to 25°C (68°F to 77°F); do not refrigerate. Multiple-dose vials must be used within 48 hours after initial entry. Solutions diluted for infusion should be stored at room temperature; do not refrigerate. Manufacturer-recommended dilutions and stability of parenteral admixture at room temperature are as follows:</p>
<p style="text-indent:-2em;margin-left:4em;">Each 5 mL of drug solution per 125 mL D5W - stable for 6 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Each 5 mL of drug solution per 100 mL D5W - stable for 4 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Each 5 mL of drug solution per 75 mL D5W - stable for 2 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Stability information when diluted in other infusion solutions (eg, NS) may be available; refer to compatibility database and/or manufacturer's product labeling for details.</p>
<p style="text-indent:-2em;margin-left:2em;">Suspension, tablet: Store at controlled room temperature of 15°C to 25°C (59°F to 77°F). Protect from light.</p></div>
<div class="block usep drugH1Div" id="F53566260"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Treatment of urinary tract infections caused by susceptible <i>Escherichia coli</i>, <i>Klebsiella</i> and <i>Enterobacter</i> spp, <i>Morganella morganii</i>, <i>Proteus mirabilis</i>, and <i>Proteus vulgaris</i> (FDA approved in ages ≥2 months and adults); treatment of acute otitis media due to <i>Haemophilus influenzae</i> or <i>Streptococcus pneumoniae</i> (FDA approved in ages ≥2 months and adults); prophylaxis and treatment of <i>Pneumocystis jirovecii</i> pneumonitis (PCP) (FDA approved in pediatric patients [age not specified] and adults); treatment of enteritis caused by <i>Shigella flexneri</i> or <i>Shigella sonnei</i> (FDA approved in ages ≥2 months and adults); acute exacerbations of chronic bronchitis due to susceptible strains of <i>H. influenzae</i> or <i>S. pneumoniae</i> (FDA approved in adults); traveler's diarrhea due to enterotoxigenic <i>E. coli</i> (FDA approved in adults); has also been used for the treatment of skin and soft tissue infections, osteoarticular infections, exit-site or tunnel infections in patients with peritoneal dialysis catheters, brucellosis, cyclosporiasis, cystoisosporiasis, melioidosis, meningitis, Q fever, and for treatment or prophylaxis of toxoplasmosis.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Treatment of <i>P. jirovecii</i> pneumonitis (PCP), <i>Shigella</i>, and severe or complicated urinary tract infections due to<i> E. coli</i>, <i>Klebsiella</i> and <i>Enterobacter</i> spp, <i>M. morganii</i>, <i>P. mirabilis</i>, and <i>P. vulgaris</i> (FDA approved in ages ≥2 months and adults); has also been used in treatment of severe or complicated infections caused by susceptible bacteria when oral therapy is not feasible.</p></div>
<div class="block mst drugH1Div" id="F154917"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Bactrim may be confused with bacitracin, Bactine, Bactroban</p>
<p style="text-indent:-2em;margin-left:4em;">Co-trimoxazole may be confused with clotrimazole</p>
<p style="text-indent:-2em;margin-left:4em;">Septra may be confused with Ceptaz, Sectral</p>
<p style="text-indent:-2em;margin-left:4em;">Septra DS may be confused with Semprex-D</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Sulfamethoxazole and Trimethoprim is identified in the Beers Criteria as a potentially inappropriate medication to be used with caution in patients ≥65 years of age with decreased CrCl and on ACE inhibitors, angiotensin receptor-neprilysin inhibitors, or ARBs due to increased risk of hyperkalemia (Beers Criteria [AGS 2023]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pediatric patients: High-risk medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">KIDs List: Sulfonamides, when used in neonates, are identified on the Key Potentially Inappropriate Drugs in Pediatrics (KIDs) list and should be avoided due to risk of kernicterus (weak recommendation; very low quality of evidence) (PPA [Meyers 2020]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F154902"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">Refer to individual components.</p></div>
<div class="block dri drugH1Div" id="F154851"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: Sulfonamides may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amantadine: Trimethoprim may enhance the adverse/toxic effect of Amantadine. Specifically, the risk of myoclonus or delirium may be increased. Trimethoprim may increase the serum concentration of Amantadine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amodiaquine: Sulfamethoxazole may enhance the neutropenic effect of Amodiaquine.  Management: Avoid coadministration of sulfamethoxazole/trimethoprim and amodiaquine in HIV-infected patients when possible due to the possible increased risk for neutropenia. If coadministration is required, monitor closely for neutropenia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amodiaquine: Trimethoprim may enhance the neutropenic effect of Amodiaquine. Trimethoprim may increase the serum concentration of Amodiaquine.  Management: Avoid coadministration of sulfamethoxazole/trimethoprim and amodiaquine in HIV-infected patients when possible due to the possible increased risk for neutropenia. If coadministration is required, monitor closely for neutropenia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Androgens: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin II Receptor Blockers: Trimethoprim may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin-Converting Enzyme Inhibitors: Trimethoprim may enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">AzaTHIOprine: Sulfamethoxazole may enhance the myelosuppressive effect of AzaTHIOprine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">AzaTHIOprine: Trimethoprim may enhance the myelosuppressive effect of AzaTHIOprine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloroprocaine (Systemic): May diminish the therapeutic effect of Sulfonamide Antibiotics. Management: Avoid concurrent use of chloroprocaine and systemic sulfonamide-based antimicrobials whenever possible.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofarabine: OCT2 Inhibitors may increase the serum concentration of Clofarabine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Sulfonamide Antibiotics may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Sulfonamide Antibiotics may decrease the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dalfampridine: OCT2 Inhibitors may increase the serum concentration of Dalfampridine.  Management: Consider alternatives to this combination. Carefully weigh the risk of seizures against the benefit of combining OCT2 inhibitors with dalfampridine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daprodustat: CYP2C8 Inhibitors (Weak) may increase the serum concentration of Daprodustat. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Systemic): Trimethoprim may increase the serum concentration of Dapsone (Systemic). Dapsone (Systemic) may increase the serum concentration of Trimethoprim. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexketoprofen: May enhance the adverse/toxic effect of Sulfonamides.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Digoxin: Trimethoprim may increase the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dofetilide: Trimethoprim may increase the serum concentration of Dofetilide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eplerenone: Trimethoprim may enhance the hyperkalemic effect of Eplerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin: May decrease the serum concentration of Trimethoprim. Trimethoprim may increase the serum concentration of Fosphenytoin. Management: Consider alternatives to this combination when possible, to avoid potential decreased trimethoprim efficacy and increased phenytoin concentrations/effects.  Monitor patients receiving this combination closely for both of these possible effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Glucose Lowering Effects: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypoglycemia-Associated Agents: May enhance the hypoglycemic effect of other Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">LamiVUDine: Trimethoprim may increase the serum concentration of LamiVUDine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leucovorin Calcium-Levoleucovorin: May diminish the therapeutic effect of Trimethoprim. Management: Avoid concurrent use of leucovorin or levoleucovorin with trimethoprim (plus sulfamethoxazole) for <i>Pneumocystis jirovecii</i> pneumonia.  If trimethoprim is used for another indication, monitor closely for reduced efficacy.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Local Anesthetics: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maitake: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mecamylamine: Sulfonamides may enhance the adverse/toxic effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Memantine: Trimethoprim may enhance the adverse/toxic effect of Memantine. Specifically, the risk of myoclonus and/or delirium may be increased. Trimethoprim may increase the serum concentration of Memantine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mercaptopurine: Sulfamethoxazole may enhance the myelosuppressive effect of Mercaptopurine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mercaptopurine: Trimethoprim may enhance the myelosuppressive effect of Mercaptopurine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetFORMIN: MATE1/2-K Inhibitors may increase the serum concentration of MetFORMIN. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methenamine: May enhance the adverse/toxic effect of Sulfonamide Antibiotics. Specifically, the combination may result in the formation of an insoluble precipitate in the urine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: Trimethoprim may enhance the adverse/toxic effect of Methotrexate.  Management: Consider avoiding concomitant use of methotrexate and either sulfamethoxazole or trimethoprim. If used concomitantly, monitor for the development of signs and symptoms of methotrexate toxicity (e.g., bone marrow suppression).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetroNIDAZOLE (Systemic): May enhance the adverse/toxic effect of Products Containing Propylene Glycol. A disulfiram-like reaction may occur.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ornidazole: May enhance the adverse/toxic effect of Products Containing Propylene Glycol. Specifically, a disulfiram-like reaction may occur.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegvisomant: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phenytoin: Trimethoprim may increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Trimethoprim.  Management: Consider alternatives to this combination when possible, to avoid potential decreased trimethoprim efficacy and increased phenytoin concentrations/effects.  Monitor patients receiving this combination closely for both of these possible effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phenytoin: Sulfamethoxazole may increase the serum concentration of Phenytoin.  Management: Avoid coadministration of phenytoin and sulfamethoxazole. If coadministered, monitor phenytoin concentrations and for evidence of phenytoin toxicity. Risk of toxicity is increased with sulfamethoxazole/trimethoprim combination product.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium P-Aminobenzoate: May diminish the therapeutic effect of Sulfonamide Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">PRALAtrexate: Trimethoprim may increase the serum concentration of PRALAtrexate. More specifically, trimethoprim may decrease excretion of pralatrexate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PRALAtrexate: Sulfamethoxazole may increase the serum concentration of PRALAtrexate. More specifically, sulfamethoxazole may decrease excretion of pralatrexate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procainamide: Trimethoprim may increase serum concentrations of the active metabolite(s) of Procainamide. Trimethoprim may increase the serum concentration of Procainamide.  Management: Consider alternatives to trimethoprim-containing regimens to avoid this interaction. If coadministered, monitor for increased procainamide adverse effects (increased QTc) if trimethoprim is initiated/dose increased.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procaine: May diminish the therapeutic effect of Sulfonamide Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prothionamide: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pyrimethamine: May enhance the adverse/toxic effect of Trimethoprim.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Quinolones may diminish the therapeutic effect of Agents with Blood Glucose Lowering Effects. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repaglinide: CYP2C8 Inhibitors (Weak) may increase the serum concentration of Repaglinide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: May decrease the serum concentration of Trimethoprim. Trimethoprim may increase the serum concentration of RifAMPin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: May decrease the serum concentration of Sulfamethoxazole. Sulfamethoxazole may increase the serum concentration of RifAMPin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sapropterin: Trimethoprim may decrease the serum concentration of Sapropterin. Specifically, trimethoprim may decrease tissue concentrations of tetrahydrobiopterin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secnidazole: Products Containing Propylene Glycol may enhance the adverse/toxic effect of Secnidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Spironolactone: Trimethoprim may enhance the hyperkalemic effect of Spironolactone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfonylureas: Sulfonamide Antibiotics may enhance the hypoglycemic effect of Sulfonylureas. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Sulfonamide Antibiotics may enhance the anticoagulant effect of Vitamin K Antagonists.  Management: Consider reducing the vitamin K antagonist dose by 10% to 20% prior to starting the sulfonamide antibiotic. Monitor INR closely to further guide dosing.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zidovudine: May enhance the neutropenic effect of Trimethoprim. Trimethoprim may increase the serum concentration of Zidovudine.<i> Risk C: Monitor therapy</i></p></div>
<div class="block dic drugH1Div" id="F154869"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Should be taken with 8 oz of water. May be taken without regard to meals.</p></div>
<div class="block rep_considerations drugH1Div" id="F55045622"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Sulfamethoxazole/trimethoprim is recommended for the acute treatment of Q fever (<i>C. burnetii</i>) in pregnant patients; however, it is an alternative agent in nonpregnant adults. Patients should avoid pregnancy for ≥1 month after treatment. Pregnancy testing is recommended in patients who may become pregnant prior to therapy (CDC [Anderson 2013]).</p>
<p style="text-indent:-2em;margin-left:2em;">Sulfamethoxazole/trimethoprim may be appropriate for the treatment of bacterial prostatitis, a condition associated with sexual dysfunction (Lipsky 2010). Treatment of prostatitis may or may not improve semen quality. Sulfamethoxazole/trimethoprim may also be associated with transient disruption of spermatogenesis, but effects on semen parameters are conflicting (Drobnis 2017; Samplaski 2015).</p></div>
<div class="block pri drugH1Div" id="F154867"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Sulfamethoxazole and trimethoprim cross the placenta.</p>
<p style="text-indent:0em;margin-top:2em;">An increased risk of congenital malformations (neural tube defects, cardiovascular malformations, urinary tract defects, oral clefts, club foot) following maternal use of sulfamethoxazole and trimethoprim during pregnancy has been observed. Trimethoprim interferes with folic acid metabolism, decreasing maternal levels. Adequate maternal folic acid supplementation may decrease the risk of some birth defects (Crider 2009; Czeizel 2001; Hernandez-Diaz 2000; Hernandez-Diaz 2001; Matok 2009).</p>
<p style="text-indent:0em;margin-top:2em;">Due to theoretical concerns that sulfonamides cross the placenta and may cause kernicterus in the newborn, neonatal health care providers should be informed if maternal sulfonamide therapy is used near the time of delivery (HHS [OI adult] 2022); avoidance of sulfamethoxazole/trimethoprim during the third trimester is recommended by some guidelines (specific weeks of gestation may vary as noted below).</p>
<p style="text-indent:0em;margin-top:2em;">The pharmacokinetics of sulfamethoxazole and trimethoprim are similar to nonpregnant pharmacokinetic values in early pregnancy (Ylikorkala 1973).</p>
<p style="text-indent:0em;margin-top:2em;">Sulfamethoxazole/trimethoprim is recommended for the treatment and prophylaxis of<i> Pneumocystis jirovecii</i> pneumonia (PCP) in pregnant patients with HIV because of the considerable maternal benefits of therapy. However, due to the risk of birth defects, supplemental folic acid at high doses (&gt;0.4 mg/day) may be considered during the first trimester only. When sulfamethoxazole/trimethoprim is used during the first trimester, a fetal ultrasound is recommended at 18 to 20 weeks' gestation to evaluate fetal anatomy (HHS [OI adult] 2022).</p>
<p style="text-indent:0em;margin-top:2em;">Sulfamethoxazole/trimethoprim is recommended for the primary treatment of symptomatic <i>Isospora belli</i> infection as well as secondary prophylaxis in pregnant patients with HIV. Treatment for secondary prophylaxis can be withheld during the first trimester due to concerns of birth defects associated with sulfamethoxazole/trimethoprim therapy (HHS [OI adult] 2022).</p>
<p style="text-indent:0em;margin-top:2em;">Sulfamethoxazole/trimethoprim is recommended for the acute treatment of Q fever (<i>Coxiella burnetii</i>) in pregnant patients (alternative agent in nonpregnant adults). Untreated first trimester maternal infection may lead to miscarriage; premature delivery may occur when infection occurs later in pregnancy. Acute infection during pregnancy also increases the risk of chronic maternal infection. Treatment decreases the risk of adverse pregnancy outcomes and adverse events in subsequent pregnancies. Treatment with sulfamethoxazole/trimethoprim is recommended throughout pregnancy up to 32 weeks' gestation (withhold sulfamethoxazole/trimethoprim during the last 8 weeks of gestation due to the risk of kernicterus). Monitoring should continue for 24 months after delivery to evaluate possible progression to chronic disease (CDC [Anderson 2013]).</p>
<p style="text-indent:0em;margin-top:2em;">Sulfamethoxazole/trimethoprim is recommended for the primary prophylaxis of <i>Toxoplasma gondii</i> encephalitis (TE) in pregnant patients with HIV. The risks of fetal exposure to sulfamethoxazole/trimethoprim during the first trimester should be balanced with the risk TE (HHS [OI adult] 2022).</p>
<p style="text-indent:0em;margin-top:2em;">Sulfamethoxazole/trimethoprim is approved for the treatment of urinary tract infections (UTIs) in adults. Some guidelines prefer alternative antibiotics for UTIs in pregnancy as well as avoiding use in the third trimester (Betschart 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Sulfamethoxazole/trimethoprim is not recommended for the treatment of granuloma inguinale during pregnancy (recommended as an alternative therapy in nonpregnant patients) (CDC [Workowski 2021]).</p>
<p style="text-indent:0em;margin-top:2em;">Sulfamethoxazole/trimethoprim may be used as part of a treatment regimen when brucellosis is diagnosed during pregnancy (not the preferred treatment in nonpregnant patients). Untreated maternal brucellosis infection may cause adverse pregnancy outcomes including spontaneous abortion or transmission to the infant. Treatment with sulfamethoxazole/trimethoprim is not recommended after 36 weeks' gestation due to the risk of kernicterus (Bosilkovski 2020; CDC brucellosis reference guide 2017).</p>
<p style="text-indent:0em;margin-top:2em;">Sulfamethoxazole/trimethoprim is used in the management of plague (<i>Yersinia pestis</i>). Untreated infections in pregnant patients may result in hemorrhage (including postpartum hemorrhage), maternal and fetal death, preterm birth, and stillbirth. Limited data suggest maternal-fetal transmission of <i>Y. pestis</i> can occur if not treated. Pregnant patients should be treated for Y. pestis; parenteral antibiotics are preferred for initial treatment when otherwise appropriate. Sulfamethoxazole/trimethoprim may be used as an alternative antibiotic for treating pregnant patients with bubonic, pharyngeal, pneumonic, or septicemic plague. Sulfamethoxazole/trimethoprim may also be used as an alternative antibiotic for pre- and postexposure prophylaxis in pregnant patients exposed to <i>Y. pestis.</i> Treatment and prophylaxis for plague with sulfamethoxazole/trimethoprim can be used regardless of trimester (CDC [Nelson 2021]).</p></div>
<div class="block mopp drugH1Div" id="F53566249"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC, renal function, sodium, potassium, glucose; observe for change in bowel frequency. Liver function (with longer-term use); urinalysis (if clinical presentation indicates need).</p></div>
<div class="block pha drugH1Div" id="F154845"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Sulfamethoxazole interferes with bacterial folic acid synthesis and growth via inhibition of dihydrofolic acid formation from para-aminobenzoic acid; trimethoprim inhibits dihydrofolic acid reduction to tetrahydrofolate resulting in sequential inhibition of enzymes of the folic acid pathway</p></div>
<div class="block phk drugH1Div" id="F154863"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Rapid; almost completely (90% to 100%).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Both SMX and TMP distribute to middle ear fluid, sputum, vaginal fluid; TMP also distributes into bronchial secretions.</p>
<p style="text-indent:-2em;margin-left:4em;">V<sub>d</sub>: TMP:</p>
<p style="text-indent:-2em;margin-left:6em;">Neonates (GA: 28 to 40 weeks; PNA: &lt;3 days): ~2.7 L/kg (range: 1.3 to 4.1 hours) (Springer 1982).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants: 1.5 L/kg (Hoppu 1989).</p>
<p style="text-indent:-2em;margin-left:6em;">Children 1 to 10 years: 0.86 to 1 L/kg (Hoppu 1987).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: ~1.3 L/kg (Hoppu 1987).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: SMX: ~70%, TMP: ~44%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic, both to multiple metabolites; SMX to hydroxy (via CYP2C9) and acetyl derivatives, and also conjugated with glucuronide; TMP to oxide and hydroxy derivatives; the free forms of both SMX and TMP are therapeutically active.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">TMP: Prolonged in renal failure.</p>
<p style="text-indent:-2em;margin-left:6em;">Neonates (GA: 28 to 40 weeks; PNA: &lt;3 days): ~19 hours; range: 11 to 27 hours (Springer 1982).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants: ~4.6 hours; range: 3 to 6 hours (Hoppu 1989).</p>
<p style="text-indent:-2em;margin-left:6em;">Children 1 to 10 years: 3.7 to 5.5 hours (Hoppu 1987).</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents &gt;10 years: 8.19 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: 6 to 11 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">SMX: 9 to 12 hours, prolonged in renal failure.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Oral: 1 to 4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Both are excreted in urine as metabolites and unchanged drug.</p></div>
<div class="block phksp drugH1Div" id="F51221469"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Patients with severely impaired renal function exhibit an increase in the half-lives of both components, requiring dosage adjustments.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Total body clearance of trimethoprim was 19% lower in elderly patients.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F154870"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Bactrim | Balkatrin | Cotrim | Imexim | Lagatrim | Nopil | Nortrim | Notrime | Omsat | Oribact | Septazole | Septrin | Sulfoprima | Sulfotrim | Sutrim | System | Trimol | Urtium</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Adrenol | Bacticel | Bactrim | Bactrim forte | Cotrimox | Cotrimoxazol | Cotrimoxazol richet forte | Cotrizol-g | Danferane | Dosulfin forte | Lescot | Netocur | Novidrine | Spectrex | Sulfagrand | Tritenk | Tritenk forte</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Bactrim | Cotribene | Cotrimoxazol genericon pharma | Eusaprim | Oecotrim</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Bactrim | Cm trimeth s/meth | Cosig | Resprim | Resprim forte | Sbpa trimeth smeth | Septrin | Trimethoprim sulfa | Trimethoprim sulfamethoxazole | Trimoxazole-bc | Tw trimeth s/meth</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Actrim | Adtrim | Alcot | Antrim | Apcetrim | Aptrim | Avlotrin | Bactacin | Bactazol | Bactipront | Bactronil | Bioprim | Biotrim | Bitrim | Centrim | Chemotrim | Chemozole | Citrim | Colotrim | Cosat | Cotrazen | Cotrilin | Cotrim | Cotrizol | Cots | Deotrim | Ditrim | Doctrim | Editrim | Ethitrim | Fisat | G-cotrimoxazole | Gentrim | Getrim | Japtrim | Jasotrim | Litrim | M-trim | Maktrim | Meditrim | Megaset | Megatrim | Methoprim | Methotrin | Metrim | Micogyl | Motrim | Napatrim | Navatrim | Neoset | Neotrim | Octrim | Omnatrim | Orgastran | Patrim | Pharmatrim | Politrim | Primazol | Rasat | Regtin | Rematrim | Retrim | Ribatrim | Rimazole | Saltrim | Satrim | Seematrim | Seftrim | Septazol | Septrin | Servitrim | Sinatrim | Sitrim | Skytrin | Soma ds | Strim | Sulphatrim | Sulprim | Sultra | Sumetrolim | Suprim | Suptrim | Synac | Synotrim | Theratrim | Tricot | Trimeton | Trimetrin | Trimezol | Trimox | Tytrim | Unitrim | Utrin | Zaxol</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Bactrim | Co-trimoxazole | Cotrim | Eusaprim</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Altrim | Berlocid | Bibactin | Captrim | Co-trimoxazole | Cotrex | Cotrim | Cotrimoxazole | Cotrimoxazole tm | Cotrimoxazole ubigen | Deptrin | Mortin forte | Philco cotri</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Bactrim | Berlocid | Biseptol | Primotren | Septrin | Sulfaprim | Sumetrolim | Trimezol</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Assepium | Bac-sulfitrin | Bacfar | Bacmetrin | Bacprotin | Bacris | Bacsulfaprim | Bacteracin | Bacteracin f | Bactricin | Bactrim | Bactrisan | Bactropin | Baczin | Baklinger | Batrox | Belfactrim | Belfactrin | Belfactrin f | Benectrin | Benectrin f | Biotrin | Dientrin | Ectrin | Espectrin | Espectroprima | Furp sulfametoxazol + trimetoprima | Gamactrin | Genoctrin | Ibtrim | Infectrin | Infectrin f | Katrim | Leotrim | Lifactrin | Lupectrin | Mapitrim | Medtrim | Metoprin | Neotrin | Pulkrin | Qiftrim | Qiftrin | Roytrin | Selectrim | Selectrin | Septiolan | Septoprin | Silpin | Subtrax | Sulfametosazol con trimetoprim | Sulfametoxazol + trimetoprima | Sulftrin | Teutrin | Tricban | Trimexazol | Trimezol | Uropol</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Bactrim | Cotrim | Escoprim | Helveprim | Nopil | Sigaprim | Supracombin</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Altrim | Altrim forte | Apo sulfatrim | Bactrim | Bactrim forte | Bibactin | Bibactin fort | Captrim | Cotri care | Cotrimoxazole | Cotrimoxazole tm | Phartrim | Sulfran | Sulfran ds | Sultrim fort | Trimac | Trimoprim | Trimoxol</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Bacterol | Bactrimel | Co-trimoxazol | Cotrimoxazol | Infesin | Introcin | Irgagen | Micinovo | Normacol | Plurisul | Septrin | Septrin forte | Trelibec</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Compound sulfamethoxazole | Fu fang huang an jia e zuo fen san | Nuo da ming | Nuo de fei | Smz (co) | Sulfamethoxazole c</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Bactigram F | Bactisol | Bactrim | Bactrim f | Baxul f | Cotrimoxazol | Decasulf forte | Mediprim | Mediprim f | Oxitoprim | Penivacs | Septrin | Sulfametoxazol + trimetoprima | Sulfametoxazol trimetoprima | Sulfinam | Sulfinam s | Sulmet | Sulthrim | Sulthrim-f | Sultrifar | Sultrifar f | Sultrivon-f | Sultropim | Supribac | Supribac f | Supribac simple | Terasulf | Trime rande f | Trimeran | Trimeril | Trimesulf | Trimesulf f | Trimesulf forte | Trimesulf-f | Trimetoprim + sulfametoxazol | Trimetoprim sulfa | Trimetoprim sulfametoxazol | Trimetoprim sulfametoxazol f | Trimetoprim sulfametoxazol mk | Trimetoprima sulfa f | Trimetoprima sulfametoxazol | Trimetoprin sulfa | Trimetropina sulfametoxazol | Trimex | Trimsul | Trisolvat | Trisulfa | Trisulfa f | Tritosul f | Trixid | Weiditrin | Xazotrim</span>;</li>
<li>
<span class="countryCode">(CR)</span> <span class="country">Costa Rica</span><span class="countrySeparator">: </span><span class="drugName">SEPTRAN</span>;</li>
<li>
<span class="countryCode">(CU)</span> <span class="country">Cuba</span><span class="countrySeparator">: </span><span class="drugName">Cotrimoxazol</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Apo sulfatrim | Bactrim | Biseptol | Bismoral | Cotrimoxazol | Cotrimoxazol al forte | Cotripharm | Oribact | Primotren | Sumetrolim</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Bactoreduct | Bactrim | Co-trimoxazole | Cotrim | Cotrim abz | Cotrim diolan | Cotrim e | Cotrim forte | Cotrim forte eu rho | Cotrim Forte-ratiopharm | Cotrim hefa | Cotrim hexal | Cotrim holsten saft | Cotrim tablinen | Cotrim-CT | Cotrim-ratiopharm | Cotrim-sandoz | Cotrimox wolff | Cotrimoxazol al | Cotrimoxazol al forte | Cotrimstada | Eusaprim | Eusaprim k | Microtrim | Sigaprim | Sulfotrimin | Tms</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Sulfametoxazol med trimetoprim SAD</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Apotrinelax | Bacticel | Bactrilac | Bactrin | Bactrizole | Baxolex | Cladon | Cotrim | Justeprim | Lisaprin | Metomide | Metoprin | Polibatrin | Primasulf | Quisulyn | S.T. Forte | SEPTRAN | Sulfamer | Sulfatropim | Sulftran | Sulgotri | Sultrima | Teof | Trimesul | Trimetoprim &amp; sulfametoxazol | Trimetoprim sulfametoxazol iberofarmaco | Trimetoprin sulfa | Trisul | Tritosul</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Bacterol | Bacticel | Bactoprim | Bactricida | Bactrim | Bitrim | Cotribac forte | Cotrimoxazol | Cotrimoxazol forte | Cotrimoxazol pediatrico | Danferane | Fametrim forte | Fametrim simple | Fametrim sulfa | Fametrin sulfa | H.g. sulfatrim | Krobactrol | Meprim | Nopil | Omsat | Suftrex | Sulfacif | Sulfaprim | Sulfatalpin | Sulfatrim | Supracombin | Trimetoprim sulfa | Trimetoprima | Trimetotal | Trimezol | Trimol | Zoltrim</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Bactrim | Bactrim ds | Bactrim forte | Berlocid | Biseptol | Co-trimoxazol | Co-trimoxazole | Cotribene | Cotrimoxazol | Oriprim | Septrin | Sulfatrim | Sulfotrim | Trimesol</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Bacticure | Chemotrim | Co-trimoxazole | Coprimasept | Cotrazim | Cotril | Cotril forte | Epitrim | Farcotrim | Septazole | Septrin | Sulfatrim | Sulfatrim ds | Sutaprim | Sutrim | Sutrim forte</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Abactrim | Eduprim | Gobens trim | Septrin</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Astrim | Cadiprim | Co-trimoxazole | Cotri | Deprim | Ifitrim | Sulfamethoxazole and trimethoprim | Sulphamethoxazole + trimethoprim</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Bactrim | Cotrim | Eusaprim | Oribact | Sulfotrim | Trimetsol | Trimosulfa</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Bactrim | Cotrim | Cotrimoxazole dakota pharm | Cotrimoxazole Ratiopharm | Cotrimoxazole rpg | Eusaprim</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Bactrim | Chemotrim | Co trimoxazol | Co trimoxazole | Co trimoxazole cox | Co trimoxazole knt | Comixco | Comox | Fectrim | Laratrim | Nodilon | Septrin</span>;</li>
<li>
<span class="countryCode">(GH)</span> <span class="country">Ghana</span><span class="countrySeparator">: </span><span class="drugName">Cotrim paediatric | Escotrim</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Bactrimel | Cotrim e ratiopharm | Septrin | Solfoton</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Chemoprim | Cobacide | Dhatrin | Eurotrim | Letus | Po Trim | Septol | Septrin | Sulphathoprim | Suprim | Synco-smzt | Trimetrin | Trimezol | Trimezole</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Sinersul | Sulotrim</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Bactrim | Cotripharm | Huma-trimel | Sumetrolim</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Abatrim | Abditri | Aditrim | Altrim | Bactoprim combi | Bactricid | Bactrim | Bactrizol | Bimactrim | Centrim | Co-trim | Co-trimoxazole | Coprim | Cotrim | Cotrimol | Cotrimoxazole | Decatrim | Dotrim | Dumotrim | Erphatrim | Fameprim | Fatibact | Graprima | Gunametrim | Hexaprim | Hufacid | Ikaprim | Inatrim | Infatrim | Kaftrim | Kemocid | Kentricid | Kotrimoksazol | Lapikot | Licoprima | Maxtrim | Meditrim | Megatrim | Meprotrin | Miratrim | Moxalas | Nufaprim | Omegtrim | Ottoprim | Pehatrim | Primadex | Primatrim | Primavon | Primazole | Primsulfon | Ratrim | Saltrim | Sanprima | Septrin | Sisoprim | Spectrem | Sulprim | Sultrimmix | System | Toxaprim | Trimeta | Trimezol | Triminex | Trimoxsul | Trixzol | Trizole | Ulfaprim | Wiatrim | Xepaprim | Yekaprim | Zecatrim | Zoltrim | Zultrop</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Antrimox | Septrin | Septrin paediatric</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Diseptyl | Resprim | Septrin</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Alaxol | Alco | Alcorim-f | Anprim | Antrima | Bacitran | Bactoprim | Bactosain | Bactostab | Bactrim | Bioprim | Centrim | Chemotrin | Cidaprim | Ciplin | Co-trimoxa | Co-trimoxazole | Colizole | Combact | Coprime | Cosulf | Cotran | Cotribid | Cotrim | Cotrimax | Cotrimoxazole | Cotrizole | Creptrim | Erotrim | Fabrol | Gatrima | Hatrix | Isoprim | Klotrim | Kolibitor | Kombina | L trim | Larprim | Lykaprim | Macprim | Maxiprim | Moly | Mortin | Neuroprim | Okatrim | Oriprim | Otrim | Rancotrim | Rizol | Rolprim | Salgatran | Sepmax | Septabid | Septabid-2 | Septinix | SEPTRAN | Stan | Suprin | Synastat | Synetra | Tabrol | Torrid | Tprim | Trima | Trimco | Trimex | Trimex ds | Trimox | Trimozol | Trimzole ds | Trisolak forte | Trisulfose | Trisuprim | Unitran | Woktrin ds | Wypal | X-trim</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Dadprim | Furaprim | Hayprim | Kindiprim | Metheprim | Methoprim | Piotrim | Safaprim | Sulfatrime</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">Primazol | Primazol sterkar</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Bacterial | Bactrim | Bactrimel | Chemitrim | Eusaprim | System | Trimesulf</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Bactrim | Balkatrin | Lagatrim | Notrim | Septrin | Sulprim | Trimidar m | Trimol | Urtium</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Bactramin | Baktar | Daiphen | Oxaprim | Septerin | Stopan | Urodown</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Alcorim | Alprim | Astrim | Bactifenin | Bactrim | Bactrim forte | Bactron | Betrim | Biotrim | Biotrim ds | Bisepton | Ciplin | Ciplin ds | Co tri | Co trimoxazole | Cosatrim | Cosatrim ds | Cotreich | Cotrikant | Cotrim | Cotrimoxazole | Dacotri ds | Lagatrim | Lagatrim forte | Lecotrim | Lecotrim forte | Maxotrim | Megatrim | Mortin | Osstrim | Otrim ds | Primox | Septrin | Shalphatrim | Shetrim | Sulfamethoxazole and trimethoprim | Sulfatrim | Sulfatrim forte | Sulfran | Sulfran ds | Sulfran paediatric | Sulprim | Sultrim | Trimoprim | Trimoxol | Trimoxol ds | Trizole | Unitrim | Unitrim ds | Vircot | Zeetrim</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Alltarim | Bactrim | Canprim | Cotoram | Cotrim | Madroxin | Metorim | Pentrin | Septrin | Sinotrim | Sinotrim F | Sulprim | Sultase | Sultorim | Sultrim | T-s | Triprim | Ts | U-prin | Uprina</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Bactrim | Nopil | Septrin | Theraprim | Trimol</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Bactekod | Bactrim | Co trimoxazole | Cotrimoxazole | Lagatrim | Mediprim | Septrin | Tms | Trimexazol | Trimoxazol</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Apo sulfatrim | Bactekod | Bactrim | Biseptol | Bitrim | Blexon | Ciplin | Cotrimoxazol | Cotripharm | Duo septol | Groseptol | Oribact | Oriprim | Primotren | Rancotrim | Septrin | Sinersul | Sulfaton | Sumetrolin | Trimetop duplo | Trimezol</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Bactrim | Co-trimoxazole | Cotrim | Cotrimoxazole | Eusaprim</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Antrima | Apo sulfatrim | Bactekod | Bactrim | Berlocid | Biseptol | Blexon | Ciplin | Cotrim | Cotrimoxazol | Cotripharm | Duo septol | Groseptol | Nopil | Oribact | Oriprim | Primotren | Septrin | Sulfaton | Sumetrolin | Trimesolphar | Trimetop duplo | Trimezol</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Apo sulfatrim | Bactrim forte | Berlocid | Co-trim | Eusaprim | Microcetim | Sulfaprim | Tms | Trimox | Trisulfa | Trixazol | Trixazol fort</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Andoprim | Anitrim | Apotrinelax | Bactelan | Bacteric | Bactide | Bactiver | Bactrim | Bactrim f | Bactropin | Bateral | Bioprim | Bisultrim | Dertrin | Dertrin s | Ectaprim | Ectaprim f | Eutrim | Kaltrim f | Maxtrim | Maxtrim f | Maxtrim p | Metoxiprim | Neofatrim | Octiban | Odisulfan | Ormoprim | Pisatrina | Polibatrin | Polibatrin f | Pribac | Septrin | Septrin f | Servitrim | Servitrim-f | Soltrim | Soltrim f | Sulfawal-t | Sulfort | Sultiprim | Suxprim | Thriazol | Thriazol-s | Tribakin | Trimetoger | Trimetoprima con sulfametoxazol | Trimetoprima y sulfametoxazol | Trimetox | Trimexazol | Trimexazol f | Trimexole f | Ts bac | Vanadyl</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Apo sulfatrim | Bacin | Bactrim | Baserin | Chemix | Co primazol | Co primox | Co-trimoxa | Co-trimoxazole | Co-Trimoxazole Pharmaniaga | Comazole | Comazole n | Coprime | Cotrim | Cotrimoxazole | Dhatrin | Dynaprim | Primzole | Rancotrim | Resprim m | Septrin | Setrim | Sulfaprim | Sulfatrim | Suprim | Trimexazole | Trimezole | Trizole</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Acartrin | Albetrin | Bradtrim | Cika cotrim | Co trimoxazole | Co trox | Co-trimoxazole | Coptrine | Cotrikris | Emtrim | Emtrim forte | Esitrim | Faptrimox | Garytrim | Jawatrim | Kisitrim | Mopson co trimoxazole | Osworth cotrimoxazole | Paltrin | Pantrim | Pectrim | Pistrin | Rancotrim forte | Samtrim | Tecotrim | Trimac | Trimac forte | Tutrim | Unitrim | Vadis co trimoxazole</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Bactrimel | Co trimoxazol cf | Co trimoxazol forte cf | Co-trimoxazol | Co-Trimoxazol A | Co-trimoxazol flx | Cotrimoxazol | Cotrimoxazol aurobindo | Eusaprim</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Bactrim | Bactrim camp | Bactrimel | Bactrimel specifik | Cotrim | Cotrim-ratiopharm | Eusaprim | Trimesolphar macura | Trimetoprim sulfa gea</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Apo sulfatrim | Bactrim | Cotrimoxazole | Septrin | Trimel | Trisul</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Apo-bactotrim | Bacsulfin | Bacsulfin forte | Bacterol | Bacteromycin forte | Bacticel | Bactraxole forte | Bactrim | Bactrim f | Bactrim forte | Bactriplus | Balcotrin forte | Beckatrim forte | Biotrim | Broncoflam | Cipaprim | Cotrimoxazol | Dientrin | Dolatrim | Drossul | Droxol | Eliprim | Exazol | Infectrim | Infesul | Lusaprim | Maflux forte | Maflux pediatrico | Massulf | Mebryn | Medibiot | Megabroncoflam | Myctrim | Novotrim plus | Paldix forte | Plurisul | Quibac forte | Ropsil | Roxtrim | Sanaprim | Sanaprim forte | Sanatrim forte | Sanatrim pediatrico | Septrin | Sulfa 100 + trim 20 | Sulfa 200 + trima 40 | Sulfa 400 + trima 80 | Sulfa 800 + trima 160 | Sulfa maxx forte | Sulfamethoxazole and trimethoprim | Sulfametoxazol + trimetoprima | Sulfametoxazol y trimetoprima mf | Sulfaquilab forte | Sulphax | Sulphytrim forte | Sulphytrim junior | Sultrima | Sumetoprim | Suprasulf | Suprim | Suprimass | Tribaxon | Trimesulfin | Trimetoprim sulfa | Trimetoprim sulfa genfar | Trimexasol | Trimfasul | Trimol | Zitrim | Zitrim forte</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Abetrim | Alcotri | Allibac | Bacidal | Bactille-ts | Bactrex | Bactrim | Bactrinol | Bacxal | Baczole | Bantizol | Bestofens | Biogenerics cotrimoxazole | Boie cotrimoxazole | Chemoprim | Chromo-z | Ciplin | Ciplin ds | Colimox | Combi-methoxan | Combizole | Costazole | Cotrexel | Cotribase | Cotrimoxazol | Cotrimoxazole | Cozole | Ctr | Dhatrin | Diazole | Dli cotrimoxazole | Drilozole | Embatrim forte | Fedimed | Forteprim | Genoxzole | Genzaprim | Globaxol | Intrafort | Jenetrol | Jestrim | Kassemox | Kathrex | Katrim | Kindoprim | Lacreozole | Lafayette cotrimoxazole | Lagatrim | Leprim | Lictora | Macromed | Medic aid cotrimoxazole | Microbid | Microbid ds | Moxadden | Moxzole | Necorzole | Neotrim | Nuruzole | Onetrim | Penzole | Pharex co-trimoxazole | Primecotrix | Procor | Renatrim | Rimezone | Rotrace | Scribcin | Septrin | Septrol | Servitrim | Sigatrim | Suprex | Syltrifil | Syndal | Synermed | Synerzole | Thoprim | Timizol | Triforam | Trihexal | Trim-s | Trimephar | Trimocom | Trimoxavin | Trimoxis | Trimoxol | Triphimox | Trisulcom | Trizole | Trymerin | Urethrax | Xanazole | Zamboprim | Zerrprim | Zolbach | Zolmed | Zoltrijem</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Aksotran | Albrotran | Amoxazol | Amtran | Amtril | Antibac | Antrima | Aratran | Ascotran | Bactrim | Biotran | Biprim | Boschtrim | Btran | Caretran | Chemizol | Chemotran | Clinitran | Co trifa | Co trimoxazole | Co-trimoxazol | Colitran | Comax | Cotri | Cotrim | Cotrimax | Cotrimaxazole | Cotrimoxazole | Cotrisul | Cotrizole | Cozol | Dosatran | Dubac | Dutran | Eroprim | Fakzol | Flocot | Hicot | Infectran | Kaytran | Kotazol | Lifzol | Lobact | Longasal | Mactran | Martiprim | Maxol | Maxzol | Mazatrim | Meditran | Mexaprim | Mexazole | Naftran | Nicotrim | Novozole | Octil-s | Octran | Opiran | Orgastran | Ostrin forte | Pabtran | Pakzole | Penetrin | Pharmazol | Phartex | Polytran | Primox | Radisulf | Rascotran | Rexaprim | Santrix | Saptri | Saptrim | Semozol | Sepiran | Septazol | SEPTRAN | Septran ds | Septrawin | Siltran | Smartrim | Sosetran | Sulfarim | Sulforin | Sulphaprim | Sulphatran | Sulprim | Sumitran | Suptrex | Synbac | Therasept | Tricare | Trimex | Trimoxin | Triprim | Trisep | Trizol | Wiltran | Xa-zole | Zactron | Zantran | Zeptra | Zolebid</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Bactrim | Biseptol | Duo septol | Groseptol | Sumetrolin | Two septol</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Bactrim | Bactrim ds | Bethaprim | Septra | Septra ds | Sulfamethoxazole and trimethoprim | Sulfatrim | Sultrex</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Bactrim | Cotrim forte | Cotrimoxazol | Cotrimoxazol teva | Cotrimoxazole Ratiopharm | Metomide | Septrin</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Bacterol | Bacterol forte | Bacterol pediatrico | Bactrim | Bactrim forte | Camex s | Camex s forte | Co trimoxazol caplin point | Meditrin | Septoprim | Septoprim forte | Sulamin | Sulamin forte | Sulditen | Sulditen forte | Sulfa sepsidin | Sulfa sepsidin forte | Sulfagrand | Sulfametoxazol + trimetoprim bilac | Sulfametoxazol + trimetoprim kirei | Sulfametoxazol + trimetoprima bilac | Sulfametozaxol trimetoprim dasanti | Sulfatrim | Teraprodil | Teraprodil forte | Trimetoprima sulfametoxazol cellofarm | Trimezol | Trimezol forte | Trimsul | Trimsul forte</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Apo-Sulfatrim | Bactrim | Bactrim Forte | Chemotrim | Chemotrim Forte | Cotrimhexal Forte | Farcotrim | Septrin | Septrin DS | Trimol | Trimol DS</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Bactrim | Berlocid | Biseptol | Biseptrim | Bitrim | Blexon | Cotrim diolan | Cotrimoxazol | Resprim | Septrin</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Apo sulfatrim | Bacteriof.klebs pn | Bactrim | Bactrim forte | Berlocid | Bi septin | Bicotrim | Biseptol | Brifeseptol | Ciplin | Co-trimoxazole | Co-trimoxazole akri | Co-trimoxazole sti | Cotrimol | Cotrimoxazol | Cotrimoxazol vatch | Cotripharm | Duo septol | Dvaseptol | Groseptol | Oriprim | Rancotrim | Septrin | Sulfaton | Sumetrolim | Trimezol | Trimosul</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo sulfatrim | Bactrim | Balkatrin | Balkatrin forte | Chemotrim | Nortrime | Septazol | Septrin | Sutrim | Theraprim | Trimol</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Bactrim | Bactrim forte | Eusaprim | Triferm sulfa | Trimetoprim sulfa | Trimetoprim sulfa gea</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Bacin | Chemix | Chemoprim | Dhatrin | Mortin | Primzole | Resprim | Septrin | Sulfaprim | Suprim | Syntoprim | Trimaxazole</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Eusaprim | Primotren | Septrin pediatrico | Sinersul | Sulotrim</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Berlocid | Biseptol | Bismoral | Nopil | Oriprim | Primotren | Sinersul | Sumetrolim</span>;</li>
<li>
<span class="countryCode">(SL)</span> <span class="country">Sierra Leone</span><span class="countrySeparator">: </span><span class="drugName">Co trimoxazole | Mihitrim | Welcotrim</span>;</li>
<li>
<span class="countryCode">(SV)</span> <span class="country">El Salvador</span><span class="countrySeparator">: </span><span class="drugName">Trimetoprim sulfametoxazole cr</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Actin | Bacin | Bacoprim | Bactoprim | Bactrim | Baczole | Basatin | Betam | Canamed | Chemoprim | Co tri | Co-tasian | Co-trimed | Co-trimed d/s | Co-trimoxazole | Cofatrim | Comox | Coprim | Cotri | Cotrim | Cotrim forte | Cotrimoxazole | Cotrixyl-L | G prim | Gaprim | K.B.Famate | Ko-kure | Lastrim | Lastrim C | Letus | M-Moxa | M-trim | Maxitrin | Maxitrin-C | Medcotrim | Metrim | Metrim-f | Metrim-h | Metxaprim | Microtrim | Motrim | Moxatrim | Panatrim | Po Trim | Rancotrim | Septra | Septrin | Septrin-s | Servitrim | Spectrim | Sulfamet | Sulfometh | Sulfotrim | Sulfotrim Ped | Sulprim | Sulprimed | Sultrim | Suntrim | Supim | Sutrim | Trimetrin | Trimexazole | Trimoxin | Trimytrim | Triprim | Trixzol | Win trim</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Altrim | Bactekod | Bactrim | Balkatrin | Berlocid | Cotrim | Cotrimox | Eusaprim | Sulfatrim | Sumetrolim</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Bactrim | Bactrim forte | Bakton | Baktrisid DS | Baktrol | Bibakrim | Biotrin | Kemoprim | Kemoprim fort | Metoprim | Mikrosid | Septrin | Sulfaprim | Trifen | Trimoks</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Andcide | Bacdan | Bacidim | Bacin | Bactrim | Baktacin | Baktar | Baktsin | Beyliyan | Bicidium | Chemix | Co trimoxazol | Co-trimoxazole | Coyenlin | Euctrim | Nopil | Pantrim | Senfihu | Septrin | Shuo mai pei lin ding | Sigaprim | Sinotrim | Sinzuin | Sioclofen | Someprim | Sulfatrim | Sulfotrim | Sultrim | Sultrimerim | Suprin | Tonz | Trimazole | Trimerin | Trimesin | Trimezol | Trimezole | Trimox | Waribact ts</span>;</li>
<li>
<span class="countryCode">(TZ)</span> <span class="country">Tanzania, United Republic of</span><span class="countrySeparator">: </span><span class="drugName">Septrin | Shetrim</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Bactiseptol | Bactrim | Berlocid | Bi sept farmak | Bicotrim | Biseptazol | Biseptol | Blexon | Co-trimoxazole | Cotrimoxazol | Duo septol | Groseptol | Oriprim | Rancotrim | Raseptol | Rivoprim | Septrin | Sinersul | Sulfaton | Sumetrolim | Trimosul | Tryseptolum</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Alprim | Astrim | Betrim | Ciplin | Ciplin ds | Co trimoxazole | Cosatrim | Cosatrim ds | Cotramox | Cotrikant | Cotrim | Cotrimoxazole | Emtrim | Emtrim forte | K trim | Kam cotri | L trim | L trim ds | Lecotrim | Megatrim | Renetrim | Renetrim d.s | Septrin | Simtrim | Sulfamethoxazole and trimethoprim | Sulfran | Sulfran ds | Sulphatrim | Trimago | Unitrim | Zeptrin</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Bacteracin f | Bacticel | Bactrim | Bactrim forte | Cotrimoxazol | Danferane | Herixina | Sistrim | Sistrim forte | Spectrex | Sulfatrim | Sulphax | Ultrim</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Bactrimel | Bactron | Baxolex | Co-sultrin | Cotrimoxazol | Forcrim | Novactil | Sulfametoxazol/trimetoprim | Sultrim fuerte | Trimesul forte | Trimetoprim + sulfametoxazol | Trimetoprim sulfa | Trimetoprim sulfametoxazol | Trimetoprim/sulfametoxazol | Trimetoprima sulfametoxazol | Trimetropim y sulfametoxazol | Tripur</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Agi cotrim | Bidiseptol | Bisepthabi | Cotrimstada forte | Disulfa | Dutased | Pms cotrim | Sanseptol | Sulfatrim | Tanacotrimf | Tidacotrim | Trimeseptol | Vacotrim</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Adco-co-trimoxazole | Aspen Cotrimazole | Bactrim | Bencole | Co trimoxazole biotech | Co-trimoxazole | Cocydal | Cotrim | Cozole | Dino-Bac | Doctrim | Fabubac | Ilvitrim | Lagatrim | Meditrim | Merck-co-trimoxazol | Mezenol | Micro co-trimoxazole | Micro-cotrimoxazol | Norisep | Novatrim | Nucotrim | Purbac | Purbac Ds | Q-med co-trimoxazole | Rolab-co-trimoxazole | SEPTRAN | Spectrim | Trimethox | Trimzol | Xerazole | Xeroprim</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Astrim | Bacrizole | Bactrizole | Betrim | Cadiprim | Ciplin | Ciplin ds | Co trimoxazole | Combact | Cotrim | Cotrimoxazole | Cotrizole | Fortrim a | L trim | Lyseptol | Megatrim | Mezenol | Ml cotri | Purbac | Rancotrim | Shetrim | Sulfamethoxazole and trimethoprim | Sulfatrim | Sulfatrim forte | Sulfran | Sulfran ds | Suprim | Timizol | Tprim | Trim | Trimago</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Bencole | Ciplin | Co-trimoxazole | Cotrimoxazole | Cotrizole | Cotrizole ds | Mezenol | Mortin | Novabact | Stritrim | Sulfamethoxazole and trimethoprim | Umoxazole</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18637204">
<a name="18637204"></a>Abusin S, Johnson S. Sulfamethoxazole/Trimethoprim induced liver failure: a case report. <i>Cases J</i>. 2008;1(1):44. doi:10.1186/1757-1626-1-44<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/18637204/pubmed" id="18637204" target="_blank">18637204</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33068096">
<a name="33068096"></a>Acharya A, Acharya SP, Bhattarai TR. Cotrimoxazole induced Steven Johnson Syndrome: A Case Report. <i>JNMA J Nepal Med Assoc</i>. 2020;58(229):702-704. doi:10.31729/jnma.4999<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/33068096/pubmed" id="33068096" target="_blank">33068096</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19319232">
<a name="19319232"></a>Accorinti M. Ocular bartonellosis. <i>Int J Med Sci</i>. 2009;6(3):131-132. doi:10.7150/ijms.6.131<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/19319232/pubmed" id="19319232" target="_blank">19319232</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31958969">
<a name="31958969"></a>Afolabi TM, Goodlet KJ, Fairman KA. Association of antibiotic treatment duration with recurrence of uncomplicated urinary tract infection in pediatric patients. <i>Ann Pharmacother</i>. 2020;54(8):757-766. doi:10.1177/1060028019900650<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/31958969/pubmed" id="31958969" target="_blank">31958969</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Agha.2021">
<a name="Agha.2021"></a>Agha R, Goldberg MB. Shigella infection: treatment and prevention in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 17, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3873890">
<a name="3873890"></a>Ahn YH, Goldman JM. Trimethoprim-sulfamethoxazole and hyponatremia. <i>Ann Intern Med</i>. 1985;103(1):161-162. doi:10.7326/0003-4819-103-1-161_3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/3873890/pubmed" id="3873890" target="_blank">3873890</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33067334">
<a name="33067334"></a>Aithal GP, Palaniyappan N, China L, et al. Guidelines on the management of ascites in cirrhosis. <i>Gut</i>. 2021;70(1):9-29. doi:10.1136/gutjnl-2020-321790<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/33067334/pubmed" id="33067334" target="_blank">33067334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10393376">
<a name="10393376"></a>Alappan R, Buller GK, Perazella MA. Trimethoprim-sulfamethoxazole therapy in outpatients: is hyperkalemia a significant problem?. <i>Am J Nephrol</i>. 1999;19(3):389-394. doi:10.1159/000013483<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/10393376/pubmed" id="10393376" target="_blank">10393376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16444382">
<a name="16444382"></a>Alvarez RF, Mattos AA, Corrêa EB, Cotrim HP, Nascimento TV. Trimethoprim-sulfamethoxazole versus norfloxacin in the prophylaxis of spontaneous bacterial peritonitis in cirrhosis. <i>Arq Gastroenterol</i>. 2005;42(4):256-262. doi:10.1590/s0004-28032005000400012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/16444382/pubmed" id="16444382" target="_blank">16444382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.2021">
<a name="AAP.2021"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021-2024 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21873693">
<a name="21873693"></a>American Academy of Pediatrics (AAP) Subcommittee on Urinary Tract Infection, Steering Committee on Quality improvement and Management. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. <i>Pediatrics. </i>2011;128(3):595-610.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/21873693/pubmed" id="21873693" target="_blank">21873693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17470834">
<a name="17470834"></a>Andersohn F, Konzen C, Garbe E. Systematic review: agranulocytosis induced by nonchemotherapy drugs. <i>Ann Intern Med</i>. 2007;146(9):657-665. doi:10.7326/0003-4819-146-9-200705010-00009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/17470834/pubmed" id="17470834" target="_blank">17470834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23535757">
<a name="23535757"></a>Anderson A, Bijlmer H, Fournier PE, et al. Diagnosis and management of Q fever--United States, 2013: recommendations from CDC and the Q Fever Working Group. <i>MMWR Recomm Rep.</i> 2013;62(RR-03):1-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/23535757/pubmed" id="23535757" target="_blank">23535757</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Anderson.2021">
<a name="Anderson.2021"></a>Anderson DJ, Sexton DJ. Antimicrobial prophylaxis for prevention of surgical site infection in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 5, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12963573">
<a name="12963573"></a>Andrès E, Noel E, Maloisel F. Trimethoprim-sulfamethoxazole-induced life-threatening agranulocytosis. <i>Arch Intern Med</i>. 2003;163(16):1975-1976. doi:10.1001/archinte.163.16.1975<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/12963573/pubmed" id="12963573" target="_blank">12963573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28879784">
<a name="28879784"></a>Andrès E, Mourot-Cottet R. Non-chemotherapy drug-induced neutropenia - an update. <i>Expert Opin Drug Saf</i>. 2017;16(11):1235-1242. doi:10.1080/14740338.2017.1376645<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/28879784/pubmed" id="28879784" target="_blank">28879784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31042112">
<a name="31042112"></a>Anger J, Lee U, Ackerman AL, et al. Recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU guideline.<i> J Urol</i>. 2019;202(2):282-289. doi: 10.1097/JU.0000000000000296.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/31042112/pubmed" id="31042112" target="_blank">31042112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12861854">
<a name="12861854"></a>Anliker MD, Wüthrich B. Acute generalized exanthematous pustulosis due to sulfamethoxazole with positive lymphocyte transformation test (LTT). <i>J Investig Allergol Clin Immunol</i>. 2003;13(1):66-68.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/12861854/pubmed" id="12861854" target="_blank">12861854</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2785785">
<a name="2785785"></a>Anti-infective drug use in relation to the risk of agranulocytosis and aplastic anemia. A report from the International Agranulocytosis and Aplastic Anemia Study. <i>Arch Intern Med</i>. 1989;149(5):1036-1040.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/2785785/pubmed" id="2785785" target="_blank">2785785</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.1">
<a name="Bradley.1"></a>Antimicrobial therapy according to clinical syndromes. In: Bradley JS, Nelson JD, Barnett ED, et al, eds. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 27th ed. American Academy of Pediatrics; 2021: chap 1.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20585070">
<a name="20585070"></a>Antoniou T, Gomes T, Juurlink DN, Loutfy MR, Glazier RH, Mamdani MM. Trimethoprim-sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: a population-based study. <i>Arch Intern Med</i>. 2010;170(12):1045-1049.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/20585070/pubmed" id="20585070" target="_blank">20585070</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21911446">
<a name="21911446"></a>Antoniou T, Gomes T, Mamdani MM, et al. Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study. <i>BMJ</i>. 2011;343.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/21911446/pubmed" id="21911446" target="_blank">21911446</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25646289">
<a name="25646289"></a>Antoniou T, Hollands S, Macdonald EM, et al. Trimethoprim-sulfamethoxazole and risk of sudden death among patients taking spironolactone. <i>CMAJ</i>. 2015;187(4):E138-143.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/25646289/pubmed" id="25646289" target="_blank">25646289</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18162038">
<a name="18162038"></a>Ariza J, Bosilkovski M, Cascio A, et al. Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations. <i>PLoS Med</i>. 2007;4(12):e317. doi:10.1371/journal.pmed.0040317<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/18162038/pubmed" id="18162038" target="_blank">18162038</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21175904">
<a name="21175904"></a>Arndt PA, Garratty G, Wolf CF, Rivera M. Haemolytic anaemia and renal failure associated with antibodies to trimethoprim and sulfamethoxazole. <i>Transfus Med</i>. 2011;21(3):194-198. doi:10.1111/j.1365-3148.2010.01061.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/21175904/pubmed" id="21175904" target="_blank">21175904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians, 2007, 154.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8229498">
<a name="8229498"></a>Ashkenazi S, Amir J, Waisman Y, et al. A Randomized, Double-Blind Study Comparing Cefixime and Trimethoprim-Sulfamethoxazole in the Treatment of Childhood Shigellosis. <i>J Pediatr</i>. 1993;123(5):817-821.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/8229498/pubmed" id="8229498" target="_blank">8229498</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19221284">
<a name="19221284"></a>Azfar RS, Cohn J, Schaffer A, Kim EJ. Trimethoprim sulfamethoxazole-induced sweet syndrome. <i>Arch Dermatol</i>. 2009;145(2):215-216. doi:10.1001/archderm.145.2.215<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/19221284/pubmed" id="19221284" target="_blank">19221284</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23891358">
<a name="23891358"></a>Babayev R, Terner S, Chandra S, Radhakrishnan J, Mohan S. Trimethoprim-associated hyponatremia. <i>Am J Kidney Dis</i>. 2013;62(6):1188-1192. doi:10.1053/j.ajkd.2013.06.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/23891358/pubmed" id="23891358" target="_blank">23891358</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bactrim.1">
<a name="Bactrim.1"></a>Bactrim (sulfamethoxazole and trimethoprim) injection [prescribing information]. Cranbury, NJ: Sun Pharmaceuticals; May 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bactrim.2">
<a name="Bactrim.2"></a>Bactrim and Bactrim DS (sulfamethoxazole and trimethoprim) [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries Inc; April 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bactrim.3">
<a name="Bactrim.3"></a>Bactrim Pedatric Suspension (sulfamethoxazole and trimethoprim) [prescribing information]. Cranbury, NJ: Sun Pharmaceuticals; May 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Berbari.2022">
<a name="Berbari.2022"></a>Baddour LM, Chen AF. Prosthetic joint infection: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 1, 2022b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baddour.2019a">
<a name="Baddour.2019a"></a>Baddour LM, Harper M. Animal bites (dogs, cats, and other mammals): Evaluation and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 27, 2023a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baddour.2019b">
<a name="Baddour.2019b"></a>Baddour LM, Harper M. Human bites: evaluation and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 27, 2023b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baddour.2018">
<a name="Baddour.2018"></a>Baddour LM. Impetigo. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 5, 2022c.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36043414">
<a name="36043414"></a>Baddour LM, Weimer MB, Wurcel AG, et al; American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; and Council on Peripheral Vascular Disease. Management of infective endocarditis in people who inject drugs: a scientific statement from the American Heart Association. <i>Circulation</i>. 2022b;146(14):e187-e201. doi:10.1161/CIR.0000000000001090<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/36043414/pubmed" id="36043414" target="_blank">36043414</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29292282">
<a name="29292282"></a>Balighian E, Burke M. Urinary tract infections in children. <i>Pediatr Rev</i>. 2018;39(1):3-12. doi:10.1542/pir.2017-0007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/29292282/pubmed" id="29292282" target="_blank">29292282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23262188">
<a name="23262188"></a>Bapani S, Epperla N, Kasirye Y, Mercier R, Garcia-Montilla R. ADAMTS13 deficiency and thrombotic thrombocytopenic purpura associated with trimethoprim-sulfamethoxazole. <i>Clin Med Res</i>. 2013;11(2):86-90. doi:10.3121/cmr.2012.1105<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/23262188/pubmed" id="23262188" target="_blank">23262188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25047526">
<a name="25047526"></a>Ben Salem C, Badreddine A, Fathallah N, Slim R, Hmouda H. Drug-induced hyperkalemia. <i>Drug Saf</i>. 2014;37(9):677-692.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/25047526/pubmed" id="25047526" target="_blank">25047526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3501774">
<a name="3501774"></a>Berg PA, Daniel PT. Co-trimoxazole-induced hepatic injury--an analysis of cases with hypersensitivity-like reactions. <i>Infection</i>. 1987;15(suppl 5):S259-S264. doi:10.1007/BF01643200<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/3501774/pubmed" id="3501774" target="_blank">3501774</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32365216">
<a name="32365216"></a>Betschart C, Albrich WC, Brandner S, et al. Guideline of the Swiss Society of Gynaecology and Obstetrics (SSGO) on acute and recurrent urinary tract infections in women, including pregnancy. <i>Swiss Med Wkly</i>. 2020;150:w20236. doi:10.4414/smw.2020.20236<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/32365216/pubmed" id="32365216" target="_blank">32365216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33942342">
<a name="33942342"></a>Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. <i>Hepatology</i>. 2021;74(2):1014-1048. doi:10.1002/hep.31884<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/33942342/pubmed" id="33942342" target="_blank">33942342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9641580">
<a name="9641580"></a>Bijl AM, Van der Klauw MM, Van Vliet AC, Stricker BH. Anaphylactic reactions associated with trimethoprim. <i>Clin Exp Allergy</i>. 1998;28(4):510-512. doi:10.1046/j.1365-2222.1998.00258.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/9641580/pubmed" id="9641580" target="_blank">9641580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7794554">
<a name="7794554"></a>Bissuel F, Cotte L, Crapanne JB, et al, “Trimethoprim-Sulphamethoxazole Rechallenge in 20 Previously Allergic HIV-Infected Patients After Homeopathic,” <i>AIDS</i>, 1995, 9(4):407-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/7794554/pubmed" id="7794554" target="_blank">7794554</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16165719">
<a name="16165719"></a>Björnsson E, Jerlstad P, Bergqvist A, Olsson R. Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. <i>Scand J Gastroenterol</i>. 2005;40(9):1095-1101. doi:10.1080/00365520510023846<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/16165719/pubmed" id="16165719" target="_blank">16165719</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30558872">
<a name="30558872"></a>Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. <i>Lancet</i>. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/30558872/pubmed" id="30558872" target="_blank">30558872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31782698">
<a name="31782698"></a>Bosilkovski M, Arapović J, Keramat F. Human brucellosis in pregnancy - an overview. <i>Bosn J Basic Med Sci</i>. 2020;20(4):415-422. doi:10.17305/bjbms.2019.4499<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/31782698/pubmed" id="31782698" target="_blank">31782698</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33650077">
<a name="33650077"></a>Bosilkovski M, Keramat F, Arapović J. The current therapeutical strategies in human brucellosis. <i>Infection</i>. 2021;49(5):823-832. doi:10.1007/s15010-021-01586-w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/33650077/pubmed" id="33650077" target="_blank">33650077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34734902">
<a name="34734902"></a>Bouferraa Y, Bou Zerdan M, Hamouche R, Azar E, Afif C, Jabbour R. Neurobrucellosis: brief review. <i>Neurologist</i>. 2021;26(6):248-252. doi:10.1097/NRL.0000000000000348<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/34734902/pubmed" id="34734902" target="_blank">34734902</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29255730">
<a name="29255730"></a>Bowen AC, Carapetis JR, Currie BJ, Fowler V Jr, Chambers HF, Tong SYC. Sulfamethoxazole-Trimethoprim (Cotrimoxazole) for Skin and Soft Tissue Infections Including Impetigo, Cellulitis, and Abscess. <i>Open Forum Infect Dis</i>. 2017;4(4):ofx232. doi:10.1093/ofid/ofx232<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/29255730/pubmed" id="29255730" target="_blank">29255730</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25172376">
<a name="25172376"></a>Bowen AC, Tong SY, Andrews RM, et al. Short-course oral co-trimoxazole versus intramuscular benzathine benzylpenicillin for impetigo in a highly endemic region: an open-label, randomised, controlled, non-inferiority trial. <i>Lancet</i>. 2014;384(9960):2132-2140. doi:10.1016/S0140-6736(14)60841-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/25172376/pubmed" id="25172376" target="_blank">25172376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15303450">
<a name="15303450"></a>Brackett CC, Singh H, Block JH. Likelihood and mechanisms of cross-allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group. <i>Pharmacotherapy</i>. 2004;24(7):856-870. doi:10.1592/phco.24.9.856.36106<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/15303450/pubmed" id="15303450" target="_blank">15303450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23327981">
<a name="23327981"></a>Bratzler DW, Dellinger EP, Olsen KM, et al; American Society of Health-System Pharmacists; Infectious Disease Society of America; Surgical Infection Society; Society for Healthcare Epidemiology of America. Clinical practice guidelines for antimicrobial prophylaxis in surgery. <i>Am J Health Syst Pharm</i>. 2013;70(3):195-283. doi:10.2146/ajhp120568<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/23327981/pubmed" id="23327981" target="_blank">23327981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24910807">
<a name="24910807"></a>Brown GR. Cotrimoxazole - optimal dosing in the critically ill. <i>Ann Intensive Care</i>. 2014;4:13. doi:10.1186/2110-5820-4-13<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/24910807/pubmed" id="24910807" target="_blank">24910807</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23478961">
<a name="23478961"></a>Brown KA, Khanafer N, Daneman N, Fisman DN. Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. <i>Antimicrob Agents Chemother</i>. 2013;57(5):2326-2332. doi:10.1128/AAC.02176-12<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/23478961/pubmed" id="23478961" target="_blank">23478961</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25240332">
<a name="25240332"></a>Bruner KE, Coop CA, White KM. Trimethoprim-sulfamethoxazole-induced aseptic meningitis-not just another sulfa allergy. <i>Ann Allergy Asthma Immunol</i>. 2014;113(5):520-526. doi:10.1016/j.anai.2014.08.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/25240332/pubmed" id="25240332" target="_blank">25240332</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25985401">
<a name="25985401"></a>Buijs BS, van den Berk GE, Boateng CP, Hoepelman AI, van Maarseveen EM, Arends JE. Cross-reactivity between darunavir and trimethoprim-sulfamethoxazole in HIV-infected patients. <i>AIDS</i>. 2015;29(7):785-791. doi:10.1097/QAD.0000000000000612<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/25985401/pubmed" id="25985401" target="_blank">25985401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32391402">
<a name="32391402"></a>Butler-Laporte G, Smyth E, Amar-Zifkin A, Cheng MP, McDonald EG, Lee TC. Low-dose TMP-SMX in the treatment of <i>Pneumocystis jirovecii</i> pneumonia: a systematic review and meta-analysis. <i>Open Forum Infect Dis</i>. 2020;7(5):ofaa112. doi:10.1093/ofid/ofaa112<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/32391402/pubmed" id="32391402" target="_blank">32391402</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2498187">
<a name="2498187"></a>Calabrò V, Cascone A, Malaspina P, Battistuzzi G. Glucose-6-phosphate dehydrogenase (G6PD) deficiency in southern Italy: a case of G6PD A(-) associated with favism. <i>Haematologica</i>. 1989;74(1):71-73.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/2498187/pubmed" id="2498187" target="_blank">2498187</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24750132">
<a name="24750132"></a>Can C, Akkelle E, Bay B, Arıcan O, Yalçın O, Yazicioglu M. Generalized fixed drug eruption in a child due to trimethoprim/sulfamethoxazole. <i>Pediatr Allergy Immunol</i>. 2014;25(4):413-415. doi:10.1111/pai.12204<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/24750132/pubmed" id="24750132" target="_blank">24750132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27424851">
<a name="27424851"></a>Carroll TG, Carroll MG. Methemoglobinemia in a pediatric oncology patient receiving sulfamethoxazole/trimethoprim prophylaxis. <i>Am J Case Rep</i>. 2016;17:499-502. doi:10.12659/ajcr.897820<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/27424851/pubmed" id="27424851" target="_blank">27424851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2020.2">
<a name="CDC.2020.2"></a>Centers for Disease Control and Prevention (CDC). Brucellosis reference guide: exposures, testing, and prevention. <a href="https://www.cdc.gov/brucellosis/pdf/brucellosi-reference-guide.pdf" target="_blank">https://www.cdc.gov/brucellosis/pdf/brucellosi-reference-guide.pdf</a>. Updated February 2017. Accessed August 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2017">
<a name="CDC.2017"></a>Centers for Disease Control and Prevention (CDC). DPDx - Laboratory identification of parasitic diseases of public health concern. Cystoisosporiasis. <a href="https://www.cdc.gov/dpdx" target="_blank">https://www.cdc.gov/dpdx</a>. Updated November 29, 2013b. Accessed October 13, 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2020">
<a name="CDC.2020"></a>Centers for Disease Control and Prevention (CDC). FAQs for clinicians about C. diff. <a href="https://www.cdc.gov/cdiff/clinicians/faq.html" target="_blank">https://www.cdc.gov/cdiff/clinicians/faq.html</a>. Updated March 27, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2009">
<a name="CDC.2009"></a>Centers for Disease Control and Prevention (CDC), "Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children," <i>MMWR Recomm Rep</i>, 2009, 58(RR-11):1-166. Available at http://www.antimicrobe.org/h04c.files/history/CDC-HIV%20ExposeInfectChildren-2009.pdf
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2012">
<a name="CDC.2012"></a>Centers for Disease Control and Prevention (CDC). National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS): Human Isolates Final Report, 2010. Atlanta, Georgia: US Department of Health and Human Services, CDC, 2012. <a href="https://www.cdc.gov/narms/pdf/2010-annual-report-narms.pdf" target="_blank">https://www.cdc.gov/narms/pdf/2010-annual-report-narms.pdf</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control and Prevention (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2016">
<a name="CDC.2016"></a>Centers for Disease Control and Prevention (CDC). Nocardiosis: laboratory diagnostics and treatment. <a href="https://www.cdc.gov/nocardiosis/health-care-workers/laboratory-diagnostics.html" target="_blank">https://www.cdc.gov/nocardiosis/health-care-workers/laboratory-diagnostics.html</a>. Updated March 30, 2016. Accessed October 13, 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2013">
<a name="CDC.2013"></a>Centers for Disease Control and Prevention (CDC). Treatment for cyclosporiasis. <a href="https://www.cdc.gov/parasites/cyclosporiasis/health_professionals/tx.html" target="_blank">https://www.cdc.gov/parasites/cyclosporiasis/health_professionals/tx.html</a>. Updated January 10, 2013a. Accessed October 10, 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25754159">
<a name="25754159"></a>Chalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. <i>Gastroenterology</i>. 2015;148(7):1340-52.e7. doi:10.1053/j.gastro.2015.03.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/25754159/pubmed" id="25754159" target="_blank">25754159</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28762375">
<a name="28762375"></a>Chalasani N, Reddy KRK, Fontana RJ, et al. Idiosyncratic drug induced liver injury in African-Americans is associated with greater morbidity and mortality compared to Caucasians. <i>Am J Gastroenterol</i>. 2017;112(9):1382-1388. doi:10.1038/ajg.2017.215<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/28762375/pubmed" id="28762375" target="_blank">28762375</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22053600">
<a name="22053600"></a>Chantachaeng W, Chularojanamontri L, Kulthanan K, Jongjarearnprasert K, Dhana N. Cutaneous adverse reactions to sulfonamide antibiotics. <i>Asian Pac J Allergy Immunol</i>. 2011;29(3):284-289.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/22053600/pubmed" id="22053600" target="_blank">22053600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19620336">
<a name="19620336"></a>Cheng AC, McBryde ES, Wuthiekanun V, et al. Dosing regimens of cotrimoxazole (trimethoprim-sulfamethoxazole) for melioidosis. <i>Antimicrob Agents Chemother.</i> 2009;53(10):4193-4199. doi:10.1128/AAC.01301-08<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/19620336/pubmed" id="19620336" target="_blank">19620336</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Choo.1995">
<a name="Choo.1995"></a>Choo V. UK Revises Indications for Co-Trimoxazole. <i>Lancet</i>. 1995;346(8968):175.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23551893">
<a name="23551893"></a>Clajus C, Kühn-Velten WN, Schmidt JJ, et al. Cotrimoxazole plasma levels, dialyzer clearance and total removal by extended dialysis in a patient with acute kidney injury: risk of under-dosing using current dosing recommendations. <i>BMC Pharmacol Toxicol</i>. 2013;14:19. doi:10.1186/2050-6511-14-19<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/23551893/pubmed" id="23551893" target="_blank">23551893</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1749295">
<a name="1749295"></a>Cockerill FR, Edson RS. Trimethoprim-Sulfamethoxazole. <i>Mayo Clin Proc</i>. 1991;66(12):1260-1269.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/1749295/pubmed" id="1749295" target="_blank">1749295</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17966006">
<a name="17966006"></a>Cordero-Ampuero J, Esteban J, Garcia-Cimbrelo E, Munuera L, Escobar R. Low relapse with oral antibiotics and two-stage exchange for late arthroplasty infections in 40 patients after 2-9 years. <i>Acta Orthopaedica.</i> 2007;78(4):511-519.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/17966006/pubmed" id="17966006" target="_blank">17966006</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19884587">
<a name="19884587"></a>Crider KS, Cleves MA, Reefhuis J, et al. Antibacterial Medication Use During Pregnancy and Risk of Birth Defects: National Birth Defects Prevention Study. <i>Arch Pediatr Adolesc Med</i>. 2009;163(11):978-985.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/19884587/pubmed" id="19884587" target="_blank">19884587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20823279">
<a name="20823279"></a>Curkovic I, Lüthi B, Franzen D, Ceschi A, Rudiger A, Corti N. Trimethoprim/Sulfamethoxazole pharmacokinetics in two patients undergoing continuous venovenous hemodiafiltration. <i>Ann Pharmacother</i>. 2010;44(10):1669‐1672. doi:10.1345/aph.1P160<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/20823279/pubmed" id="20823279" target="_blank">20823279</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Currie.2021">
<a name="Currie.2021"></a>Currie B, Anstey NM. Melioidosis: treatment and prevention. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 21, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11738517">
<a name="11738517"></a>Czeizel AE, Rockenbauer M, Sørensen HT, et al. The Teratogenic Risk of Trimethoprim-Sulfonamides: A Population Based Case-Control Study. <i>Reprod Toxicol</i>. 2001;15(6):637-646.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/11738517/pubmed" id="11738517" target="_blank">11738517</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28657870">
<a name="28657870"></a>Daum RS, Miller LG, Immergluck L, et al. A placebo-controlled trial of antibiotics for smaller skin abscesses. <i>N Engl J Med</i>. 2017;376(26):2545-2555. doi:10.1056/NEJMoa1607033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/28657870/pubmed" id="28657870" target="_blank">28657870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12962348">
<a name="12962348"></a>Della-Giustina K, Chow G. Medications in Pregnancy and Lactation. <i>Emerg Med Clin North Am</i>. 2003;21(3):585-613.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/12962348/pubmed" id="12962348" target="_blank">12962348</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30664553">
<a name="30664553"></a>Desai M, Fathallah J, Nutalapati V, Saligram S. Antibiotics versus no antibiotics for acute uncomplicated diverticulitis: a systematic review and meta-analysis. <i>Dis Colon Rectum</i>. 2019;62(8):1005-1012. doi:10.1097/DCR.0000000000001324<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/30664553/pubmed" id="30664553" target="_blank">30664553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24879980">
<a name="24879980"></a>Devarbhavi H, Andrade RJ. Drug-induced liver injury due to antimicrobials, central nervous system agents, and nonsteroidal anti-inflammatory drugs. <i>Semin Liver Dis</i>. 2014;34(2):145-161. doi:10.1055/s-0034-1375956<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/24879980/pubmed" id="24879980" target="_blank">24879980</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dixon.1">
<a name="Dixon.1"></a>Dixon JM. Lactational mastitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 31, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11200867">
<a name="11200867"></a>Don BR. The effect of trimethoprim on potassium and uric acid metabolism in normal human subjects. <i>Clin Nephrol</i>. 2001;55(1):45-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/11200867/pubmed" id="11200867" target="_blank">11200867</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34983426">
<a name="34983426"></a>Dong Y, Sun D, Wang Y, et al. Evaluation of the current guidelines for antibacterial therapy strategies in patients with cirrhosis or liver failure. <i>BMC Infect Dis</i>. 2022;22(1):23. doi:10.1186/s12879-021-07018-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/34983426/pubmed" id="34983426" target="_blank">34983426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29876667">
<a name="29876667"></a>Dorn JM, Alpern M, McNulty C, Volcheck GW. Sulfonamide drug allergy. <i>Curr Allergy Asthma Rep</i>. 2018;18(7):38. doi:10.1007/s11882-018-0791-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/29876667/pubmed" id="29876667" target="_blank">29876667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1093649">
<a name="1093649"></a>Dow D. Trimethoprim-sulfamethoxazole in the treatment of chronic prostatitis. <i>Can Med Assoc J</i>. 1975;112(13 Spec No):26-27.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/1093649/pubmed" id="1093649" target="_blank">1093649</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29256130">
<a name="29256130"></a>Drobnis EZ, Nangia AK. Antimicrobials and male reproduction. <i>Adv Exp Med Biol</i>. 2017;1034:131-161. doi:10.1007/978-3-319-69535-8_10<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/29256130/pubmed" id="29256130" target="_blank">29256130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12077579">
<a name="12077579"></a>Eliaszewicz M, Flahault A, Roujeau JC, et al. Prospective evaluation of risk factors of cutaneous drug reactions to sulfonamides in patients with AIDS. <i>J Am Acad Dermatol</i>. 2002;47(1):40-46. doi:10.1067/mjd.2002.120468<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/12077579/pubmed" id="12077579" target="_blank">12077579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20633946">
<a name="20633946"></a>European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. <i>J Hepatol.</i> 2010;53(3):397-417. doi:10.1016/j.jhep.2010.05.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/20633946/pubmed" id="20633946" target="_blank">20633946</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29653741">
<a name="29653741"></a>European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. <i>J Hepatol</i>. 2018;69(2):406-460. doi:10.1016/j.jhep.2018.03.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/29653741/pubmed" id="29653741" target="_blank">29653741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOH">
<a name="Expert.DOH"></a>Expert opinion. Senior Hepatic Editorial Team: Matt Harris, PharmD, MHS, BCPS, FAST; Jeong Park, PharmD, MS, BCTXP, FCCP, FAST; Arun Jesudian, MD; Sasan Sakiani, MD.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOO">
<a name="Expert.DOO"></a>Expert opinion. Senior Obesity Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Eyre.2019">
<a name="Eyre.2019"></a>Eyre RC. Evaluation of acute scrotal pain in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 1, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11565082">
<a name="11565082"></a>Fishman JA. Prevention of infection caused by Pneumocystis carinii in transplant recipients. <i>Clin Infect Dis.</i> 2001;33(8):1397-1405.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/11565082/pubmed" id="11565082" target="_blank">11565082</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31077616">
<a name="31077616"></a>Fishman JA, Gans H; AST Infectious Diseases Community of Practice. Pneumocystis jiroveci in solid organ transplantation: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clin Transplant</i>. 2019;33(9):e13587. doi:10.1111/ctr.13587<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/31077616/pubmed" id="31077616" target="_blank">31077616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22351681">
<a name="22351681"></a>Fraser TN, Avellaneda AA, Graviss EA, Musher DM. Acute kidney injury associated with trimethoprim/sulfamethoxazole. <i>J Antimicrob Chemother</i>. 2012;67(5):1271-1277. doi:10.1093/jac/dks030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/22351681/pubmed" id="22351681" target="_blank">22351681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30777258">
<a name="30777258"></a>Galli L, Venturini E, Bassi A, et al. Common community-acquired bacterial skin and soft-tissue infections in children: an intersociety consensus on impetigo, abscess, and cellulitis treatment. <i>Clin Ther</i>. 2019;41(3):532-551.e17. doi:10.1016/j.clinthera.2019.01.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/30777258/pubmed" id="30777258" target="_blank">30777258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29492352">
<a name="29492352"></a>Gaudel P, Qavi AH, Basak P. Life-threatening thrombocytopenia secondary to trimethoprim/sulfamethoxazole. <i>Cureus</i>. 2017;9(12):e1963. doi:10.7759/cureus.1963<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/29492352/pubmed" id="29492352" target="_blank">29492352</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24259630">
<a name="24259630"></a>Gentry CA, Nguyen AT. An evaluation of hyperkalemia and serum creatinine elevation associated with different dosage levels of outpatient trimethoprim-sulfamethoxazole with and without concomitant medications. <i>Ann Pharmacother.</i> 2013;47(12):1618-1626. doi:10.1177/1060028013509973<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/24259630/pubmed" id="24259630" target="_blank">24259630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GOLD.1">
<a name="GOLD.1"></a>Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for prevention, diagnosis and management of COPD: 2022 report. https://goldcopd.org/2023-gold-report-2/. Updated 2023. Accessed January 30, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Goldenberg.2019">
<a name="Goldenberg.2019"></a>Goldenberg DL, Sexton DJ. Septic arthritis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 1, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Golightly.2013">
<a name="Golightly.2013"></a>Golightly LK, Teitelbaum I, Kiser TH, et al, eds. <i>Renal Pharmacotherapy</i>. New York, NY: Springer Science; 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6230976">
<a name="6230976"></a>Gordin FM, Simon GL, Wofsy CB, Mills J. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. <i>Ann Intern Med</i>. 1984;100(4):495-499. doi:10.7326/0003-4819-100-4-495<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/6230976/pubmed" id="6230976" target="_blank">6230976</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8304370">
<a name="8304370"></a>Gordin F, Gibert C, Schmidt ME. Clostridium difficile colitis associated with trimethoprim-sulfamethoxazole given as prophylaxis for Pneumocystis carinii pneumonia. <i>Am J Med</i>. 1994;96(1):94-95. doi:10.1016/0002-9343(94)90124-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/8304370/pubmed" id="8304370" target="_blank">8304370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20308389">
<a name="20308389"></a>Grant MH, Ravreby H, Lorber B. Cure of Listeria monocytogenes meningitis after early transition to oral therapy.<i> Antimicrob Agents Chemother.</i> 2010;54(5):2276-2277. doi:10.1128/AAC.01815-09<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/20308389/pubmed" id="20308389" target="_blank">20308389</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8328737">
<a name="8328737"></a>Greenberg S, Reiser IW, Chou SY, Porush JG. Trimethoprim-sulfamethoxazole induces reversible hyperkalemia. <i>Ann Intern Med</i>. 1993;119(4):291-295. doi:10.7326/0003-4819-119-4-199308150-00007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/8328737/pubmed" id="8328737" target="_blank">8328737</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31796504">
<a name="31796504"></a>Grinlington L, Choo S, Cranswick N, Gwee A. Non-β-lactam antibiotic hypersensitivity reactions. <i>Pediatrics</i>. 2020;145(1):e20192256. doi:10.1542/peds.2019-2256<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/31796504/pubmed" id="31796504" target="_blank">31796504</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11170940">
<a name="11170940"></a>Guerrant RL, Van Gilder T, Steiner TS, et al; Infectious Diseases Society of America. Practice guidelines for the management of infectious diarrhea. <i>Clin Infect Dis</i>. 2001;32(3):331-351.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/11170940/pubmed" id="11170940" target="_blank">11170940</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hooton.2021a">
<a name="Hooton.2021a"></a>Gupta K. Acute simple cystitis in women. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 5, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hooton.2021b">
<a name="Hooton.2021b"></a>Gupta K. Acute simple cystitis in adult males. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 5, 2022b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hooton.2021c">
<a name="Hooton.2021c"></a>Gupta K. Recurrent simple cystitis in women. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 5, 2022c.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hooton.2021d">
<a name="Hooton.2021d"></a>Gupta K. Acute complicated urinary tract infection (including pyelonephritis) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 5, 2022d.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21292654">
<a name="21292654"></a>Gupta K, Hooton TM, Naber KG, et al; Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases.<i> Clin Infect Dis.</i> 2011;52(5):e103-e120. doi:10.1093/cid/ciq257<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/21292654/pubmed" id="21292654" target="_blank">21292654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27869362">
<a name="27869362"></a>Hall RG Nd, Pasipanodya JG, Meek C, Leff RD, Swancutt M, Gumbo T. Fractal geometry-based decrease in trimethoprim-sulfamethoxazole concentrations in overweight and obese people. <i>CPT Pharmacometrics Syst Pharmacol.</i> 2016;5(12):674-681. doi:10.1002/psp4.12146<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/27869362/pubmed" id="27869362" target="_blank">27869362</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3608139">
<a name="3608139"></a>Harle DG, Baldo BA, Smal MA, Van Nunen SA. An immunoassay for the detection of IgE antibodies to trimethoprim in the sera of allergic patients. <i>Clin Allergy</i>. 1987;17(3):209-216. doi:10.1111/j.1365-2222.1987.tb02005.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/3608139/pubmed" id="3608139" target="_blank">3608139</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3237218">
<a name="3237218"></a>Harle DG, Baldo BA, Wells JV. Drugs as allergens: detection and combining site specificities of IgE antibodies to sulfamethoxazole. <i>Mol Immunol</i>. 1988;25(12):1347-1354. doi:10.1016/0161-5890(88)90050-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/3237218/pubmed" id="3237218" target="_blank">3237218</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-13553575">
<a name="13553575"></a>Harris RC, Lucey JF, Maclean JR. Kernicterus in premature infants associated with low concentrations of bilirubin in the plasma. <i>Pediatrics</i>. 1958;21(6):875-884.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/13553575/pubmed" id="13553575" target="_blank">13553575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hasbun.2021">
<a name="Hasbun.2021"></a>Hasbun R. Initial therapy and prognosis of community-acquired bacterial meningitis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 12, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19397464">
<a name="19397464"></a>Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. <i>Pharmacotherapy.</i> 2009;29(5):562-577.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/19397464/pubmed" id="19397464" target="_blank">19397464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22146873">
<a name="22146873"></a>Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. <i>J Antimicrob Chemother</i>. 2012;67(3):742-748. doi:10.1093/jac/dkr508<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/22146873/pubmed" id="22146873" target="_blank">22146873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hernandez.2001">
<a name="Hernandez.2001"></a>Hernández-Díaz S and Mitchell AA, Author reply, <i>NEJM</i>, 2001, 344(12): 934-5.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11096168">
<a name="11096168"></a>Hernández-Díaz S, Werler MM, Walker AM, et al. Folic Acid Antagonists During Pregnancy and the Risk of Birth Defects. <i>N Engl J Med</i>. 2000;343(22):1608-1614.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/11096168/pubmed" id="11096168" target="_blank">11096168</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36000348">
<a name="36000348"></a>Hirai T, Shiraishi C, Nakai S, Ushiro M, Hanada K, Iwamoto T. Population kinetic-pharmacodynamic analysis of serum potassium in patients receiving sulfamethoxazole/trimethoprim. <i>Basic Clin Pharmacol Toxicol.</i> 2022;131(5):380-391. doi:10.1111/bcpt.13783<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/36000348/pubmed" id="36000348" target="_blank">36000348</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7885125">
<a name="7885125"></a>Hoge CW, Shlim DR, Ghimire M, et al. Placebo-controlled trial of co-trimoxazole for cyclospora infections among travellers and foreign residents in Nepal [published correction appears in <i>Lancet</i>. 1995;345(8956):1060]. <i>Lancet.</i> 1995;345(8951):691-693.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/7885125/pubmed" id="7885125" target="_blank">7885125</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31700852">
<a name="31700852"></a>Hoosen K, Mosam A, Dlova NC, Grayson W. An update on adverse cutaneous drug reactions in HIV/AIDS. <i>Dermatopathology (Basel)</i>. 2019;6(2):111-125. doi:10.1159/000496389<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/31700852/pubmed" id="31700852" target="_blank">31700852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3816021">
<a name="3816021"></a>Hoppu K. Age Differences in Trimethoprim Pharmacokinetics: Need for Revised Dosing in Children? <i>Clin Pharmacol Ther</i>. 1987;41(3):336-343.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/3816021/pubmed" id="3816021" target="_blank">3816021</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2705795">
<a name="2705795"></a>Hoppu K. Changes in trimethoprim pharmacokinetics after the newborn period. <i>Arch Dis Child</i>. 1989;64(3):343-345.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/2705795/pubmed" id="2705795" target="_blank">2705795</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8479489">
<a name="8479489"></a>Hughes W, Leoung G, Kramer F, et al. Comparison of Atovaquone (566C80) With Trimethoprim-Sulfamethoxazole to Treat <i>Pneumocystis carinii</i> Pneumonia in Patients With AIDS. <i>N Engl J Med</i>. 1993;328(21):1521-1527.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/8479489/pubmed" id="8479489" target="_blank">8479489</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-412099">
<a name="412099"></a>Hughes WT, Kuhn S, Chaudhary S, et al. Successful chemoprophylaxis for <i>Pneumocystis carinii</i> pneumonitis. <i>N Engl J Med</i>. 1977;297(26):1419-1426. doi:10.1056/NEJM197712292972602<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/412099/pubmed" id="412099" target="_blank">412099</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3495732">
<a name="3495732"></a>Hughes WT, Rivera GK, Schell MJ, Thornton D, Lott L. Successful intermittent chemoprophylaxis for <i>Pneumocystis carinii</i> pneumonitis. <i>N Engl J Med</i>. 1987;316(26):1627-1632. doi:10.1056/NEJM198706253162604<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/3495732/pubmed" id="3495732" target="_blank">3495732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8498418">
<a name="8498418"></a>Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. <i>Am J Obstet Gynecol</i>. 1993;168(5):1393-1399. doi:10.1016/s0002-9378(11)90771-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/8498418/pubmed" id="8498418" target="_blank">8498418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2785757">
<a name="2785757"></a>Jarosinki PF, Kennedy PE, Gallelli JF. Stability of Concentrated Trimethoprim-Sulfamethoxazole Admixtures. <i>AJHP</i>. 1989;46(4):732-737.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/2785757/pubmed" id="2785757" target="_blank">2785757</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7479194">
<a name="7479194"></a>Jick H, Derby LE. A Large Population-Based Follow-Up Study of Trimethoprim-Sulfamethoxazole, Trimethoprim, and Cephalexin for Uncommon Serious Drug Toxicity. <i>Pharmacotherapy</i>. 1995;15(4):428-432.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/7479194/pubmed" id="7479194" target="_blank">7479194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7715367">
<a name="7715367"></a>Jick H, Derby LE. Is Co-Trimoxazole Safe? <i>Lancet</i>. 1995;345(8957):1118-1119.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/7715367/pubmed" id="7715367" target="_blank">7715367</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2287564">
<a name="2287564"></a>Johnson MP, Goodwin SD, Shands JW Jr. Trimethoprim-sulfamethoxazole anaphylactoid reactions in patients with AIDS: case reports and literature review. <i>Pharmacotherapy</i>. 1990;10(6):413-416.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/2287564/pubmed" id="2287564" target="_blank">2287564</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23855313">
<a name="23855313"></a>Kardaun SH, Sekula P, Valeyrie-Allanore L, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. <i>Br J Dermatol</i>. 2013;169(5):1071-1080. doi:10.1111/bjd.12501<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/23855313/pubmed" id="23855313" target="_blank">23855313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25531772">
<a name="25531772"></a>Kesner JM, Yardman-Frank JM, Mercier RC, et al. Trimethoprim and sulfamethoxazole transmembrane clearance during modeled continuous renal replacement therapy. <i>Blood Purif</i>. 2014;38(3-4):195‐202. doi:10.1159/000368884<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/25531772/pubmed" id="25531772" target="_blank">25531772</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31495421">
<a name="31495421"></a>Khan DA, Knowles SR, Shear NH. Sulfonamide hypersensitivity: fact and fiction. <i>J Allergy Clin Immunol Pract</i>. 2019;7(7):2116-2123. doi:10.1016/j.jaip.2019.05.034<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/31495421/pubmed" id="31495421" target="_blank">31495421</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8327297">
<a name="8327297"></a>Khuri-Bulos NA, Daoud AH, Azab SM. Treatment of childhood brucellosis: results of a prospective trial on 113 children. <i>Pediatr Infect Dis J</i>. 1993;12(5):377-381. doi:10.1097/00006454-199305000-00005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/8327297/pubmed" id="8327297" target="_blank">8327297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6972183">
<a name="6972183"></a>Kobrinsky NL, Ramsay NK. Acute megaloblastic anemia induced by high-dose trimethoprim-sulfamethoxazole. <i>Ann Intern Med</i>. 1981;94(6):780-781. doi:10.7326/0003-4819-94-6-780<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/6972183/pubmed" id="6972183" target="_blank">6972183</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15996741">
<a name="15996741"></a>Kocak Z, Hatipoglu CA, Ertem G, et al. Trimethoprim-sulfamethoxazole induced rash and fatal hematologic disorders. <i>J Infect</i>. 2006;52(2):e49-e52. doi:10.1016/j.jinf.2005.05.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/15996741/pubmed" id="15996741" target="_blank">15996741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28893787">
<a name="28893787"></a>Kosaka M, Ushiki A, Ikuyama Y, et al. A four-center retrospective study of the efficacy and toxicity of low-dose trimethoprim-sulfamethoxazole for the treatment of pneumocystis pneumonia in patients without HIV infection. <i>Antimicrob Agents Chemother</i>. 2017;61(12):e01173-17. doi:10.1128/AAC.01173-17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/28893787/pubmed" id="28893787" target="_blank">28893787</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25201401">
<a name="25201401"></a>Kuyucu S, Mori F, Atanaskovic-Markovic M, et al. Hypersensitivity reactions to non-betalactam antibiotics in children: an extensive review. <i>Pediatr Allergy Immunol</i>. 2014;25(6):534-543. doi:10.1111/pai.12273<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/25201401/pubmed" id="25201401" target="_blank">25201401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31145496">
<a name="31145496"></a>La Hoz RM, Morris MI; AST Infectious Diseases Community of Practice. Intestinal parasites including Cryptosporidium, Cyclospora, Giardia, and Microsporidia, Entamoeba histolytica, Strongyloides, Schistosomiasis, and Echinococcus: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clin Transplant</i>. 2019a;33(9):e13618. doi:10.1111/ctr.13618<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/31145496/pubmed" id="31145496" target="_blank">31145496</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30900295">
<a name="30900295"></a>La Hoz RM, Morris MI; Infectious Diseases Community of Practice of the American Society of Transplantation. Tissue and blood protozoa including toxoplasmosis, Chagas disease, leishmaniasis, Babesia, Acanthamoeba, Balamuthia, and Naegleria in solid organ transplant recipients- guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clin Transplant</i>. 2019b;33(9):e13546. doi:10.1111/ctr.13546<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/30900295/pubmed" id="30900295" target="_blank">30900295</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18556490">
<a name="18556490"></a>Lee M, Bozzo P, Einarson A, et al. Urinary Tract Infections in Pregnancy. <i>Can Fam Physician</i>. 2008;54(6):853-854.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/18556490/pubmed" id="18556490" target="_blank">18556490</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9184713">
<a name="9184713"></a>Lee AJ, Maddix DS. Trimethoprim/sulfamethoxazole-induced hypoglycemia in a patient with acute renal failure. <i>Ann Pharmacother</i>. 1997;31(6):727-732. doi:10.1177/106002809703100611<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/9184713/pubmed" id="9184713" target="_blank">9184713</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11303827">
<a name="11303827"></a>Leiberman A, Leibovitz E, Piglansky L, et al. Bacteriologic and clinical efficacy of trimethoprim-sulfamethoxazole for treatment of acute otitis media. <i>Pediatr Infect Dis J</i>. 2001;20(3):260-264. doi:10.1097/00006454-200103000-00009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/11303827/pubmed" id="11303827" target="_blank">11303827</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8783685">
<a name="8783685"></a>Lerner PI. Nocardiosis. <i>Clin Infect Dis.</i> 1996;22(6):891-903.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/8783685/pubmed" id="8783685" target="_blank">8783685</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lewis.2021">
<a name="Lewis.2021"></a>Lewis SS, Zaas A. Stenotrophomonas maltophilia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 5, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20628102">
<a name="20628102"></a>Li PK, Szeto CC, Piraino B, et al. Peritoneal Dialysis-Related Infections Recommendations: 2010 Update. <i>Perit Dial Int</i>. 2010;30(4):393-423<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/20628102/pubmed" id="20628102" target="_blank">20628102</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32270503">
<a name="32270503"></a>Li YJ, Phillips E, Dellinger A, et al. HLA-B*14:01 and HLA-B*35:01 are associated with trimethoprim-sulfamethoxazole induced liver injury. <i>Hepatology</i>. Published online April 9, 2020. doi:10.1002/hep.31258<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/32270503/pubmed" id="32270503" target="_blank">32270503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23439909">
<a name="23439909"></a>Lieberthal AS, Carroll AE, Chonmaitree T, et al. The diagnosis and management of acute otitis media [published correction appears in <i>Pediatrics</i>. 2014;133(2):346]. <i>Pediatrics.</i> 2013;131(3):e964-999.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/23439909/pubmed" id="23439909" target="_blank">23439909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21193785">
<a name="21193785"></a>Limper AH, Knox KS, Sarosi GA, et al; American Thoracic Society Fungal Working Group. An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients.<i> Am J Respir Crit Care Med.</i> 2011;183(1):96-128. doi:10.1164/rccm.2008-740ST<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/21193785/pubmed" id="21193785" target="_blank">21193785</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16912251">
<a name="16912251"></a>Lin D, Tucker MJ, Rieder MJ. Increased adverse drug reactions to antimicrobials and anticonvulsants in patients with HIV infection. <i>Ann Pharmacother</i>. 2006;40(9):1594-1601. doi:10.1345/aph.1G525<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/16912251/pubmed" id="16912251" target="_blank">16912251</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17606548">
<a name="17606548"></a>Lindemulder S, Albano E. Successful intermittent prophylaxis with trimethoprim/sulfamethoxazole 2 days per week for <i>Pneumocystis carinii</i> (<i>jiroveci</i>) pneumonia in pediatric oncology patients. <i>Pediatrics</i>. 2007;120(1):e47-e51. doi:10.1542/peds.2006-1360<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/17606548/pubmed" id="17606548" target="_blank">17606548</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28905389">
<a name="28905389"></a>Linnik YA, Tsui EW, Martin IW, et al. The first reported case of concurrent trimethoprim-sulfamethoxazole-induced immune hemolytic anemia and thrombocytopenia. <i>Transfusion</i>. 2017;57(12):2937-2941. doi:10.1111/trf.14315<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/28905389/pubmed" id="28905389" target="_blank">28905389</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23171644">
<a name="23171644"></a>Lipsitz R, Garges S, Aurigemma R, et al. Workshop on treatment of and postexposure prophylaxis for <i>Burkholderia pseudomallei</i> and <i>B. mallei</i> Infection, 2010. <i>Emerg Infect Dis</i>. 2012;18(12):e2. doi:10.3201/eid1812.120638<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/23171644/pubmed" id="23171644" target="_blank">23171644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15306988">
<a name="15306988"></a>Lipsky BA. Medical treatment of diabetic foot infections. <i>Clin Infect Dis</i>. 2004;39(suppl 2):S104-S114.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/15306988/pubmed" id="15306988" target="_blank">15306988</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20459324">
<a name="20459324"></a>Lipsky BA, Byren I, Hoey CT. Treatment of bacterial prostatitis. <i>Clin Infect Dis</i>. 2010;50(12):1641-1652. doi:10.1086/652861<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/20459324/pubmed" id="20459324" target="_blank">20459324</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22619242">
<a name="22619242"></a>Lipsky BA, Berendt AR, Cornia PB, et al; Infectious Diseases Society of America. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. <i>Clin Infect Dis.</i> 2012;54(12):e132-e173. doi:10.1093/cid/cis346<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/22619242/pubmed" id="22619242" target="_blank">22619242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21208910">
<a name="21208910"></a>Liu C, Bayer A, Cosgrove SE, et al; Infectious Diseases Society of America. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant <i>Staphylococcus aureus</i> infections in adults and children. <i>Clin Infect Dis</i>. 2011;52(3):e18-e55. doi:10.1093/cid/ciq146<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/21208910/pubmed" id="21208910" target="_blank">21208910</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30458864">
<a name="30458864"></a>Liu P, Ranches GP, Gold JA. Trimethoprim-sulfamethoxazole induced circulatory shock in a human immunodeficiency virus uninfected patient: a case report and review. <i>BMC Pharmacol Toxicol</i>. 2018;19(1):76. doi:10.1186/s40360-018-0269-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/30458864/pubmed" id="30458864" target="_blank">30458864</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24612987">
<a name="24612987"></a>Lontos S, Shelton E, Angus PW, et al. A randomized controlled study of trimethoprim-sulfamethoxazole versus norfloxacin for the prevention of infection in cirrhotic patients. <i>J Dig Dis</i>. 2014;15(5):260-267. doi:10.1111/1751-2980.12132<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/24612987/pubmed" id="24612987" target="_blank">24612987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3492908">
<a name="3492908"></a>Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T. QT prolongation and torsades de pointes after administration of trimethoprim-sulfamethoxazole. <i>Am J Cardiol</i>. 1987;59(4):376-377. doi:10.1016/0002-9149(87)90824-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/3492908/pubmed" id="3492908" target="_blank">3492908</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2649867">
<a name="2649867"></a>Lubani MM, Dudin KI, Sharda DC, et al. A multicenter therapeutic study of 1100 children with brucellosis. <i>Pediatr Infect Dis J</i>. 1989;8(2):75-78.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/2649867/pubmed" id="2649867" target="_blank">2649867</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7490442">
<a name="7490442"></a>Lundstrom TS, Sobel JD. Vancomycin, Trimethoprim-Sulfamethoxazole, and Rifampin. <i>Infect Dis Clin North Am</i>. 1995;9(3):747-767.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/7490442/pubmed" id="7490442" target="_blank">7490442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27550992">
<a name="27550992"></a>Maertens J, Cesaro S, Maschmeyer G, et al. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. <i>J Antimicrob Chemother</i>. 2016;71(9):2397-2404. doi:10.1093/jac/dkw157<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/27550992/pubmed" id="27550992" target="_blank">27550992</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32293218">
<a name="32293218"></a>Mahmood SB, Abou Zahr Z. Systemic lupus erythematosus triggered by trimethoprim-sulfamethoxazole. <i>Scand J Rheumatol</i>. 2020;49(6):507-508. doi:10.1080/03009742.2020.1719543<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/32293218/pubmed" id="32293218" target="_blank">32293218</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14712321">
<a name="14712321"></a>Mainra RR, Card SE. Trimethoprim-sulfamethoxazole-associated hepatotoxicity - part of a hypersensitivity syndrome. <i>Can J Clin Pharmacol</i>. 2003;10(4):175-178.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/14712321/pubmed" id="14712321" target="_blank">14712321</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1608685">
<a name="1608685"></a>Margileth AM. Antibiotic therapy for cat-scratch disease: clinical study of therapeutic outcome in 268 patients and a review of the literature. <i>Pediatr Infect Dis J</i>. 1992;11(6):474-478.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/1608685/pubmed" id="1608685" target="_blank">1608685</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3495027">
<a name="3495027"></a>Markowitz N, Saravolatz LD. Use of trimethoprim-sulfamethoxazole in a glucose-6-phosphate dehydrogenase-deficient population. <i>Rev Infect Dis</i>. 1987;9(suppl 2):S218-S229. doi:10.1093/clinids/9.supplement_2.s218<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/3495027/pubmed" id="3495027" target="_blank">3495027</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23465020">
<a name="23465020"></a>Martin SI, Fishman JA; AST Infectious Diseases Community of Practice. Pneumocystis pneumonia in solid organ transplantation. <i>Am J Transplant.</i> 2013;13(suppl 4):272-279. doi:10.1111/ajt.12119<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/23465020/pubmed" id="23465020" target="_blank">23465020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12588198">
<a name="12588198"></a>Masters PA, O'Bryan TA, Zurlo J, Miller DQ, Joshi N. Trimethoprim-sulfamethoxazole revisited. <i>Arch Intern Med</i>. 2003;163(4):402-410. doi:10.1001/archinte.163.4.402<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/12588198/pubmed" id="12588198" target="_blank">12588198</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12617574">
<a name="12617574"></a>Masur H, Kaplan JE, Holmes KK; US Public Health Service; Infectious Diseases Society of America. Guidelines for preventing opportunistic infections among HIV-Infected persons – 2002. Recommendations of the US Public Health Service and the Infectious Diseases Society of America. <i>Ann Intern Med</i>. 2002;137(5, pt 2):435-478.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/12617574/pubmed" id="12617574" target="_blank">12617574</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10826870">
<a name="10826870"></a>Mathews WA, Manint JE, Kleiss J. Trimethoprim-sulfamethoxazole-induced hypoglycemia as a cause of altered mental status in an elderly patient. <i>J Am Board Fam Pract</i>. 2000;13(3):211-212. doi:10.3122/15572625-13-3-211<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/10826870/pubmed" id="10826870" target="_blank">10826870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20002091">
<a name="20002091"></a>Matok I, Gorodischer R, Koren G, et al. Exposure to Folic Acid Antagonists During the First Trimester of Pregnancy and the Risk of Major Malformations.<i> Br J Clin Pharmacol</i>. 2009;68(6):956-962.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/20002091/pubmed" id="20002091" target="_blank">20002091</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-May.2023">
<a name="May.2023"></a>May DB. Trimethoprim-sulfamethoxazole: an overview. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 27, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28085573">
<a name="28085573"></a>Mazuski JE, Tessier JM, May AK, et al. The Surgical Infection Society revised guidelines on the management of intra-abdominal infection. <i>Surg Infect (Larchmt)</i>. 2017;18(1):1-76. doi:10.1089/sur.2016.261<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/28085573/pubmed" id="28085573" target="_blank">28085573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29462280">
<a name="29462280"></a>McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). <i>Clin Infect Dis</i>. 2018;66(7):e1-e48. doi:10.1093/cid/cix1085<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/29462280/pubmed" id="29462280" target="_blank">29462280</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-236820">
<a name="236820"></a>Meares EM. Long-term therapy of chronic bacterial prostatitis with trimethoprim-sulfamethoxazole. <i>Can Med Assoc J</i>. 1975;112(13 spec No):22-25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/236820/pubmed" id="236820" target="_blank">236820</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36703246">
<a name="36703246"></a>Meng L, Mui E, Ha DR, Stave C, Deresinski SC, Holubar M. Comprehensive guidance for antibiotic dosing in obese adults: 2022 update.<i> Pharmacotherapy.</i> 2023;43(3):226-246. doi:10.1002/phar.2769<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/36703246/pubmed" id="36703246" target="_blank">36703246</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21817950">
<a name="21817950"></a>Messina AF, Namtu K, Guild M, Dumois JA, Berman DM. Trimethoprim-sulfamethoxazole therapy for children with acute osteomyelitis. <i>Pediatr Infect Dis J</i>. 2011;30(12):1019-1021. doi:10.1097/INF.0b013e31822db658<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/21817950/pubmed" id="21817950" target="_blank">21817950</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32265601">
<a name="32265601"></a>Meyers RS, Thackray J, Matson KL, et al. <i>K</i>ey Potentially <i>I</i>nappropriate <i>D</i>rugs in Pediatrics: The KIDs List. <i>J Pediatr Pharmacol Ther</i>. 2020;25(3):175-191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/32265601/pubmed" id="32265601" target="_blank">32265601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Meyrier.2022">
<a name="Meyrier.2022"></a>Meyrier A, Fekete T. Acute bacterial prostatitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 1, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Meyrier.2021">
<a name="Meyrier.2021"></a>Meyrier A, Fekete T. Chronic bacterial prostatitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 23, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29758282">
<a name="29758282"></a>Micheletti RG, Chiesa-Fuxench Z, Noe MH, et al. Stevens-johnson syndrome/toxic epidermal necrolysis: a multicenter retrospective study of 377 adult patients from the United States. <i>J Invest Dermatol</i>. 2018;138(11):2315-2321. doi:10.1016/j.jid.2018.04.027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/29758282/pubmed" id="29758282" target="_blank">29758282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31142578">
<a name="31142578"></a>Miller JO, Taylor J, Goldman JL. Severe acute respiratory failure in healthy adolescents exposed to trimethoprim-sulfamethoxazole. <i>Pediatrics</i>. 2019;143(6).<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/31142578/pubmed" id="31142578" target="_blank">31142578</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25785967">
<a name="25785967"></a>Miller LG, Daum RS, Creech CB, et al; DMID 07-0051 Team. Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections. <i>N Engl J Med</i>. 2015;372(12):1093-1103. doi:10.1056/NEJMoa1403789<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/25785967/pubmed" id="25785967" target="_blank">25785967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Miller.1974">
<a name="Miller.1974"></a>Miller RD, Salter AJ. The passage of trimethoprim/sulfamethoxazole into breast milk and its significance. Proceedings of the 8th international congress of chemotherapy, Athens. <i>Hellenic Soc Chemother. </i>1974;1:687-691.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35576513">
<a name="35576513"></a>Mitchell KB, Johnson HM, Rodríguez JM, et al; Academy of Breastfeeding Medicine. Academy of Breastfeeding Medicine clinical protocol #36: the mastitis spectrum, revised 2022. <i>Breastfeed Med</i>. 2022;17(5):360-376. doi:10.1089/bfm.2022.29207.kbm<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/35576513/pubmed" id="35576513" target="_blank">35576513</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19698015">
<a name="19698015"></a>Mitrano JA, Spooner LM, Belliveau P. Excretion of antimicrobials used to treat methicillin-resistant <i>Staphylococcus aureus</i> infections during lactation: safety in breastfeeding infants. <i>Pharmacotherapy</i>. 2009;29(9):1103-1109.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/19698015/pubmed" id="19698015" target="_blank">19698015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30549322">
<a name="30549322"></a>Mitta A, Curtis BR, Reese JA, George JN. Drug-induced thrombocytopenia: 2019 update of clinical and laboratory data. <i>Am J Hematol</i>. 2019;94(3):E76-E78. doi:10.1002/ajh.25379<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/30549322/pubmed" id="30549322" target="_blank">30549322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17805350">
<a name="17805350"></a>Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. <i>J Invest Dermatol</i>. 2008;128(1):35-44. doi:10.1038/sj.jid.5701033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/17805350/pubmed" id="17805350" target="_blank">17805350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11486285">
<a name="11486285"></a>Montoya JG, Giraldo LF, Efron B, et al. Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center.<i> Clin Infect Dis.</i> 2001;33(5):629-640.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/11486285/pubmed" id="11486285" target="_blank">11486285</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28535235">
<a name="28535235"></a>Moran GJ, Krishnadasan A, Mower WR, et al. Effect of cephalexin plus trimethoprim-sulfamethoxazole vs cephalexin alone on clinical cure of uncomplicated cellulitis: a randomized clinical trial. <i>JAMA</i>. 2017;317(20):2088-2096. doi:10.1001/jama.2017.5653<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/28535235/pubmed" id="28535235" target="_blank">28535235</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12924488">
<a name="12924488"></a>Mori H, Kuroda Y, Imamura S, et al. Hyponatremia and/or hyperkalemia in patients treated with the standard dose of trimethoprim-sulfamethoxazole. <i>Intern Med</i>. 2003;42(8):665-669. doi:10.2169/internalmedicine.42.665<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/12924488/pubmed" id="12924488" target="_blank">12924488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9205827">
<a name="9205827"></a>Myers MW, Jick H. Hospitalization for serious blood and skin disorders following co-trimoxazole. <i>Br J Clin Pharmacol</i>. 1997;43(6):649-651. doi:10.1046/j.1365-2125.1997.00590.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/9205827/pubmed" id="9205827" target="_blank">9205827</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6975241">
<a name="6975241"></a>Naber K, Vergin H, Weigand W. Pharmacokinetics of Co-trimoxazole and Co-tetroxazine in Geriatric Patients. <i>Infection</i>. 1981;9(5):239-243.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/6975241/pubmed" id="6975241" target="_blank">6975241</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8672842">
<a name="8672842"></a>Nahata MC. Dosage regimens of trimethoprim/sulfamethoxazole (TPM/SMX) in patients with renal dysfunction. <i>Ann Pharmacother</i>. 1995;29(12):1300.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/8672842/pubmed" id="8672842" target="_blank">8672842</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28779879">
<a name="28779879"></a>Nakashima K, Aoshima M, Nakashita T, et al. Low-dose trimethoprim-sulfamethoxazole treatment for pneumocystis pneumonia in non-human immunodeficiency virus-infected immunocompromised patients: a single-center retrospective observational cohort study. <i>J Microbiol Immunol Infect</i>. 2018;51(6):810-820. doi:10.1016/j.jmii.2017.07.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/28779879/pubmed" id="28779879" target="_blank">28779879</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24274783">
<a name="24274783"></a>Nayak SU, Simon GL. Myocarditis after trimethoprim/sulfamethoxazole treatment for ehrlichiosis. <i>Emerg Infect Dis</i>. 2013;19(12):1975-1977. doi:10.3201/eid1912.121459<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/24274783/pubmed" id="24274783" target="_blank">24274783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34264565">
<a name="34264565"></a>Nelson CA, Meaney-Delman D, Fleck-Derderian S, et al; Contributors. Antimicrobial treatment and prophylaxis of plague: recommendations for naturally acquired infections and bioterrorism response. <i>MMWR Recomm Rep</i>. 2021;70(3):1-27. doi:10.15585/mmwr.rr7003a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/34264565/pubmed" id="34264565" target="_blank">34264565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nemecek.2019">
<a name="Nemecek.2019"></a>Nemecek BD, Hammond DA, eds. <i>Demystifying Drug Dosing in Renal Dysfunction</i>. American Society of Health-System Pharmacists; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23412562">
<a name="23412562"></a>Neumann S, Krause SW, Maschmeyer G, von Lilienfeld-Toal M; Infectious Diseases Working Party (AGIHO); German Society of Hematology and Oncology (DGHO). Primary prophylaxis of bacterial infections and <i>Pneumocystis jirovecii</i> pneumonia in patients with hematological malignancies and solid tumors: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). <i>Ann Hematol.</i> 2013;92(4):433-442. doi:10.1007/s00277-013-1698-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/23412562/pubmed" id="23412562" target="_blank">23412562</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3500644">
<a name="3500644"></a>Nissenson AR, Wilson C, Holazo A. Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole during hemodialysis. <i>Am J Nephrol</i>. 1987;7(4):270‐274. doi:10.1159/000167484<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/3500644/pubmed" id="3500644" target="_blank">3500644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7727887">
<a name="7727887"></a>Noto H, Kaneko Y, Takano T, et al. Severe Hyponatremia and Hyperkalemia Induced by Trimethoprim-Sulfamethoxazole in Patients With <i>Pneumocystis carinii</i> Pneumonia. <i>Intern Med</i>. 1995;34(2):96-99.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/7727887/pubmed" id="7727887" target="_blank">7727887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21375132">
<a name="21375132"></a>Nunnari G, Celesia BM, Bellissimo F, et al. Trimethoprim-sulfamethoxazole-associated severe hypoglycaemia: a sulfonylurea-like effect. <i>Eur Rev Med Pharmacol Sci</i>. 2010;14(12):1015-1018.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/21375132/pubmed" id="21375132" target="_blank">21375132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Odell1958">
<a name="Odell1958"></a>Odell GB, Hopkins J. In vitro studies of the effect of sulfonamides on bilirubin. <i>AMA J Disease of Children</i>. 1958;96:535-536.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/Odell1958/pubmed" id="Odell1958" target="_blank">Odell1958</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7393813">
<a name="7393813"></a>Ogilvie AL, Toghill PJ. Cholestatic jaundice due to co-trimoxazole. <i>Postgrad Med J</i>. 1980;56(653):202-204. doi:10.1136/pgmj.56.653.202<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/7393813/pubmed" id="7393813" target="_blank">7393813</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20645862">
<a name="20645862"></a>Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE), Mocroft A, Reiss P, Kirk O, et al. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count &lt;200 cells/microL? [published correction appears in <i>Clin Infect Dis.</i> 2010;51(9):1114]. <i>Clin Infect Dis.</i> 2010;51(5):611-619. doi:10.1086/655761<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/20645862/pubmed" id="20645862" target="_blank">20645862</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23223583">
<a name="23223583"></a>Osmon DR, Berbari EF, Berendt AR, et al; Infectious Diseases Society of America. Diagnosis and management of prosthetic joint infection: clinical practice guideline by the Infectious Diseases Society of America. <i>Clin Infect Dis.</i> 2013,56(1):e1-e25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/23223583/pubmed" id="23223583" target="_blank">23223583</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31899808">
<a name="31899808"></a>Oussalah A, Yip V, Mayorga C, et al. Genetic variants associated with T cell-mediated cutaneous adverse drug reactions: A PRISMA-compliant systematic review-An EAACI position paper. <i>Allergy</i>. 2020;75(5):1069-1098. doi:10.1111/all.14174<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/31899808/pubmed" id="31899808" target="_blank">31899808</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2678767">
<a name="2678767"></a>Paap CM, Nahata MC. Clinical use of trimethoprim/sulfamethoxazole during renal dysfunction. <i>DICP</i>. 1989;23(9):646-654. doi:10.1177/106002808902300903<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/2678767/pubmed" id="2678767" target="_blank">2678767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33523485">
<a name="33523485"></a>Pai MP. Antimicrobial dosing in specific populations and novel clinical methodologies: obesity. <i>Clin Pharmacol Ther.</i> 2021;109(4):942-951. doi:10.1002/cpt.2181<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/33523485/pubmed" id="33523485" target="_blank">33523485</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23457080">
<a name="23457080"></a>Pallin DJ, Binder WD, Allen MB, et al. Clinical trial: comparative effectiveness of cephalexin plus trimethoprim-sulfamethoxazole versus cephalexin alone for treatment of uncomplicated cellulitis: a randomized controlled trial. <i>Clin Infect Dis</i>. 2013;56(12):1754-1762. doi:10.1093/cid/cit122<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/23457080/pubmed" id="23457080" target="_blank">23457080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7944073">
<a name="7944073"></a>Pape JW, Verdier RI, Boncy M, Johnson WD Jr. Cyclospora infection in adults infected with HIV. Clinical manifestations, treatment, and prophylaxis. <i>Ann Intern Med.</i> 1994;121(9):654-657.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/7944073/pubmed" id="7944073" target="_blank">7944073</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25179404">
<a name="25179404"></a>Parekh TM, Raji M, Lin YL, Tan A, Kuo YF, Goodwin JS. Hypoglycemia after antimicrobial drug prescription for older patients using sulfonylureas. <i>JAMA Intern Med</i>. 2014;174(10):1605-1612. doi:10.1001/jamainternmed.2014.3293<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/25179404/pubmed" id="25179404" target="_blank">25179404</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pemberton.2021">
<a name="Pemberton.2021"></a>Pemberton JH. Acute colonic diverticulitis: medical management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 5, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10738846">
<a name="10738846"></a>Perazella MA. Trimethoprim-induced hyperkalaemia: clinical data, mechanism, prevention and management. <i>Drug Saf</i>. 2000;22(3):227-236. doi:10.2165/00002018-200022030-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/10738846/pubmed" id="10738846" target="_blank">10738846</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25999169">
<a name="25999169"></a>Persichino J, Sutjita M. Anaphylactic-like reaction from trimethoprim-sulfamethoxazole in a patient with AIDS. <i>Int J STD AIDS</i>. 2016;27(7):595-597. doi:10.1177/0956462415587442<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/25999169/pubmed" id="25999169" target="_blank">25999169</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3261315">
<a name="3261315"></a>Platt R, Dreis MW, Kennedy DL, Kuritsky JN. Serum sickness-like reactions to amoxicillin, cefaclor, cephalexin, and trimethoprim-sulfamethoxazole. <i>J Infect Dis</i>. 1988;158(2):474-477. doi:10.1093/infdis/158.2.474<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/3261315/pubmed" id="3261315" target="_blank">3261315</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9496402">
<a name="9496402"></a>Porras MC, Lecumberri JN, Castrillón JL. Trimethoprim/sulfamethoxazole and metabolic acidosis in HIV-infected patients. <i>Ann Pharmacother</i>. 1998;32(2):185-189. doi:10.1345/aph.17042<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/9496402/pubmed" id="9496402" target="_blank">9496402</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31507152">
<a name="31507152"></a>Ramos JT, Romero CA, Belda S, et al. Clinical practice update of antifungal prophylaxis in immunocompromised children. <i>Rev Esp Quimioter</i>. 2019;32(5):410-425.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/31507152/pubmed" id="31507152" target="_blank">31507152</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7202951">
<a name="7202951"></a>Ransohoff DF, Jacobs G. Terminal hepatic failure following a small dose of sulfamethoxazole-trimethoprim. <i>Gastroenterology</i>. 1981;80(4):816-819.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/7202951/pubmed" id="7202951" target="_blank">7202951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10157546">
<a name="10157546"></a>Reinke CM, Thomas JK, Graves AH. Apparent hemolysis in an AIDS patient receiving trimethoprim/sulfamethoxazole: case report and literature review. <i>J Pharm Technol</i>. 1995;11(6):256-295. doi:10.1177/875512259501100607<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/10157546/pubmed" id="10157546" target="_blank">10157546</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30817024">
<a name="30817024"></a>Restrepo A, Clark NM; Infectious Diseases Community of Practice of the American Society of Transplantation. Nocardia infections in solid organ transplantation: guidelines from the Infectious Diseases Community of Practice of the American Society of Transplantation. <i>Clin Transplant</i>. 2019;33(9):e13509. doi:10.1111/ctr.13509<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/30817024/pubmed" id="30817024" target="_blank">30817024</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20949552">
<a name="20949552"></a>Reuben A, Koch DG, Lee WM; Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. <i>Hepatology</i>. 2010;52(6):2065-2076. doi:10.1002/hep.23937<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/20949552/pubmed" id="20949552" target="_blank">20949552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24795142">
<a name="24795142"></a>RIVUR Trial Investigators, Hoberman A, Greenfield SP, et al. Antimicrobial prophylaxis for children with vesicoureteral reflux. <i>N Engl J Med</i>. 2014;370(25):2367-2376. doi:10.1056/NEJMoa1401811<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/24795142/pubmed" id="24795142" target="_blank">24795142</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15551160">
<a name="15551160"></a>Roushan MR, Gangi SM, Ahmadi SA. Comparison of the efficacy of two months of treatment with co-trimoxazole plus doxycycline vs. co-trimoxazole plus rifampin in brucellosis. <i>Swiss Med Wkly</i>. 2004;134(37-38):564-568.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/15551160/pubmed" id="15551160" target="_blank">15551160</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16732154">
<a name="16732154"></a>Roushan MR, Mohraz M, Janmohammadi N, Hajiahmadi M. Efficacy of cotrimoxazole and rifampin for 6 or 8 weeks of therapy in childhood brucellosis. <i>Pediatr Infect Dis J</i>. 2006;25(6):544-545. doi:10.1097/01.inf.0000219403.91975.ce<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/16732154/pubmed" id="16732154" target="_blank">16732154</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18082208">
<a name="18082208"></a>Roussey-Kesler G, Gadjos V, Idres N, et al. Antibiotic prophylaxis for the prevention of recurrent urinary tract infection in children with low grade vesicoureteral reflux: results from a prospective randomized study. <i>J Urol</i>. 2008;179(2):674-679. doi:10.1016/j.juro.2007.09.090<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/18082208/pubmed" id="18082208" target="_blank">18082208</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Runyon.1">
<a name="Runyon.1"></a>Runyon BA. Spontaneous bacterial peritonitis in adults: treatment and prophylaxis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 20, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28708801">
<a name="28708801"></a>Saavedra-Lozano J, Falup-Pecurariu O, Faust SN, et al. Bone and joint infections. <i>Pediatr Infect Dis J</i>. 2017;36(8):788-799. doi:10.1097/INF.0000000000001635<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/28708801/pubmed" id="28708801" target="_blank">28708801</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26101108">
<a name="26101108"></a>Samplaski MK, Nangia AK. Adverse effects of common medications on male fertility. <i>Nat Rev Urol</i>. 2015;12(7):401-413. doi:10.1038/nrurol.2015.145<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/26101108/pubmed" id="26101108" target="_blank">26101108</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5561865">
<a name="5561865"></a>Schiff D, Chan G, Stern L. Fixed drug combinations and the displacement of bilirubin from albumin. <i>Pediatrics</i>. 1971;48(1):139-141.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/5561865/pubmed" id="5561865" target="_blank">5561865</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33840441">
<a name="33840441"></a>Schwenk HT, Khan A, Kohlman K, et al. Toxoplasmosis in pediatric hematopoietic stem cell transplantation patients. <i>Transplant Cell Ther</i>. 2021;27(4):292-300. doi:10.1016/j.jtct.2020.11.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/33840441/pubmed" id="33840441" target="_blank">33840441</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Septra.1">
<a name="Septra.1"></a>Septra and Septra DS (sulfamethoxazole/trimethoprim) [prescribing information]. New York, NY: Pfizer; November 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Septra.2">
<a name="Septra.2"></a>Septra (sulfamethoxazole/trimethoprim) [product monograph]. Oakville, Ontario, Canada: Aspen Pharmacare Canada Inc; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sethi.2022">
<a name="Sethi.2022"></a>Sethi S, Murphy TF. Management of infection in exacerbations of chronic obstructive pulmonary disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 16, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sexton2019a">
<a name="Sexton2019a"></a>Sexton DJ, Sampson JH. Intracranial epidural abscess. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 21, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sexton.2019b">
<a name="Sexton.2019b"></a>Sexton DJ, Sampson JH. Spinal epidural abscess. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 21, 2022b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28719679">
<a name="28719679"></a>Shah SD, Cifu AS. Management of acute diverticulitis. <i>JAMA</i>. 2017;318(3):291-292. doi:10.1001/jama.2017.6373<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/28719679/pubmed" id="28719679" target="_blank">28719679</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29053792">
<a name="29053792"></a>Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America clinical practice guidelines for the diagnosis and management of infectious diarrhea. <i>Clin Infect Dis</i>. 2017;65(12):e45-e80. doi:10.1093/cid/cix669<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/29053792/pubmed" id="29053792" target="_blank">29053792</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-13370229">
<a name="13370229"></a>Silverman WA, Andersen DH, Blanc WA, Crozier DN. A difference in mortality rate and incidence of kernicterus among premature infants allotted to two prophylactic antibacterial regimens. <i>Pediatrics</i>. 1956;18(4):614-625.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/13370229/pubmed" id="13370229" target="_blank">13370229</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7887554">
<a name="7887554"></a>Singh N, Gayowski T, Yu VL, Wagener MM. Trimethoprim-sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis: a randomized trial. <i>Ann Intern Med</i>. 1995;122(8):595-598. doi:10.7326/0003-4819-122-8-199504150-00007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/7887554/pubmed" id="7887554" target="_blank">7887554</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7075646">
<a name="7075646"></a>Singlas E, Colin JN, Rottembourg J, et al. Pharmacokinetics of sulfamethoxazole--trimethoprim combination during chronic peritoneal dialysis: effect of peritonitis. <i>Eur J Clin Pharmacol</i>. 1982;21(5):409‐415. doi:10.1007/BF00542328<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/7075646/pubmed" id="7075646" target="_blank">7075646</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15242722">
<a name="15242722"></a>Slatore CG, Tilles SA. Sulfonamide hypersensitivity. <i>Immunol Allergy Clin North Am</i>. 2004;24(3):477-vii. doi:10.1016/j.iac.2004.03.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/15242722/pubmed" id="15242722" target="_blank">15242722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29217891">
<a name="29217891"></a>Slim R, Asmar N, Yaghi C, Honein K, Sayegh R, Chelala D. Trimethoprim-sulfamethoxazole-induced hepatotoxicity in a renal transplant patient. <i>Indian J Nephrol</i>. 2017;27(6):482-483. doi:10.4103/ijn.IJN_339_16<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/29217891/pubmed" id="29217891" target="_blank">29217891</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11281744">
<a name="11281744"></a>Snow V, Lascher S, Mottur-Pilson C; Joint Expert Panel on Chronic Obstructive Pulmonary Disease of the American College of Chest Physicians and the American College of Physicians-American Society of Internal Medicine. Evidence base for management of acute exacerbations of chronic obstructive pulmonary disease. <i>Ann Intern Med.</i> 2001;134(7):595-599.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/11281744/pubmed" id="11281744" target="_blank">11281744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Southwick.2019">
<a name="Southwick.2019"></a>Southwick FS. Treatment and prognosis of bacterial brain abscess. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 23, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Spach.1">
<a name="Spach.1"></a>Spach DH, Kaplan SL. Treatment of cat scratch disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 2, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Spelman.2018">
<a name="Spelman.2018"></a>Spelman D, Baddour LM. Acute cellulitis and erysipelas in adults: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 25, 2023b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Spelman.1">
<a name="Spelman.1"></a>Spelman D, Baddour LM. Skin abscesses in adults: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 25, 2023a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Spelman2019b">
<a name="Spelman2019b"></a>Spelman D. Treatment of nocardiosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 7, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7062219">
<a name="7062219"></a>Springer C, Eyal F, and Michel J, "Pharmacology of Trimethoprim-Sulfamethoxazole in Newborn Infants," <i>J Pediatr</i>, 1982, 100(4):647-50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/7062219/pubmed" id="7062219" target="_blank">7062219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6992677">
<a name="6992677"></a>Stamm WE, Counts GW, Wagner KF, et al. Antimicrobial prophylaxis of recurrent urinary tract infections: a double-blind, placebo-controlled trial. <i>Ann Intern Med</i>. 1980;92(6):770-775. doi: 10.7326/0003-4819-92-6-770.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/6992677/pubmed" id="6992677" target="_blank">6992677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2197450">
<a name="2197450"></a>Stapleton A, Latham RH, Johnson C, Stamm WE. Postcoital antimicrobial prophylaxis for recurrent urinary tract infection. A randomized, double-blind, placebo-controlled trial. <i>JAMA</i>. 1990;264(6):703-706.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/2197450/pubmed" id="2197450" target="_blank">2197450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25477258">
<a name="25477258"></a>Stein R, Dogan HS, Hoebeke P, et al. Urinary tract infections in children: EAU/ESPU guidelines. <i>Eur Urol</i>. 2015;67(3):546-558. doi:10.1016/j.eururo.2014.11.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/25477258/pubmed" id="25477258" target="_blank">25477258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24973422">
<a name="24973422"></a>Stevens DL, Bisno AL, Chambers HF, et al; Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2014;59(2):e10-e52. doi:10.1093/cid/ciu444<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/24973422/pubmed" id="24973422" target="_blank">24973422</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26453777">
<a name="26453777"></a>Stollman N, Smalley W, Hirano I; AGA Institute Clinical Guidelines Committee. American Gastroenterological Association Institute guideline on the management of acute diverticulitis. <i>Gastroenterology</i>. 2015;149(7):1944-1949. doi:10.1053/j.gastro.2015.10.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/26453777/pubmed" id="26453777" target="_blank">26453777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stout.2022">
<a name="Stout.2022"></a>Stout J. Clinical manifestations, diagnosis, and treatment of plague (Yersinia pestis infection). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 21, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16500599">
<a name="16500599"></a>Strevel EL, Kuper A, Gold WL. Severe and protracted hypoglycaemia associated with co-trimoxazole use. <i>Lancet Infect Dis</i>. 2006;6(3):178-182. doi:10.1016/S1473-3099(06)70414-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/16500599/pubmed" id="16500599" target="_blank">16500599</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Somerset.1">
<a name="Somerset.1"></a>Sulfamethoxazole and trimethoprim injection [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA Inc; September 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ANI.1">
<a name="ANI.1"></a>Sulfamethoxazole and trimethoprim suspension [prescribing information]. Gurney, IL: Akorn Operating Company LLC; August 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AApharma.1">
<a name="AApharma.1"></a>Sulfatrim tablets (sulfamethoxazole/trimethoprim) [product monograph]. Vaughan, Ontario, Canada: AA Pharma Inc; July 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AApharma.2">
<a name="AApharma.2"></a>Sulfatrim DS tablets (sulfamethoxazole/trimethoprim) [product monograph]. Vaughan, Ontario, Canada: AA Pharma Inc; July 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AApharma.3">
<a name="AApharma.3"></a>Sulfatrim Pediatric tablets (sulfamethoxazole/trimethoprim) [product monograph]. Vaughan, Ontario, Canada: AA Pharma Inc; July 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-PharmAssoc.1">
<a name="PharmAssoc.1"></a>Sulfatrim Pediatric suspension (sulfamethoxazole/trimethoprim) [prescribing information]. Greenville, SC: Pharmaceutical Associates Inc; October 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32986699">
<a name="32986699"></a>Sullivan RP, Marshall CS, Anstey NM, Ward L, Currie BJ. 2020 Review and revision of the 2015 Darwin melioidosis treatment guideline; paradigm drift not shift. <i>PLoS Negl Trop Dis</i>. 2020;14(9):e0008659. doi:10.1371/journal.pntd.0008659<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/32986699/pubmed" id="32986699" target="_blank">32986699</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26899755">
<a name="26899755"></a>Syed Q, Hendler KT, Koncilja K. The impact of aging and medical status on dysgeusia. <i>Am J Med</i>. 2016;129(7):753.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/26899755/pubmed" id="26899755" target="_blank">26899755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34864936">
<a name="34864936"></a>Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America guidance on the treatment of AmpC β-lactamase-producing enterobacterales, carbapenem-resistant <i>Acinetobacter baumannii</i>, and <i>Stenotrophomonas maltophilia</i> infections. <i>Clin Infect Dis</i>. 2022;74(12):2089-2114. doi:10.1093/cid/ciab1013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/34864936/pubmed" id="34864936" target="_blank">34864936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6331808">
<a name="6331808"></a>Thies PW, Dull WL. Trimethoprim-sulfamethoxazole-induced cholestatic hepatitis. Inadvertent rechallenge. <i>Arch Intern Med</i>. 1984;144(8):1691-1692. doi:10.1001/archinte.144.8.1691<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/6331808/pubmed" id="6331808" target="_blank">6331808</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Thomas.2019">
<a name="Thomas.2019"></a>Thomas CF, Limper AH. Treatment and prevention of pneumocystis pneumonia in patients without HIV. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 7, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24099411">
<a name="24099411"></a>Thyagarajan B, Deshpande SS. Cotrimoxazole and neonatal kernicterus: a review. <i>Drug Chem Toxicol</i>. 2014;37(2):121-129. doi:10.3109/01480545.2013.834349<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/24099411/pubmed" id="24099411" target="_blank">24099411</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31181351">
<a name="31181351"></a>Tissot-Dupont H, Gouriet F, Oliver L, et al. High-dose trimethoprim-sulfamethoxazole and clindamycin for Staphylococcus aureus endocarditis. <i>Int J Antimicrob Agents</i>. 2019;54(2):143-148. doi:10.1016/j.ijantimicag.2019.06.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/31181351/pubmed" id="31181351" target="_blank">31181351</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19747629">
<a name="19747629"></a>Tomblyn M, Chiller T, Einsele H, et al; Center for International Blood and Marrow Research; National Marrow Donor program; European Blood and Marrow Transplant Group; American Society of Blood and Marrow Transplantation; Canadian Blood and Marrow Transplant Group; Infectious Diseases Society of America; Society for Healthcare Epidemiology of America; Association of Medical Microbiology and Infectious Disease Canada; Centers for Disease Control and Prevention. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective [published correction appears in <i>Biol Blood Marrow Transplant.</i> 2010;16(2):294]. <i>Biol Blood Marrow Transplant.</i> 2009;15(10):1143-1238. doi: 10.1016/j.bbmt.2009.06.019.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/19747629/pubmed" id="19747629" target="_blank">19747629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20415992">
<a name="20415992"></a>Tong SY, Andrews RM, Kearns T, et al. Trimethopim-sulfamethoxazole compared with benzathine penicillin for treatment of impetigo in Aboriginal children: a pilot randomised controlled trial. <i>J Paediatr Child Health</i>. 2010;46(3):131-133. doi:10.1111/j.1440-1754.2010.01697.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/20415992/pubmed" id="20415992" target="_blank">20415992</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9624473">
<a name="9624473"></a>Torre D, Casari S, Speranza F, et al, “Randomized Trial of Trimethoprim-Sulfamethoxazole Versus Pyrimethamine-Sulfadiazine for Therapy of Toxoplasmic Encephalitis in Patients With AIDS. Italian Collaborative Study Group,” <i>Antimicrob Agents Chemother</i>, 1998, 42(6):1346-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/9624473/pubmed" id="9624473" target="_blank">9624473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2513939">
<a name="2513939"></a>Trienekens TA, Stobberingh EE, Winkens RA, Houben AW. Different lengths of treatment with co-trimoxazole for acute uncomplicated urinary tract infections in women. <i>BMJ</i>. 1989;299(6711):1319-1322. doi:10.1136/bmj.299.6711.1319<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/2513939/pubmed" id="2513939" target="_blank">2513939</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16163635">
<a name="16163635"></a>Trotman RL, Williamson JC, Shoemaker DM. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. <i>Clin Infect Dis.</i> 2005;41(8):1159-1166.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/16163635/pubmed" id="16163635" target="_blank">16163635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27542610">
<a name="27542610"></a>Tsapepas D, Chiles M, Babayev R, et al. Incidence of hyponatremia with high-dose trimethoprim-sulfamethoxazole exposure. <i>Am J Med</i>. 2016;129(12):1322-1328. doi:10.1016/j.amjmed.2016.07.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/27542610/pubmed" id="27542610" target="_blank">27542610</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15494903">
<a name="15494903"></a>Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. <i>Clin Infect Dis.</i> 2004;39(9):1267-1284.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/15494903/pubmed" id="15494903" target="_blank">15494903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28203777">
<a name="28203777"></a>Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America's clinical practice guidelines for healthcare-associated ventriculitis and meningitis. <i>Clin Infect Dis</i>. 2017;64(6):e34-e65. doi:10.1093/cid/ciw861<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/28203777/pubmed" id="28203777" target="_blank">28203777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.3">
<a name="HHS.3"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. <a href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections</a>. Updated September 28, 2022a. Accessed November 17, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.7">
<a name="HHS.7"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines</a>. Accessed August 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2">
<a name="HHS.2"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. <a href="https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines</a>. Updated August 18, 2021. Accessed August 20, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.5">
<a name="HHS.5"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. <a href="https://clinicalinfo.hiv.gov/en/guidelines/pediatric-opportunistic-infection/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/pediatric-opportunistic-infection/whats-new</a>. Updated March 19, 2021. Accessed August 20, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9027435">
<a name="9027435"></a>van der Klauw MM, Wilson JH, Stricker BH. Drug-associated anaphylaxis: 20 years of reporting in The Netherlands (1974-1994) and review of the literature. <i>Clin Exp Allergy</i>. 1996;26(12):1355-1363. doi:10.1046/j.1365-2222.1996.d01-300.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/9027435/pubmed" id="9027435" target="_blank">9027435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1678095">
<a name="1678095"></a>van der Ven AJ, Koopmans PP, Vree TB, van der Meer JW. Adverse reactions to co-trimoxazole in HIV infection. <i>Lancet</i>. 1991;338(8764):431-433. doi:10.1016/0140-6736(91)91046-w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/1678095/pubmed" id="1678095" target="_blank">1678095</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32073652">
<a name="32073652"></a>van Dijk ST, Chabok A, Dijkgraaf MG, Boermeester MA, Smedh K. Observational versus antibiotic treatment for uncomplicated diverticulitis: an individual-patient data meta-analysis. <i>Br J Surg</i>. 2020;107(8):1062-1069. doi:10.1002/bjs.11465<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/32073652/pubmed" id="32073652" target="_blank">32073652</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27216385">
<a name="27216385"></a>Vardakas KZ, Trigkidis KK, Boukouvala E, Falagas ME. Clostridium difficile infection following systemic antibiotic administration in randomised controlled trials: a systematic review and meta-analysis. <i>Int J Antimicrob Agents</i>. 2016;48(1):1-10. doi:10.1016/j.ijantimicag.2016.03.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/27216385/pubmed" id="27216385" target="_blank">27216385</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8328738">
<a name="8328738"></a>Velázquez H, Perazella MA, Wright FS, Ellison DH. Renal mechanism of trimethoprim-induced hyperkalemia. <i>Ann Intern Med</i>. 1993;119(4):296-301. doi:10.7326/0003-4819-119-4-199308150-00008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/8328738/pubmed" id="8328738" target="_blank">8328738</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37080658">
<a name="37080658"></a>Velleca A, Shullo MA, Dhital K, et al. The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients. <i>J Heart Lung Transplant</i>. 2023;42(5):e1-e141. doi:10.1016/j.healun.2022.10.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/37080658/pubmed" id="37080658" target="_blank">37080658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14969569">
<a name="14969569"></a>Veltri MA, Neu AM, Fivush BA, Parekh RS, Furth SL. Drug dosing during intermittent hemodialysis and continuous renal replacement therapy: special considerations in pediatric patients. <i>Paediatr Drugs</i>. 2004;6(1):45-65.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/14969569/pubmed" id="14969569" target="_blank">14969569</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10836915">
<a name="10836915"></a>Verdier RI, Fitzgerald DW, Johnson WD Jr, Pape JW. Trimethoprim-sulfamethoxazole compared with ciprofloxacin for treatment and prophylaxis of Isospora belli and Cyclospora cayetanensis infection in HIV-infected patients. A randomized, controlled trial. <i>Ann Intern Med</i>. 2000;132(11):885-888. doi:10.7326/0003-4819-132-11-200006060-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/10836915/pubmed" id="10836915" target="_blank">10836915</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2789377">
<a name="2789377"></a>Verne-Pignatelli J, Spickett GP, Dalgleish AG, Denman AM. Thrombophlebitis migrans following co-trimoxazole therapy. <i>Postgrad Med J</i>. 1989;65(759):51-52. doi:10.1136/pgmj.65.759.51<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/2789377/pubmed" id="2789377" target="_blank">2789377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3190184">
<a name="3190184"></a>Wadsworth SJ, Suh B. In vitro displacement of bilirubin by antibiotics and 2-hydroxybenzoylglycine in newborns. <i>Antimicrob Agents Chemother</i>. 1988;32(10):1571-1575. doi:10.1128/AAC.32.10.1571<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/3190184/pubmed" id="3190184" target="_blank">3190184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2488182">
<a name="2488182"></a>Walker SE, Paton TW, Churchill DN, Ojo B, Manuel MA, Wright N. Trimethoprim-sulfamethoxazole pharmacokinetics during continuous ambulatory peritoneal dialysis (CAPD). <i>Perit Dial Int</i>. 1989;9(1):51‐55.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/2488182/pubmed" id="2488182" target="_blank">2488182</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24145530">
<a name="24145530"></a>Wang YL, Scipione MR, Dubrovskaya Y, et al. Monotherapy with fluoroquinolone or trimethoprim-sulfamethoxazole for treatment of stenotrophomonas maltophilia infections. <i>Antimicrob Agents Chemother.</i> 2014;58(1):176-182. doi: 10.1128/AAC.01324-13.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/24145530/pubmed" id="24145530" target="_blank">24145530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24008153">
<a name="24008153"></a>Wang HK, Sheng WH, Hung CC, et al. Clinical characteristics, microbiology, and outcomes for patients with lung and disseminated nocardiosis in a tertiary hospital.<i> J Formos Med Assoc.</i> 2015;114(8):742-749. doi: 10.1016/j.jfma.2013.07.017.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/24008153/pubmed" id="24008153" target="_blank">24008153</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22851742">
<a name="22851742"></a>Warady BA, Bakkaloglu S, Newland J, et al. Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update. <i>Perit Dial Int</i>. 2012;(32 Suppl 2):S32-S86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/22851742/pubmed" id="22851742" target="_blank">22851742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29272341">
<a name="29272341"></a>Watson T, Hickok J, Fraker S, Korwek K, Poland RE, Septimus E. Evaluating the risk factors for hospital-onset Clostridium difficile infections in a large healthcare system. <i>Clin Infect Dis</i>. 2018;66(12):1957-1959. doi:10.1093/cid/cix1112<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/29272341/pubmed" id="29272341" target="_blank">29272341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Weller.2021">
<a name="Weller.2021"></a>Weller PF, Leder K. Cyclospora infection. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 17, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29388572">
<a name="29388572"></a>Wiersinga WJ, Virk HS, Torres AG, et al. Melioidosis. <i>Nat Rev Dis Primers</i>. 2018;4:17107. doi:10.1038/nrdp.2017.107<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/29388572/pubmed" id="29388572" target="_blank">29388572</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36052413">
<a name="36052413"></a>Wildenthal JA, Atkinson A, Lewis S, et al. Outcomes of partial oral antibiotic treatment for complicated Staphylococcus aureus bacteremia in people who inject drugs. <i>Clin Infect Dis.</i> 2023;76(3):487-496. doi:10.1093/cid/ciac714<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/36052413/pubmed" id="36052413" target="_blank">36052413</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29121838">
<a name="29121838"></a>Williams MF, Doss EP, Montgomery M. Possible trimethoprim-sulfamethoxazole-induced hemolytic anemia: a case report. <i>J Pharm Pract</i>. 2017;30(6):653-657. doi:10.1177/0897190016683303<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/29121838/pubmed" id="29121838" target="_blank">29121838</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10877016">
<a name="10877016"></a>Windecker R, Steffen J, Cascorbi I, Thürmann PA. Co-trimoxazole-induced liver and renal failure. Case report. <i>Eur J Clin Pharmacol</i>. 2000;56(2):191-193. doi:10.1007/s002280050740<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/10877016/pubmed" id="10877016" target="_blank">10877016</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8329509">
<a name="8329509"></a>Wolff MA, Young CL, Ramphal R. Antibiotic therapy for enterobacter meningitis: a retrospective review of 13 episodes and review of the literature. <i>Clin Infect Dis</i>. 1993;16(6):772-777. doi:10.1093/clind/16.6.772<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/8329509/pubmed" id="8329509" target="_blank">8329509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20736426">
<a name="20736426"></a>Wood GC, Underwood EL, Croce MA, et al, "Treatment of Recurrent <i>Stenotrophomonas maltophilia</i> Ventilator-Associated Pneumonia With Doxycycline and Aerosolized Colistin," <i>Ann Pharmacother</i>, 2010, 44(10):1665-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/20736426/pubmed" id="20736426" target="_blank">20736426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34292926">
<a name="34292926"></a>Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. <i>MMWR Recomm Rep</i>. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/34292926/pubmed" id="34292926" target="_blank">34292926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. https://apps.who.int/iris/handle/10665/62435. Published 2002.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.4">
<a name="WHO.4"></a>World Health Organization (WHO). Brucellosis in humans and animals. https://www.who.int/publications/i/item/9789241547130. Published 2006. Accessed October 6, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2">
<a name="WHO.2"></a>World Health Organization (WHO). Guidelines for the control of shigellosis, including epidemics due to <i>Shigella dysenteriae</i> type 1. Available at http://whqlibdoc.who.int/publications/2005/9241592330.pdf. Published 2005. Accessed September 20, 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.3">
<a name="WHO.3"></a>World Health Organization (WHO)‎. Mastitis: causes and management. https://apps.who.int/iris/handle/10665/66230. Published 2000.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33903114">
<a name="33903114"></a>Wu YSS, Cohen-Wolkowiez M, Hornik CP, et al. External evaluation of two pediatric population pharmacokinetics models of oral trimethoprim and sulfamethoxazole. <i>Antimicrob Agents Chemother</i>. 2021;65(7):e0214920. doi:10.1128/AAC.02149-20<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/33903114/pubmed" id="33903114" target="_blank">33903114</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23943179">
<a name="23943179"></a>Wulf NR, Matuszewski KA. Sulfonamide cross-reactivity: is there evidence to support broad cross-allergenicity? <i>Am J Health Syst Pharm</i>. 2013;70(17):1483-1494. doi:10.2146/ajhp120291<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/23943179/pubmed" id="23943179" target="_blank">23943179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35467409">
<a name="35467409"></a>Ye Y, Kong Y, Ma J, Shi G. Carbapenem-resistant gram-negative bacteria-related healthcare-associated ventriculitis and meningitis: antimicrobial resistance of the pathogens, treatment, and outcome. <i>Microbiol Spectr.</i> 2022;10(3):e0025322. doi:10.1128/spectrum.00253-22<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/35467409/pubmed" id="35467409" target="_blank">35467409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4743777">
<a name="4743777"></a>Ylikorkala O, Sjöstedt E, Järvinen PA, et al, "Trimethoprim-Sulfonamide Combination Administered Orally and Intravaginally in the First Trimester of Pregnancy: Its Absorption Into Serum and Transfer to Amniotic Fluid," <i>Acta Obstet Gynecol Scand</i>, 1973, 52(3):229-34.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/4743777/pubmed" id="4743777" target="_blank">4743777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20596129">
<a name="20596129"></a>Yuzurio S, Horita N, Shiota Y, Kanehiro A, Tanimoto M. Interstitial lung disease during trimethoprim/sulfamethoxazole administration. <i>Acta Med Okayama</i>. 2010;64(3):181-187. doi:10.18926/AMO/40010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/20596129/pubmed" id="20596129" target="_blank">20596129</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26897386">
<a name="26897386"></a>Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. <i>J Am Acad Dermatol. </i>2016;74(5):945-973.e33. http://www.jaad.org/article/S0190-9622(15)02614-6/pdf. Accessed May 17, 2016.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/26897386/pubmed" id="26897386" target="_blank">26897386</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20413982">
<a name="20413982"></a>Zawodniak A, Lochmatter P, Beeler A, Pichler WJ. Cross-reactivity in drug hypersensitivity reactions to sulfasalazine and sulfamethoxazole. <i>Int Arch Allergy Immunol</i>. 2010;153(2):152-156. doi:10.1159/000312632<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/20413982/pubmed" id="20413982" target="_blank">20413982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31400461">
<a name="31400461"></a>Zhang C, Van DN, Hieu C, Craig T. Drug-induced severe cutaneous adverse reactions: Determine the cause and prevention. <i>Ann Allergy Asthma Immunol</i>. 2019;123(5):483-487. doi:10.1016/j.anai.2019.08.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/31400461/pubmed" id="31400461" target="_blank">31400461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28768443">
<a name="28768443"></a>Zheng N, Wang W, Zhang JT, et al. Neurobrucellosis. <i>Int J Neurosci</i>. 2018;128(1):55-62. doi:10.1080/00207454.2017.1363747<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/28768443/pubmed" id="28768443" target="_blank">28768443</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12816 Version 569.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
